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 Abstract 
 
Intravenous immunoglobulin (IVIg) is a pool of plasma polyclonal IgG derived from 
thousands of healthy donors. Initially employed as a replacement therapy in patients suffering 
from immunodeficiency, in the 80’s, IVIg was shown to surprisingly ameliorate immune 
thrombocytopenia by some immunosuppressive properties. Since then, the use of IVIg has 
rocketed in the treatment of a wide range of autoimmune and severe inflammatory diseases.  It is 
commonly administered in the clinic at very high doses (1 to 4 g/kg) in order to achieve anti-
inflammatory effects. However, its mechanisms of action remain poorly understood. This PhD 
project aimed at investigating whether IVIg has a direct impact on immune cell populations in 
vivo in mice, characterizing the antibody response upon IVIg treatment and exploring how these 
different effects could explain the immunomodulatory properties of IVIg. 
By using an OVA-immunization mouse model, we demonstrated that IVIg was able to 
significantly reduce the OVA-specific antibody response in a dose-dependent manner, as 
observed in the clinic. Intriguingly, IVIg injection led to B- and T-cell expansion in the 
corresponding draining lymph nodes, as translated by their considerable increase in weight. IVIg 
augmented the number of CD69+ activated T cells but didn’t promote Tregs activation. Notably, 
it induced a marked stimulation of B cells as shown by the up-regulation of the co-stimulatory 
molecules CD86 and CD83, as well as the early activation marker CD69.  More strikingly, IVIg 
administration in mice resulted in the formation of large and numerous germinal centers in 
lymphoid organs. Analysis of the bone marrow revealed that less mature B cells were re-
circulating, suggesting that they get trapped in the lymph nodes. In addition, the number of total 
IgG immunoglobulin-secreting cells was greatly enhanced upon IVIg treatment, whereas the ratio 
of OVA-IgG antibodies secreting cells was diminished. All these effects were dependent on the 
presence of adjuvant and could not be reproduced by the administration of a human monoclonal 
antibody at the same high dose. These data collectively point to the direction that IVIg triggers 
immune activation, although the resulting outcome is the inhibition of the OVA-antibody 
response. This was confirmed by further data showing that IVIg raised an IVIg specific antibody 
response in mice, mainly targeted towards its variable regions.  This suggests that IVIg directly 
activates B cells after binding to the BCR most probably via an anti-idiotypic interaction. Very 
interestingly, mouse immunization with NP-Ficoll revealed that IVIg was not able to 
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significantly downregulate antibodies against a thymus-independent antigen, implying a 
competition at the T cell level.   
Research over the past decades has emphasized the role of IVIg in promoting anti-
inflammatory effects, e.g. activation of Tregs, induction of inhibitory FcγRIIB expression, 
saturation of FcRn, or modulation of co-stimulatory molecules expression on DCs. In contrast, 
our data indicate an immediate and massive immune reaction against IVIg in vivo. We propose 
that the many different variable sequences present in IVIg introduce a multitude of new foreign 
epitopes re-directing the immune system. Antigenic competition of IVIg with the response 
against OVA may occur at different stages in the immune reaction. Driven by the high diversity 
of T- and B cell epitopes, competition may occur during i) scanning of peptides by T cells on 
dendritic cells ii) priming of B cells by cognate T helper cells at the B/T cell border iii) priming 
of B cells by cognate T follicular helper cells within the germinal center.  
Therefore, we suggest that rather than acting as an active anti-inflammatory component, IVIg 
interferes with establishing an efficient immune response against a specific antigen via a huge 
diversity of epitopes re-directing the immune system towards a massive immune response against 
IVIg. 
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 Introduction 
 
1. Immune cells interplay 
The innate immunity provides immediate protection against pathogens. The innate immune 
system uses receptors that are encoded in germline and are thus specifically inherited in the 
genome. Due to their limited number, these receptors recognize features that are common to 
many pathogens. Innate immunity is thus characterized by its broad specificity and the absence of 
immunological memory. The immediate innate defenses comprise epithelial barriers, secreted 
antimicrobial proteins and the complement system. Epithelial cells from the skin, gut, lungs, 
eyes, nose and oral cavities prevent entry of pathogens by forming tight junctions. Movement of 
cilia found in lungs and gut provide another mechanical barrier. Epithelial surfaces are also 
associated with a normal microbiota composed of non-pathogenic commensal bacteria, 
competing with pathogens for nutrients and surface attachment.  Moreover epithelial cells 
produce chemical microbicide substances. For example, lysozymes contained in tears and saliva 
degrade peptidoglycan from Gram-positive bacteria. α-defensins are short positively-charged 
peptides contained in the intestinal tract attracted by the negatively charged LPS 
(lipopolysaccharide) from bacteria, which lead to pores formation and thus bacteria membrane 
disruption. Acid pH and digestive enzymes from the stomach create a non-friendly environment 
for the pathogens. Complement can also be activated early in case of infection. The complement 
system consists of numerous soluble proteins present in blood. Upon detection of a pathogen 
these inactive proteins become locally activated and trigger a series of powerful inflammatory 
events. The complement cascade can be initiated upon direct binding of complement proteins on 
the pathogen  surface or by recognition of sugar patterns on the surface of pathogens by a free 
lectin receptor. All complement pathways result in the same three consequences, meaning either 
direct elimination of the pathogen by formation of a membrane-attack complex creating pores in 
the membrane, opsonization of pathogens, or recruitment of phagocytes to the site of infection by 
release of anaphylatoxins.  
  
1.1. Innate Immunity 
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 If a pathogen crosses the epithelial barrier, in addition to the free complement receptors in 
serum it will also be neutralized by macrophages and dendritic cells (DCs) that reside in tissues 
and constitutively express phagocytic receptors. They recognize microbial components that have 
a repetitive structure, the pathogens-associated molecular patterns (PAMPs), as well as host 
molecules such as nuclear or cytosolic proteins named DAMPs (danger- associated molecular 
patterns) (Gallucci and Matzinger, 2001).  PAMPs and DAMPs are recognized via pattern 
recognition receptors (PRRs). PRRs include C-type lectin family, scavenger receptors and 
complement receptors. They bind a wide range of pathogens and enable their phagocytosis. 
Different sets of PAMPs can specifically activate different Toll-like receptors (TLRs) that are 
located on cell surface or intracellular membranes, as well as cytosol receptors, the NOD-like 
receptors (NLRs). Interaction with pathogens results in the activation of the NFκB pathway in 
macrophages and DCs, to release pro-inflammatory cytokines and chemokines. This is the acute-
phase response, which consists of the recruitment of more effector cells to sites of infection to 
destroy the pathogens. Subsequent dilation of local blood vessels allows extravasation of 
leukocytes and plasma proteins to the infection site and local blood clotting occurs to avoid 
spread of the infection. This accounts for pain, redness, fever and swelling. Neutrophils make up 
the first wave of cells that cross the blood vessel wall to enter the inflamed tissue. They are 
followed by monocytes, which differentiate either into tissue macrophages or DCs, depending on 
the cytokine environment. At the late stage of the inflammation eosinophils and lymphocytes will 
also join the infected site. Viruses induce the release of specific cytokines that activate the killer 
functions of NK cells (Natural Killers) which therefore act as an early innate defense against 
intracellular infections. The released pro-inflammatory cytokines have another important role, 
they induce the expression of co-stimulatory molecules on macrophages and DCs thus enabling 
them to act as antigen-presenting cells (APCs) to T lymphocytes and thereby initiate an adaptive 
immune response. 
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1.2.1. Priming of T cells 
If innate immunity accounts for the early detection and destruction of pathogens, it also 
produces molecules that activate and shape an appropriate adaptive immune response. In contrast 
to the innate response whose specificity is fixed in the genome, cells from the adaptive response 
can develop an enormous repertoire that consists of several billions of different antigen receptors 
(up to 10
13
). Knowing that the human genome possesses a limiting capacity of about 30 000 
genes, the broad repertoire of immunoglobulin and T cell receptors (TCR) is generated by cell 
rearrangements from gene segments (somatic recombination) which confer them a very tuned 
specificity allowing fine distinctions between closely related molecules. Unlike innate immunity, 
adaptive immunity provides long term immunological memory to protect against reinfection.  
An adaptive response is mainly driven by two types of lymphocytes: B cells, which develop 
in the bone marrow, and T cells, which develop in the thymus. T and B-cell responses are 
initiated in peripheral lymphoid organs by activated APCs, as depicted in Figure 1. APCs 
comprise three cell types: DCs, macrophages, monocytes and B cells. While DCs and 
macrophages actively take up antigens non-specifically from a broad range of pathogens and self- 
molecules by phagocytosis and macropinocytosis, B cells bind soluble molecules specifically 
through their surface immunoglobulin and internalize them by endocytosis. Once bound, 
microorganisms are engulfed in APCs and the internalized proteins are degraded to peptides that 
are then displayed as peptide: MHC complexes on the APC’s surface. At the same time, 
recognition of PAMPs and/or DAMPs by APCs via PRRs, leads to cell activation. This results in 
the up-regulation of co-stimulatory molecules CD80 and CD86 on surface of APCs as well as 
increases expression of MHC receptor. APC activation also further triggers antigen processing 
and directs APCs to migrate to peripheral lymphoid organs (spleen and lymph nodes). 
1.2. Adaptive immunity 
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Figure 1: Immune cells interplay during the adaptive immune response. 1) A dendritic cell (DC) takes up 
antigens unspecifically by macropinocytosis and processes them to peptides inside into acidified endosomes. 2) The 
pattern-recognition receptors (PRRs) sense the presence of a pathogen via the detection of pathogens-associated 
molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs). 3) For extracellular antigens, this 
results in the presentation of antigen-derived peptides on the MHCClass II molecules on the surface of the DC, 
together with the expression of co-stimulatory molecules such as CD80 or CD86. A CD4+ T cell clone recognizes 
both its specific peptide (T cell epitope) and the MHC-II molecule via its T-cell receptor (TCR). Interaction of  the 
TCR with the MHC:peptide omplexe and the CD28 with CD86/CD80 leads to T cell activation and clonal 
expansion. 4) Antigen uptake in B cells occurs via recognition by its specific B cells receptor (BCR) followed by 
endocytosis and peptides processing 5) T helper cell (Th)recognize its cognate B cell and activate it  thanks to CD40 
ligand (CD40L) / CD40 interaction. 6) Activated B cellsproliferate, undergo affinity maturation and finally 
differentiate into either antibody-secreting plasma cells or memory B cells. Cytokines released by activated T cells 
play an important role in the antibody class orientation. Adapted from A. Karle. 
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We can distinguish MHC class I and class II molecules whose function is to deliver 
peptides to the cell surface to activate the cognate T cells. MHC molecules are also commonly 
named HLA (Human Leukocyte Antigen). MHC class I molecules are expressed by all cells in 
the body except red blood cells, whereas MHC class II molecules expression is limited to 
macrophages, B cells, DCs, thymic cortical epithelial cells and to a very low extend in human to 
T cells. MHC-I is formed of a heterodimer of α-chain and β-microglobulin and MHC-II is a 
heterodimer of α-chain and β-chain (see Figure 2). 
 
Figure 2: Structure of the MHC class I molecule (a) and the MHC class II molecule (b). 
Immunobiology, 7ed.(© Garland Science 2008).  
 
Pathogen-derived proteins in the cytosol of APCs are degraded by the proteasome and peptides 
are loaded on the MHC Class I, while MHC Class II binds peptides generated in acidified 
endocytic vesicles from extracellular or intravesicular pathogens. Therefore MHC Class I 
exposes peptides derived from the intracellular compartment, and in contrast MHC Class II 
exposes peptides derived from proteins that have been taken-up from outside of the cell. MHC 
genes are highly polymorphic. Most of the allelic variation occurs specifically at the peptide-
binding groove and is thus restricted to α1 and α2 of MHC Class I and to β1 of MHC Class II, 
thus extending the range of antigens that can be recognized. Expression of each allele is co-
dominant. Polymorphism combined to polygeny ensures a broad MHC diversity and the outcome 
is an increased repertoire of peptides being able to be presented, therefore limiting the 
possibilities for a pathogen to fully escape MHC presentation. 
The TCR differs from BCR in the way that it does not bind antigen directly, but only 
recognize fragments of protein antigens presented on MHC molecules. The TCR is a heterodimer 
a) b) 
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that resembles a membrane-bound Fab fragment, composed of two transmembrane glycoprotein 
chains, α and β, each consisting of an extracellular constant and a variable region.  This antigen-
recognition part is associated with a complex of four invariant signaling chains (two ε, one δ, 
one γ) forming the CD3, and with two invariant ζ chains. All of the intracellular domains of these 
invariant chains contain ITAMs (immunoreceptor tyrosine-based activation motif) responsible of 
the signaling function of the TCR (Pitcher and van Oers, 2003) as shown on Figure 3. 
 
 Importantly, the TCR recognizes both the peptide and the MHC molecule, as demonstrated 
by (Dunlop et al., 1977), who showed that virus specific T cells could not kill MHC mismatched 
infected cells, or MHC matched uninfected cells or cells infected with unrelated viruses. T-cell 
co-receptors CD4 or CD8 bind to the non-variable region of MHC and direct T cells to the 
correct respective MHC, namely MHC-II for CD4 helper T cells and MHC-I for CD8 cytotoxic T 
cells.  
APCs take-up antigens from site of infection and upon activation by pathogens they will 
leave the periphery to enter secondary lymphoid organs via the lymph, where they mature. Free 
antigens also travel to lymphoid organs where they can be taken up and presented by APCs. 
Naïve T cells continuously re-circulate through peripheral lymphoid tissues, entering from 
arterial blood. There they scan mature APCs for their cognate peptide. If no interaction occurs, T 
cells leave via the lymph and return later into the blood. Priming of naive T cells by APCs 
requires three distinct signals: i) activation by TCR interaction with the MHC: peptide complex 
ii) survival and clonal expansion by T-cell CD28 receptor interaction with CD80/CD86 co-
Figure 3: The T-cell receptor complex (TCR). The TCR α:β 
heterodimer recognizes and binds its peptide:MHC ligand, but cannot 
signal to the cell that antigen has bound. In the functional receptor 
complex, α:β heterodimers are associated with a complex of four other 
signaling chains (two ε, one δ, one γ) collectively called CD3, and with 
two invariant ζ chains. All of the chains contain a similar motif called 
ITAM (yellow segments) required for signaling. Immunobiology, 
7ed.(© Garland Science 2008).  
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stimulatory molecules iii) differentiation into various effector cells depending on the cytokines 
produced by the APCs. Priming of naïve CD8 T cells generates cytotoxic T cells that will directly 
kill pathogen-infected cells (production of perforin, granzymes and granulysin). Variation in 
signal 3 causes naïve CD4 T cells to develop into distinct effector cells: TH1, TH2, TH17 or T 
regulatory cells (Tregs). TH1 are specialized to activate macrophages that have ingested 
pathogens to become highly microbicidal. TH2 (and to some extend TH1) provide help in B cells 
activation for the induction of the humoral immune response. TH17 promote acute inflammation 
by helping to recruit neutrophils to sites of infection. Tregs exert inhibitory actions through 
mechanisms that are not well understood.  
1.2.2. The humoral immune response 
The humoral immune response is mediated by antibodies that are secreted by plasma cells. 
Antibodies contribute to host protection by i) neutralization of pathogens and thus prevention of 
their cell-surface adherence, ii) opsonization by coating the surface of a pathogen to promote 
phagocytosis via Fc-recognition and iii) triggering complement activation to enhance 
opsonization or directly lyse the pathogen.  
Although B cells are efficient APCs to prime naïve T cells, their main function is to present 
MHC: peptides complexes on their surface to receive help from effector T cells to further initiate 
the humoral response. Two distinct signals are essential to generate an antibody response: antigen 
binding on the B cell and input signal delivered by T helper cells. First B cells are activated 
through sensing antigen via their BCR. Antigen that specifically binds to the B-cell receptor 
(BCR) is internalized to be processed to peptides, loaded on MHC molecules and presented on 
the B cell surface. The BCR complex is composed of a cell-surface immunoglobulin M (IgM) 
associated with the two invariant proteins Igα and Igβ carrying each an ITAM to form antigen-
nonspecific signaling molecules (Kurosaki, 2002), as illustrated on Figure 4. 
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Once B cells have bound antigens in the blood or lymphoid tissues, they express specific 
adhesion molecules and get trapped at the T-cell and B-cell zones border of peripheral lymphoid 
tissues. The second signal can be delivered by T helper cells in the case of a thymus-dependent 
(TD) antigen, mediated by the interaction of the CD40 ligand (CD40L) on T cells together with 
CD40 on B cells. For thymus-independent (TI) antigens, the antigen by itself can deliver the 
second signal, either by binding to a receptor of the innate immune system in case of TI-1 antigen 
(e.g. LPS), or by cross-linking BCR in case of polymeric TI-2 antigen (e.g. hapten-conjugated 
ficoll). B and T cells don’t usually recognize the same epitope, since B cell epitopes are often 
conformational whereas T cell epitopes are linear. However, they respond to the same antigen 
thanks to linked recognition, meaning B cells can only be activated by their cognate T cells.  
Once B cells have interacted with their cognate helper T cells, they start to divide and 
migrate to the red pulp of the spleen or to the medullary cords of lymph nodes, where they 
continue to proliferate and form a primary focus. A primary focus is an extrafollicular focus in 
which B cells do not undergo somatic hypermutation (SHM), but can still differentiate into short-
lived plasma cells. Some of these B cells activated in the primary focus will migrate into a 
primary lymphoid follicle where they continue their clonal expansion and form a germinal center 
(GC) (Vinuesa et al., 2009), as depicted in Figure 5.  
  
Figure 4: The B-cell receptor complex (BCR). The BCR is composed 
of a membrane bound IgM which recognizes and binds antigen but 
cannot itself generate a signal. It is associated  with antigen-non specific 
signaling molecules, the invariant proteins Igα and Igβ, having each a 
single ITAM motif (yellow segments) required for signaling. 
Immunobiology, 7ed.(© Garland Science 2008).  
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Figure 5: The germinal center reaction. See details below in the text. 
 
A germinal center is composed of a dark zone and a light zone. The dark zone is densely 
packed with highly proliferative B cells called centroblasts, whose BCRs undergo somatic 
hypermutation in their V-regions to mature their affinities. The enzyme activation-induced 
cytidine deaminase (AID) is involved in this process of immunoglobulin diversification (Eisen, 
2014), as well as in class-switch recombination. Indeed all naïve B cells express cell-surface IgM 
and IgD. Right after B cell activation the early stage of the humoral response is dominated by 
IgM antibodies production, whereas later on IgG is the most abundant antibody found in plasma, 
followed by IgA and IgE. Class-switching is also mediated by AID and the cytokine environment 
plays an important role in the antibody class orientation. The light zone of the germinal center is 
filled with less densely packed B cells named centrocytes, which show reduced proliferation but 
express higher levels of surface immunoglobulin. This will enable them to scan for their antigen 
presented as an intact molecule in the form of immune complexes on follicular DCs (FDCs) 
present in the light zone, as well (Heesters et al., 2014). Most of the random point mutations 
undergone in the dark zone during affinity maturation negatively impact the ability of a B cell to 
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bind antigen. These clones will die from apoptosis. Less frequently, mutations improve the 
affinity of a BCR for antigen, these cells will then receive survival signals from FDCs and by 
expressing MHC-II: peptide complexes they can further compete for binding to antigen-specific 
follicular helper T cells (TFH) (Vinuesa et al., 2005). By this process only B cell clones with high 
affinity for antigen will expand. Surviving B cells that have received help from TFH can then re‑
enter the GC for further affinity maturation, or exit the GC as a memory B cell or as a plasma 
cell. Plasma cells possess a high rate of Ig secretion but stop proliferating and have lost their 
ability to present MHC-II: peptides complexes. The majority of plasma cells will migrate in the 
bone-marrow to become long-lived cells and key players in the persistence of antibody responses. 
Memory B cells are long-lived, divide very slowly and secrete no antibody. Some plasma cells 
can also develop outside of the GC, whereas GC remains the dominant pathway for memory B 
cell formation (McHeyzer-Williams et al., 2012). 
Antibodies have specialized localization and functions according to their class (Brekke and 
Sandlie, 2003). IgM are produced before B cells have undergone somatic hypermutation and are 
therefore of low affinity, but because IgM form pentamers they compensate the low affinity with 
increased avidity by having multiple antigen bindings sites. IgA are mainly localised on mucus 
surfaces lining the gut and the respiratory tract, where they actively prevent pathogens from 
entering or attacking the epithelium membrane. IgG predominates in plasma, and is the only class 
to be transported through the placenta to confer passive immunity to the fetus. Both IgG and IgM 
activate complement but only IgG is suitable for promoting opsonization through binding on Fc-
receptors. IgE antibodies are mainly designed to fight parasite infections (e.g. helminths) and are 
thus present at very low levels in Western World people’s blood. Still they are able to activate 
mast cells and play a pivotal role in response to allergens. 
B cells, T cells and NK cells are all derived from a common lymphocyte progenitor located 
in the bone-marrow. Pro-B cells begin their Ig heavy μ chain genes rearrangement and if 
successful they become pre-B cells expressing intact μ heavy chain paired to “surrogate” light-
chain like- proteins that form the pre-BCR. In immature B cells the Ig light chain gene 
rearrangement has occurred and IgM associates with Igα and Igβ to express a fully functional 
BCR on their surface. At this point immature B cells are tested for their reactivity against self-
antigens, depending on signals delivered upon IgM interaction. Immature B cells with strong 
1.3. Lymphocytes development and self-tolerance 
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reactivity for self-antigens undergo apoptosis (clonal deletion), anergy (state of 
unresponsiveness) or receptor editing by further light chain gene rearrangements to produce non-
autoreactive B cells (Shlomchik, 2008). Low or non self-reactive immature B cells can leave the 
bone-marrow to travel to the spleen where they mature to express IgD on their surface, in 
addition to IgM. The development stages of a B cell are shown in Figure 6. 
 
 
Figure 6: The development stages of a B-linage cell. Immunobiology, 7ed.(© Garland Science 2008). 
 
 Some of the lymphocyte progenitors leave the bone-marrow to migrate to the thymus where 
they proliferate and differentiate into thymocytes. These CD4 CD8 double negative thymocytes 
give rise to two distinct lineages of T cells, the α:β and the γ:δ CD4-CD8- T cells. α:β cells 
express both CD4 and CD8 co-receptors at their early stage of development. Those “double-
positive” thymocytes that recognize self-peptides: MHC complexes presented on cortical thymic 
epithelial cells (cTEC) are positively selected (Klein et al., 2009) and they further mature into 
single positive CD4 T cells or into single positive CD8 T cells. These single positive mature T 
cells will then scan APCs (medullary thymic epithelial cells mTEC and DCs) and the ones that 
react too strongly with self-antigens are eliminated by apoptosis, therefore creating a pool of 
mature self-tolerant T cells that can migrate to the periphery (Palmer, 2003). This process is 
illustrated in Figure 7. 
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Figure 7: Overall scheme of T-cell development in the thymus. “Committed lymphoid progenitors arise in the 
bone marrow and migrate to the thymus. Early committed T cells lack expression of T-cell receptor (TCR), CD4 and 
CD8, and are termed double-negative (DN; no CD4 or CD8) thymocytes. DN thymocytes can be further subdivided 
into four stages of differentiation (DN1, CD44+CD25−; DN2,CD44+CD25+; DN3, CD44−CD25+; and DN4, 
CD44−CD25−). As cells progress through the DN2 to DN4 stages, they express the pre- TCR, which is composed of 
the non-rearranging pre-Tα chain and a rearranged TCR β-chain. Successful pre-TCR expression leads to substantial 
cell proliferation during the DN4 to double positive (DP) transition and replacement of the pre-TCR α-chain with a 
newly rearranged TCR α-chain, which yields a complete αβ TCR. The αβ-TCR+CD4+CD8+ (DP) thymocytes then 
interact with cortical epithelial cells that express a high density of MHC class I and class II molecules associated 
with self-peptides. The fate of the DP thymocytes depends on signalling that is mediated by interaction of the TCR 
with these self-peptide–MHC ligands. Too little signalling results in delayed apoptosis (death by neglect). Too much 
signalling can promote acute apoptosis (negative selection); this is most common in the medulla on encounter with 
strongly activating self-ligands on haematopoietic cells, particularly dendritic cells. The appropriate, intermediate 
level of TCR signalling initiates effective maturation (positive selection). Thymocytes that express TCRs that bind 
self-peptide– MHC-class-I complexes become CD8+ T cells, whereas those that express TCRs that bind self-
peptide–MHC-class-II ligands become CD4+ T cells; these cells are then ready for export from the medulla to 
peripheral lymphoid sites. SP, single positive”. (Germain, 2002). 
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The tolerance generated at this stage for both B and T cells is called the central tolerance. 
However, central tolerance is a “leaking” process, partly due to the fact that antigens from some 
tissue-specific proteins might not be found in the bone-marrow or presented on thymic cells, so 
cognate lymphocytes are unlikely to be deleted and might enter the periphery. Hence, it is 
essential to maintain peripheral tolerance, by i) anergy, ii) deletion by activation-induced cell 
death, iii) suppression by Tregs, or iv) linked recognition (B cells can only be activated by their 
cognate T cells). The MHC molecules can’t travel up to the cell surface if they are not loaded 
with a peptide. This means that if cells are not activated by a pathogen, some self-peptides are 
presented on APCs surface but without co-stimulatory molecules. Naïve T cells recognizing self-
peptides in the absence of second co-stimulus signal are not activated, instead they enter a state of 
anergy (Xing and Hogquist, 2012). This induces a long-term hyporesponsiveness in T cells, even 
if the antigen is later on presented on an APC together with co-stimulatory molecules. A high and 
constant antigen concentration, such as self-proteins that are constantly present in the body and 
abundant in some tissues, can provide strong and repeated stimulation to lymphocytes that are 
then deleted by the activation-induced cell death (AICD) mechanism (Walker and Abbas, 2002). 
A third way to maintain peripheral tolerance is mediated by Tregs that are believed to develop in 
the thymus in response to weak self-stimulation not sufficient to cause negative selection. Tregs 
are CD4+ cells expressing CD25 and the transcription factor Foxp3. When they are activated in 
the periphery, they mediate self-tolerance by inhibiting surrounding autoreactive effector T cells 
co-localized on the same APC, independently of their antigen specificity (bystander suppression) 
(Thornton and Shevach, 2000). Finally, linked recognition also helps to ensure peripheral self-
tolerance. Indeed the probability is pretty low that a given B cells and the T cell that responds to 
the same self-antigen are present at the same time, thereby limiting the chances to initiate an 
autoimmune response. 
We have seen above that central and peripheral tolerances are important to prevent 
destructive immune responses to self-tissues. The development of an autoimmune disease is a 
complex process that involves failures in one or several of these checkpoints, inducing a break-
down of self-tolerance. Autoimmune diseases are major causes of morbidity and mortality within 
the world, with higher prevalence in women (Jacobson et al., 1997; Walsh and Rau, 2000). Since 
the exact primary causes remain unknown for most of these diseases, they can’t be cured.  A 
combination of genetic predisposition (Rioux and Abbas, 2005; Wandstrat and Wakeland, 2001), 
environmental factors (smoking, diet, drugs, infection) (Bach, 2005; Dooley and Hogan, 2003) as 
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well as stochastic events (Edwards et al., 1999) is thought to influence the development of an 
autoimmune disease. Among the most common autoimmune diseases are rheumatoid arthritis 
(joint destruction), Grave’s disease (thyroid), type 1 diabetes (endocrine system), inflammatory 
bowel disease (gut), systemic lupus erythematosus (several internal organs), psoriasis (skin) and 
multiple sclerosis (nervous system). The current treatment strategies rely on immunosuppressive 
drugs to downregulate the overall immune response (Steinman et al., 2012) but the benefits of 
these drugs are counterbalanced by toxicity and serious side effects. In the last decade a wide 
range of therapeutic monoclonal antibodies targeting key receptors on immune cells have been 
developed (Rosman et al., 2013), however they do not fit for all diseases and are not effective in 
all patients. The unmet clinical needs are still high and antigen-specific therapies are missing. 
 
2. What is IVIg? 
Intravenous immunoglobulin (IVIg) is a pool of IgG purified from the blood of several 
thousand healthy donors. In early 1950’s, IVIg was introduced as a replacement therapy for 
patients with deficiency in immunoglobulins to render them less susceptible to microbial 
infections, and still remains the first-line treatment nowadays (Cunningham-Rundles, 2009). 
Such deficiencies in Ig can be caused either by common variable immunodeficiencies (CVID), 
viral infections (HIV), B cell malignancies, immunosuppressive treatments or after bone marrow 
transplantation. In 1980, Imbach et al. administrated IVIg as a replacement therapy in a boy 
affected by secondary hypogammaglobulinemia due to long-term immunosuppressive treatment 
of immune thrombocytopenia (ITP). Unexpectedly his platelet counts dramatically increased after 
IVIg infusion, and additional studies in patients with ITP but without hypogammaglobulinemia 
confirmed these results (Imbach et al., 1981). Since then the use of IVIg in patients with a variety 
of autoimmune and inflammatory disorders has considerably increased, this will be discussed in 
chapter 2.3. 
  
2.1. Origin of IVIg 
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Today sixteen brands of IVIg products are commercially available, with nine different 
manufacturing companies sharing the market (see Table 1). Products differ in their formulation 
and concentration. IVIg represented 46 % of the market of the worldwide plasma derivative 
products in 2008 (source: the Marketing Research Bureau, Inc.).  
Table 1:  Marketed products of IVIg. 
 
Human normal immunoglobulin for intravenous administration should be prepared from a 
pool of a minimum of a 1000 donors according to the European pharmacopeia. Plasma units 
collected should be negative for HIV, hepatitis viruses B and C. The methods commonly used to 
reduce the risk of viral transmission include a combination of pasteurization, low pH treatment, 
treatment with solvent and detergent, methylene blue, caprylic acid and nanofiltration (Poelsler et 
al., 2008). Nowadays manufacturing processes of IVIg are carefully designed to preserve IgG 
properties and prevent its denaturation, and thus follow tight regulation. The Ig production 
process involves steps of fractionation and purification of plasma. Plasma fractionation is 
obtained by several steps of precipitation with ethanol, followed by approved different methods 
of purification, including a combination of cation/anion exchange chromatographies (Radosevich 
and Burnouf, 2010). The final product should contain more than 95 % of intact IgG, levels of 
2.2. Production and composition 
Brand name Manufacturer Administration Form Stabilizer
Carimune NF/Sandoglobulin CSL Behring iv 3 to 12% lyophilized Sucrose
Flebogamma DIF Girfols iv 5 or 10% liquid Sorbitol
Gammagard Baxter iv 10% liquid or 5% lyophilized Glycine or Glucose, respectively
Gammaplex BPL iv 5% liquid Sorbitol, Glycine
Gammar Aventis/Behring iv 5% lyophilized Sucrose
Gammastan Talecris Biotherapeutics im 15 to 18% liquid Glycine
Gammunex-C Talecris Biotherapeutics iv or sc 10% liquid Glycine
Hizentra CSL Behring sc 20% liquid Proline
Iveegam EN Baxter iv 5% liquid Glucose
Nanogam Sanquin iv 5% liquid Glucose
Octagam Octapharma iv 5% or 10% liquid Maltose
Panglobulin CSL Behring iv 3 to 12% lyophilized Dextrose
Polygam S/D Baxter iv 5% and 10% lyophilized Glycine
Privigen CSL Behring iv 10% liquide Proline
Venoglobulin-S Alpha therapeutics iv 5% or 10% liquid D-sorbitol
Vivaglobin CSL Behring sc 16% liquid Glycine
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aggregates should be kept below 3 % (European pharmacopeia), and level of IgA should be 
minimal (mentioned on the batch label) to avoid anaphylactic shock in IgA-deficient patients 
(Lilic and Sewell, 2001). Its composition should reflect the one of a normal serum, with IgG 
isotypes present approximately in the following proportions: 60-70 % IgG1, 20-30 % IgG2, 5-
7 % IgG3, and 1-3 % IgG4. Currently IVIg preparations tend to be formulated at low pH (4-5.5) 
since it has been proven to be well tolerated by patients, but most importantly it favors product 
stability. Higher protein concentration (10 %) and reducing the time of infusion is also preferred. 
Addition of stabilizers such as polyols (sorbitol), sugars (maltose, glucose), or amino acids 
(glycine, proline) have replaced the use of sucrose which has been suspected of kidney toxicity 
(Dantal, 2013). 
IVIg formulations differ depending on the manufacturer and it’s clear that its composition 
also varies from batch to batch since no batch is derived from the same set of donors. But these 
differences are kept minimal by the implementation of specific guidelines and quality controls 
that guarantee the consistency of IVIg batches released on the market and limit the presence of 
biological or chemical impurities. 
Today the use of IVIg in the treatment of autoimmune and systemic inflammatory diseases 
largely takes over its initial indication for patients with immune deficiency as we have seen in 
chapter 2.1. Indeed, it represents more than 75 % of IVIg administrations in USA (Gelfand, 
2012). The indications approved for IVIg as anti-inflammatory therapy by the Food and Drug 
Administration (FDA) as in 2012 include Kawasaki syndrome, Chronic Inflammatory 
Demyelinating Polyneuropathy (CIDP), ITP and Multifocal Motor Neuropathy (MNN). The 
number of licensed indications for IVIg only account for half of the prescriptions (Looney and 
Huggins, 2006). This is explained by the increasing numbers of “off-labels” IVIg prescriptions 
(Kivity et al., 2010), notably for some of the most common autoimmune diseases where positive 
results have been reported in many cases, like for Grave’s disease (Antonelli et al., 1992; Leibe et 
al., 2001), Systematic lupus erythematosus (SLE) (Toubi et al., 2005; Zandman-Goddard et al., 
2005), as well as for many dermatological inflammatory diseases (Prins et al., 2007). There are 
only few exceptions so far for which IVIg treatment didn’t prove any benefit, such as for type 1 
diabetes (Colagiuri et al., 1996). Beneficial effects of IVIg also remain unclear for rheumatoid 
arthritis (RA) due to contradictory outcomes (Kanik et al., 1996; Tumiati et al., 1992). 
2.3. Medical Indications 
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Nevertheless IVIg has shown encouraging results in many other diseases in the field of 
rheumatology (Mulhearn and Bruce, 2015; Vaitla and McDermott, 2010). In 2008 more than 150 
of off-labeled uses of IVIg have been published (Leong et al., 2008), covering a wide range of 
autoimmune diseases in fields of dermatology, hematology, rheumatology, neurology, and 
transplantation. Some of them are recognized and therefore covered by US health insurance  
(Looney and Huggins, 2006). However care should be taken when interpreting results, since 
some of the published positive cases used IVIg as last option for refractory diseases, as well as 
studies resulting in ineffective treatment might not be systematically published with regards to 
the tendency of publishing only positive outcomes. Regarding potential future licensed 
indications of IVIg, more and larger clinical trials have to be undertaken.  
Administration of IVIg as a replacement therapy consists of a dose of 200-400 mg/kg body 
weight (Jolles et al., 2005), in order to achieve residual levels of IgG of at least 600 mg/dL to 
protect against pulmonary infections (de Gracia et al., 2004), one of the main complications in 
immunodeficient patients. These injections should be repeated every 3 to 4 weeks, as long as 
protection is necessary. However, achieving an anti-inflammatory effect during active phases of 
autoimmune or inflammatory diseases by using IVIg requires infusion of a much higher dose of 
1–3 g/kg body weight and is therefore considered as a high-dose therapy. This dose is also 
required to be given repeatedly each 3 to 4 weeks, in line with the half-life of IgG in human 
serum (Looney and Huggins, 2006). According to pharmacokinetics studies, the increase in 
serum IgG after IVIg treatment varies considerably between patients, showing large standard 
deviations. This of course also depends on the injection time frame which varies empirically 
between patients and diseases, as there are no specific guidelines for off-labeled indications. A 
recent study (Vlam et al., 2014) conducted with 23 patients affected with multifocal motor 
neuropathy showed that IVIg increased the total serum IgG levels in all patients after a first IVIg 
cumulative dose of 2.0 g/kg in 5 days, with a peak level at day 5 of the IVIg course of 
36.9 ± 7.8 g/L (mean ± SD). This represents an increase of about 3 fold compared to baseline 
before treatment. Three weeks after the infusions, IgG concentrations considerably dropped, but 
still remained higher than baseline (mean ∆IgG 5.4 ± SD 4.7 g/L). 74 % patients responded well 
to IVIg treatment and very interestingly mean ΔIgG was higher in IVIg responders than in non-
responders. This finding is in line with another study performed on patients with Guillain-Barré 
Syndrom and treated with 2.0 g/kg IVIg, which showed that the increase of serum IgG level 
significantly correlates with the disease recovery (Kuitwaard et al., 2009). 
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Improved quality and safety of the IVIg preparations in the past years making it a well-
tolerated treatment have certainly contributed to its increasing use in the clinic with a massive 
number of off-labeled indications. The worldwide consumption of IVIg increased by more than 
6-fold in ten years to reach more than 100 tons per year in 2010 (Imbach, 2012). The 
consumption of IVIg is increasing at an annual rate of 5 % in Europe and 11 % in the US. Canada 
is the world leading country in IVIg use and just behind is the US (Pondrom, 2014), with over 4 
million grams used in 2004 at a cost of $500 million (Nimmerjahn and Ravetch, 2007). The 
demand for IVIg therapy is ever-growing but its availability is limited, as it is a primary blood- 
and therefore finite- product, with number of blood donors as a major bottleneck. Another main 
limitation of IVIg is the high dose required for immunoregulatory properties. In general, the IgG 
yield is between 3.5 and 4.2 g/L plasma as 40 to 50 % of IgG are lost during the fractionation 
process (Buchacher and Iberer, 2006). Knowing that a blood donation is about 450 mL and that 
plasma accounts for 55 % (so 250 mL), it means that about 0.875-1.05 g/L IgG can be extracted 
from a single blood donation.  
This limited availability and the increasing use of IVIg for the treatment of more and more 
pathological conditions worldwide have resulted in shortages in supply. The first alarming 
shortage happened during the late 1990’s (Boulis et al., 2002) with a demand exceeding supply 
by about 30 % in 1998 (Bayry et al., 2007). Today, although the manufacturing processes have 
improved, IVIg still faces worldwide shortages so experts recommend the development of a 
priority system for its allocation (Pondrom, 2014).  As a results of this shortage and owing the 
increasing demand, the cost of IVIg has increased by 17 % from 2013 to 2014, and still continues 
to do so (Pondrom, 2014). The economic impact of IVIg is substantial: as an example in 2015 
Octagam 10 % (Octapharma) costs 77.8 CHF per gram. For an adult weighing 70 kg treated at 
2 g/kg this gives a price of 10 892 CHF for one single injection. In answer to the article of 
Pandrom and colleagues, Van Gent et al.  proposed to solve the IVIg shortage by developing 
cheaper IVIg “mimetics” recombinant compounds that target the IVIg receptors (van Gent and 
Kwekkeboom, 2015). 
2.4. Economic challenges 
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3. Potential mechanisms of IVIg – state of the art 
Considering the increasing costs and its supply shortage, the development of a possible 
replacement for IVIg would have a major impact on health economy. Despite its widespread use 
and broad efficacy, the mechanisms that confer IVIg its immunoregulatory properties in 
autoimmune and inflammatory disease conditions remain poorly understood. In the interest of 
developing new, safer and more effective anti-inflammatory treatments, understanding IVIg 
mechanism of therapeutic action has drawn a big interest in research. This is shown by the 613 
publications recovered in PubMed search for “IVIg” in December 2015, which is about a 2 fold 
increase within 10 years, as illustrated on Figure 8. There is evidence that both, the antibody Fab 
region and the Fc domain, might be involved in the immunomodulatory mechanisms of IVIg, and 
a broad range of mechanisms have been proposed so far, as illustrated on Figure 9, that we will 
review in the next sections. 
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Figure 8: Number of publications in PubMed for “IVIg”. As for December 2015. 
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Figure 9: F(ab′)2- and Fc-dependent pathways of IVIG activity. “Shown is an overview of the different pathways 
that have been implicated in intravenous immunoglobulin (IVIG)-mediated immunomodulation. F(ab′)2-dependent 
mechanisms include: the killing of target cells by antibody-dependent cytotoxicity (ADCC); the blockade of cell–cell 
interactions mediated by cell-surface receptors, such as CD95 and CD95 ligand (CD95L); the neutralization of 
cytokines; the neutralization of autoantibodies by anti-idiotypic antibodies; and the scavenging of the anaphylatoxins 
C3a and C5a. Fc-dependent pathways include: the saturation of the neonatal Fc receptor (FcRn); the expansion of 
regulatory T (TReg) cell populations; the blockade of immune complex binding to low-affinity Fcγ receptors 
(FcγRs); the modulation of dendritic cell activation via FcγRIII; and the modulation of activating and inhibitory 
FcγR expression on innate immune effector cells and B cells”. (Schwab and Nimmerjahn, 2013)   
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3.1.1.  Saturation of FcRn  
The neonatal Fc receptor (FcRn) is a specialized receptor that binds serum IgGs and 
protects them from degradation.  IgGs are picked up from plasma by endothelial and myeloid 
cells through pinocytosis and bind to FcRn present in the acidic endosomes. FcRn binds IgG at 
acidic pH of (<6.5) but not at neutral or higher pH. IgGs bound to FcRn are recycled to the cell 
surface and released into the circulation.  Without this protective mechanism, IgG would pass to 
the lysosome and be degraded. These specialized receptors account for the long half-life of serum 
IgG of 2-3 weeks. Thus, one possible mechanism postulated for IVIg is that the large dose of 
IgGs administered saturates the FcRn receptors and accelerates the degradation of circulating 
pathogenic autoantibodies (Yu and Lennon, 1999), as illustrated on Figure 10. 
 
Figure 10: Regulation of the Catabolism of 
IgG by FcRn. “A specialized intracellular Fc 
receptor, FcRn, that is abundant in 
endothelial cells binds pinocytosed IgG only 
in the acidic environment of the endosome. It 
releases intact IgG when its transport vesicle 
is redirected to the neutral pH of the cell 
surface. Unbound IgG is transferred to 
lysosomes for degradation. The saturation of 
FcRn in states of hypergammaglobulinemia 
accelerates the catabolism of IgG. This IgG-
depleting mechanism plausibly explains the 
temporary benefit of intravenous therapy 
with high doses of normal IgG in 
autoimmune diseases mediated by 
pathogenic IgG “. (Yu and Lennon, 1999). 
 
 
 
In mouse models of bullous pemphigoid and arthritis, IVIg treatment prevented blistering 
and resulted in a reduction in pathogenic antibodies whereas no additional protective effect was 
observed in FcRn-deficient mice (Li et al., 2005). Nevertheless, FcRn deficient mouse models are 
biased since the clearance of pathologic autoantibodies is modified and it is difficult to assess 
their pathologic effects. It is well exemplified in this study where FcRn-deficient mice were 
resistant to the autoantibody-mediated induction of skin blisters. An in vivo study in mice 
postulated that a single high-dose of IVIg reduced the concentration of a continuously infused 
3.1. Fc-dependent mechanisms 
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IgG1 monoclonal antibody (mAb) by 40 % after 3 days (Bleeker et al., 2001). These findings 
correlate with another study (Hansen and Balthasar, 2002) where a similar dose of IVIg in a rat 
model of ITP has been reported to be effective and to enhance the clearance of anti-platelet 
antibodies by a factor of 2.  When extrapolated to human, the model of Bleeker et al. predicted a 
decrease of autoantibody of about 25 %, 2 to 3 weeks after IVIg injection. This has been 
confirmed in patients with Lambert-Eaton myasthenic syndrome (Bain et al., 1996), where 
autoantibody levels gradually decreased by approximately 30 % 3 weeks after IVIg treatment, as 
well as in patients with systemic vasculitis (Jayne et al., 1993). However, in a more recent study 
of a murine ITP model, IVIg was still effective in increasing platelet counts in the absence of 
FcRn (Crow et al., 2011). Controls assessed the good binding in vivo of the antiplatelet antibodies 
to platelets in FcRn deficient mice, and they were equally well inducing ITP as in wild-type mice. 
Thus, the role of the FcRn receptor in conferring IVIg its protective mechanisms in autoantibody- 
mediated diseases is unclear. 
3.1.2.  Blockade of FcγRs 
Antibodies effector functions are crucially dependent on their interaction with the 
complement system as well as with Fc receptors. Phagocytes are activated by IgG antibodies 
which bind to their specific Fcγ receptors (FcγRs) on their surface. To distinguish antibodies 
bound to a pathogen from free circulating antibodies, low affinity FcγRs bind with higher avidity 
to multimerized antibodies bound to antigen than to monomers and only such a cross-linking can 
result in cell activation. FcγRs are crucial in mediating the effector functions of antibodies. 
Traditionally, these receptors are divided into 2 groups, based on their activating or inhibitory 
properties (Figure 11). Monocytes, macrophages, and DCs express several members of the FcγRs 
family on their cell surface and can co-express activating FcγRs with the inhibitory FcγRIIB 
(Guilliams et al., 2014).   
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Figure 11: The family of mouse and human FcγRs. “Depicted are the families of mouse (top) and human (below) 
canonical Fcγ receptors (FcγRs), which both consist of several activating receptors and one inhibitory receptor. In 
humans but not in mice, FcγRIIIB is exclusively expressed on neutrophils. The neonatal Fc receptor (FcRn) is 
responsible for the long half-life of IgG and belongs to the family of MHC class I molecules. Mouse DC-SIGN-
related protein 1 (SIGNR1) and its human orthologue DC-specific ICAM3-grabbing non-integrin (DC-SIGN) are 
also IgG-binding proteins and may be viewed as IgG glycoform-specific FcγRs. The particular requirements of these 
different receptors for IgG binding are indicated. Also shown are the functional outcomes of IgG binding to each 
receptor.” (Schwab and Nimmerjahn, 2013) 
 
FcγRs blockade was suggested as the mechanism by which platelet counts rapidly increase 
in patients with ITP after the administration of IVIg (Bussel, 2000; Crow and Lazarus, 2003), 
since platelets coated with anti-autoantibodies could not be cleared by cells whose FcγRs are 
saturated. Further supporting evidence for Fc receptor blockade was shown by an increase in 
platelet counts in patients with ITP using a monoclonal antibody directed against the FcγRIIIA 
receptor (Clarkson et al., 1986). Intravenous administration in children with acute ITP of Fcγ 
fragments prepared from plasma IgGs also resulted in a rapid increase in platelet counts (Debre et 
al., 1993).  
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The potency of IVIg in ITP patients could be explained by their capacity to inhibit 
phagocytosis in vitro in human macrophages. This inhibition most likely results from the direct 
blockade of FcγRs by IgG dimers that are present in IVIg preparations and have enhanced avidity 
for FcγRs (Nagelkerke et al., 2014; Teeling et al., 2001). However, it has also been observed that 
a human IgG preparation devoid of IgG dimers retained its therapeutic efficacy in a murine 
model of ITP (Tremblay et al., 2013), and that IVIg activity was not impaired in FcγRI and 
FcγRIII-deficient mice used in models of nephrotoxic nephritis and ITP (Kaneko et al., 2006a; 
Schwab et al., 2012a). This questions the relevance of IgG dimers in the efficacy of IVIg in ITP, 
as well as in other diseases. The main difficulty in investigating whether the blockade of FcγRs is 
relevant for IVIg immunomodulatory effects comes from the variability of FcR expression 
between mouse strains, which could explain the differences observed between the different 
studies. The expression of FcγRs also differs between mouse and humans and FcγR 
polymorphisms in humans might influence the efficacy of intravenous immunoglobulin therapy 
for patients with certain autoimmune diseases (Binstadt et al., 2003). Despite this FcγR 
variability, multimeric Fc molecules have been shown to efficiently protect in several disease 
models. Higher-order Fc-multimers demonstrated increasingly stable associations with the FcγRs 
and effectively treated collagen-induced arthritis and prevent ITP in mice (Bazin et al., 2006; Jain 
et al., 2012). Multimeric Fc molecules have also been successfully tested to rescue a murine 
model of myasthenia gravis at lower dose than IVIg (Thiruppathi et al., 2014). 
3.1.3.  Increased expression of inhibitory FcγRIIB 
The inhibitory low- affinity FcγRIIB is widely co-expressed with activating FcγRs on a 
variety immune cells, including macrophages and B cells. Cross-linking of FcγRIIB leads to a 
dominant-negative signal, resulting in cell inactivation. Combined with the triggering of 
activating FcγRs, both signals establish a threshold for cell activation in response to IgG immune 
complexes. This mechanism has been confirmed in FcγRIIB-deficient mice, which displayed 
elevated Ig levels after antigenic stimulation compared to wild-type, as well as a decreased 
threshold for mast-cell activation (Takai et al., 1996). Mice deficient in FcγRIIB have been 
shown to develop more severe autoimmune diseases, such as glomerulonephritis (Nakamura et 
al., 2000), AIA (van Lent et al., 2003), lung disease IC alveolitis (Clynes et al., 1999) and SLE 
(Yajima et al., 2003). In consequence, several studies addressed the hypothesis that FcγRIIB may 
play a role in the immune modulation of IVIg by promoting inhibitory signals within the immune 
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cells. This was first reported in 2001 in a study showing that FcγRIIB was up-regulated in the 
splenic macrophages of ITP mice after administration of IVIg and that FcγRIIB KO mice failed 
to respond to IVIG therapy (Samuelsson et al., 2001), which was confirmed by another study 
(Crow et al., 2003). Consistent with these findings, the anti-inflammatory activity of IVIg was 
abrogated in mice deficient in the inhibitory FcγRIIB in a variety of murine models, such as 
nephrotoxic nephritis (Kaneko et al., 2006a), K/BxN serum-induced arthritis (Anthony et al., 
2008b; Bruhns et al., 2003), and in the T cell-mediated experimental autoimmune 
encephalomyelitis (EAE) (Fiebiger et al., 2015). Interestingly, it has been observed that patients 
with CIDP expressed lower FcγRIIB levels on naive B cells when they remained untreated, and 
that IVIg therapy upregulated FcγRIIB expression on monocytes and B cells (Tackenberg et al., 
2009). 
Thus, modulation of FcγRIIB inhibitory signaling appears to be one of the potential 
mechanisms of IVIg. However, this theory seems quite ambivalent since the data mentioned 
above could not be fully reproduced by other research groups. Indeed, it has been shown that 
BALB/c FcγRIIB KO mice responded well to IVIg and ameliorated ITP whereas B6 did, but only 
to a lesser extend (Bazin et al., 2006). The role of FcγRIIB in IVIg efficacy was also questioned 
in another mouse study demonstrating that FcγRIIB is dispensable to ameliorate ITP upon IVIg 
injections in both BALB/c and B6 KO strains (Leontyev et al., 2012a). Nevertheless B6 mice 
required an IVIg dose 2.5 fold higher than the one used to treat BALB/c mice, showing that both, 
mouse background and IVIg dosage, are critical and can lead to misinterpretation in affirming the 
role of FcγRIIB in IVIg efficacy. Data from an in vitro study on activated human B cells argue 
against the involvement of FcγRIIB in the suppression of human tonsillar B cell activation by 
IVIg (Zhuang et al., 2002). In this study pre-incubation with IVIg failed to block binding of 
FcγRIIB-specific antibody. In addition, anti-FcγRIIB antibodies did not reverse inhibition of B 
cell proliferation or antibodies production by IVIg. A more recent study revealed that FcγRIIB is 
dispensable as IVIg could efficiently protect B6 FcγRIIB KO mice against EAE (Othy et al., 
2013). Therefore, the paradigm of FcγRIIB requirement in IVIg immunosuppressive functions 
remains questionable. 
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3.1.4. Sialylation on the Fc-fragment 
It has been well established that the Fc-mediated effects of antibodies are influenced not 
only by the antibody isotype, but also by Fc-linked carbohydrate structures (Arnold et al., 2007). 
Human IgG antibodies share a conserved N-glycosylation site within the CH2 domain of their Fc 
moieties, linked to the asparagine 297 (Asn297). As illustrated in Figure 12, this sugar side chain 
consists of a common biantennary glycan structure of four N-acetylglucosamine (GlcNAc) and 
three mannose residues, with variable additions of fucose, galactose, sialic acid, and/or bisecting 
GlcNAc residues. It has been shown that IgGs N-glycosylated structures, interposed between the 
heavy chains, are crucial for their biological activity. For instance, removal of galactose on IgGs 
confers an increased pro- inflammatory activity (Rademacher et al., 1994). In contrast, several 
studies demonstrated that the potent anti-inflammatory activity of IVIg is a direct result of Fc 
sialylation. 
 
Figure 12: Schematic diagram of the IgG N-linked glycan structures. “Eight main biantennary N-glycan 
structures can be identified. These comprised six neutral and two acidic (sialylated) glycans. The glycans are 
designated as G0, G1 and G2, according to the number of terminal galactose residues, and monosialylated and or A2, 
according to the number of terminal sialic acid residues that decorate the core pentasaccharide (GlcNAc2, Man3). 
Three of the glycans are fucosylated, giving rise to G0F, G1F and G2F structures. Monosialylation and 
monogalactosylation may occur on either the α1,3 or a α1,6 arm of the biantennary structures”.(Alavi et al., 2011). 
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In 2006, Kaneko and colleagues discovered that IgG antibodies with Fc domains carrying 
α2,6-linked sialylated N-glycans represent the anti-inflammatory portion of the IVIg (Kaneko et 
al., 2006b). Using a K/BxN serum-induced arthritis murine model, they showed that 
neuraminidase-treated IVIg, which renders them devoid of sialyic acid, were unable to inhibit the 
inflammatory process of arthritis. Another study demonstrated that in vitro α2,3-linked sialylation 
of IgG Fc did not result in anti-inflammatory activity (Anthony et al., 2008a). Since these specific 
Fc-α2,6-linked sialylated IgGs (sIgG) account for only 2-4 % of total IVIg, this would explain 
why such high doses are required to mediate therapeutic efficacy. When fractionating IVIg on a 
Sambucus nigra agglutinin (SNA)–lectin affinity column, the sialic-acid enriched fraction (SA-
IVIg) showed protection in the K/BxN arthritis model at only 1/10th of the dosage used with 
intact IVIg. Similarly to IVIg that has been shown to increase the expression of the inhibitory 
receptor FcγRIIB on effector macrophages (Bruhns et al., 2003), the mechanism of protection of 
the sIgG preparation was found to be similar (Kaneko et al., 2006b). A recombinant human IgG1 
Fc-sialylated has been engineered and shown to be effective at 33 mg/kg in the K/BxN arthritis 
model compared to native IVIg, effective at 1 g/kg (Anthony et al., 2008a). A more recent study 
confirmed these findings in four distinct murine models (two models of ITP using two distinct 
antiplatelet monoclonal antibodies, one model of inflammatory arthritis, and a model of the skin 
blistering disease epidermolysis bullosa acquisita pemphigus or EBA) (Schwab et al., 2014). 
Under both therapeutic and preventive application of IVIg, they demonstrated that the presence 
of both sialic acid on IVIg and the inhibitory FcγRIIB on macrophages was required for IVIg 
beneficial effects. The same group lately engineered a tetra-Fc–sialylated (s4-IVIg) IVIg drug 
candidate produced with IVIg as starting material which was enzymatically modified to 
maximize Fc sialylation (Washburn et al., 2015). This drug candidate revealed enhanced anti-
inflammatory activity up to 10-fold higher than IVIg across the same three animal models already 
cited above. The importance of sialylation was confirmed in another study where administration 
of sialic-acid enriched IVIg (SA-IVIg), but not non-SA-IVIg, to OVA-sensitized and intranasal 
OVA-challenged mice attenuated airway hyperresponsiveness and inflammation comparably 
with IVIg (Massoud et al., 2013). 
Anthony and colleagues have hypothesized that the anti-inflammatory mechanism of the 
sIgG fraction of IVIg is mediated through binding of the α2,6-linked sialic acid to a C-type lectin 
receptor, the SIGNR1, which is expressed primarily on splenic marginal zone macrophages in 
mice or on DCs in human (named DC-SIGN) (Anthony and Ravetch, 2010; Anthony et al., 
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2008b). Indeed, the sialylation of IgG Fc leads to a conformational change that would decrease 
the interaction with FcγRs but trigger DC-SIGN binding (Sondermann et al., 2013). Using their 
K/BxN arthritis model in mice, they further established that this interaction induced the 
production of IL-33 from the splenic marginal zone macrophages, leading to expansion of IL-4-
secreting basophils. Effector macrophages then respond by increasing expression of the 
inhibitory FcγRIIB, which shifts the response away from the damaging pro-inflammatory cascade 
(Anthony et al., 2011).  In line with the dominant expression of SIGNR1 on mouse splenic 
marginal zone macrophages, IVIg activity was also abrogated in splenectomized mice as well as 
with SIGNR1-blocking Abs or in mice deficient in SIGNR1 (Anthony et al., 2008b). However, 
the involvement of SIGNR1 in IVIg anti-inflammatory effects may not be limited to its 
expression on splenic marginal zone macrophages. Indeed, a study in splenectomized mice have 
shown that IVIg still mediates the suppression of antibody-dependent platelet depletion 
(Leontyev et al., 2012a). Similarly, another study also established that IVIg activity in ITP 
suppression was not impaired in splenectomized mice as well as in IL-33-receptor deficient mice 
or in basophil-depleted mice (Schwab et al., 2012a). Despite the lack of involvement of splenic 
resident cells, they showed that IVIg activity was still fully dependent on terminal sialic acid 
residues and SIGNR1, and therefore hypothesized that SIGNR1-positive cell populations outside 
the spleen are crucial for IVIg activity in murine ITP. Interestingly, the same group demonstrated 
in a recent study that SIGNR1 was required for IVIg to ameliorate ITP in mice only in 
prophylactic but not therapeutic conditions (Schwab et al., 2014). Some other mechanisms have 
also been proposed that could explain the relevance of the sialylation fraction in IVIg. For 
instance increasing sialylation on monoclonal antibodies IgG1 negatively impacted their cell-
surface antigen binding and subsequently lowered ADCC potency of human cells in vitro 
(Scallon et al., 2007). Another group identified that IVIg bound on DCs to the inhibitory C-type 
lectin DCIR (dendritic cell immune-receptor) and that inhibition of IgG internalization in DCs 
inhibits the effects of IVIg, but they ruled out any implication of SIGNR1 in this mechanism 
(Massoud et al., 2013).  
In contrast to the studies previously mentioned, several studies suggested that sialylation 
was not relevant for the effects of IVIg in a murine ITP (Leontyev et al., 2012b) or that  the 
protective effect of IVIg in arthritis models (K/BxN serum transfer as well as AIA) was linked to 
the Fc domain of IgG without the requirement of sialylation (Campbell et al., 2014). In an EAE 
model, it was also demonstrated that sialylation was dispensable for IVIg-mediated amelioration 
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of the disease (Othy et al., 2014). This could be explained by the fact that HPLC and 
crystallographic analyses observed no conformational changes to the Fc part upon sialylation that 
could account for the reported interaction with DC-SIGN (Crispin et al., 2013). It was also 
suggested that, rather than sialyation, it is the increased galactosylation on N-glycans which 
promotes the association between FcγRIIB and C-type lectin receptor dectin-1 (Karsten et al., 
2012). Furthermore, one can question whether the mechanism of action for IVIg reported by 
Anthony and colleagues in murine studies might play a role in the human situation. Neither DC-
SIGN nor sialylated IgG Fc fragments have been shown to be involved in the anti-inflammatory 
activity of IVIg on human DCs (Bayry et al., 2009). Phagocytosis has been studied in a human in 
vitro system and despite a remarkable inhibition by IVIg, recombinant Fc-sialylated IgG or SA-
IVIg were equally active as unsialylated IgG fractions, independently of FcγRIIB expression 
(Nagelkerke et al., 2014). The effect of IVIg on the inhibition of stimulated human T cells 
proliferation was not affected after neuraminidase treatment (Issekutz et al., 2015). IVIg 
treatment did not alter FcγRIIB mRNA expression in circulating human monocytes from 
Kawasaki patients (Abe et al., 2005) nor increased FcγRIIB expression in monocytes in children 
with ITP (Shimomura et al., 2012).  
In summary, 2-6-sialylated Fc may mediate the efficacy of IVIg in some mouse auto-
immune models but may not be relevant for others. The variation in the quality of IVIg batches, 
as well as the various mouse strains used may explain the conflicting results obtained by the 
different groups. Further investigations will be therefore needed to evaluate the contribution of 
the sialylation of IVIg in various auto-immune models. The mechanisms by which sialylation 
could lead to anti-inflammatory effects, as well as its relevance for human diseases, will also 
need to be clarified. 
3.1.5. Increase in number of regulatory T cells 
Protection of EAE by IVIg in a murine model has been associated with increase of 
peripheral CD4+CD25+Foxp3+ Tregs numbers (Ephrem et al., 2008) and these results have been 
confirmed in several recent study in murine EAE as well (Othy et al., 2013; Othy et al., 2014). 
Tregs purified from Herpes Simplex Virus infected mice and IVIg treated mice protected mice 
from fatal herpes simplex encephalitis (HSE) after adoptive transfer (Ramakrishna et al., 2011). 
Other data show that IVIg suppressed allogeneic T-cell responses to promote skin allograft 
acceptance by direct activation of Tregs, indicated by increased expression of HLA-DR, CD69 
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and CD38 and increased ZAP70 Phosphorylation (Tha-In et al., 2010). IVIg therapy in an 
intranasal ovalbumin sensitized mouse model of asthma showed that it markedly attenuated lung 
inflammation and that the draining pulmonary lymph nodes of IVIg treated mice showed a 
significant increase in Tregs (Kaufman et al., 2011). In a similar model, analogous results were 
reproduced and interestingly IVIg-primed DCs adoptively transferred to ovalbumin sensitized 
mice were also able to inhibit airway hyperresponsiveness and induce Treg cells (Massoud et al., 
2012). 
To draw an analogy to humans, Tregs have been analyzed in 11 patients with various 
autoimmune rheumatic disease, before and after IVIg treatment (Bayry et al., 2012). 6 patients 
had a significant increase in number of Tregs, with a mean delta of +5.7 % which represents a 3-4 
folds increase. Tjon and colleagues showed that high-dose, but not low-dose, IVIg treatment in 
patients enhanced the activation status of circulating Tregs, (increased of FoxP3 and HLA-DR 
expression), but interestingly the percentage of circulating Tregs remained unchanged (Tjon et 
al., 2013). Patients with Kawasaki disease (KD) showed lower Treg frequency (about 2-fold less, 
n=8) during the acute phase of disease as well as lower FoxP3 expression (Olivito et al., 2010), 
and both could be restored after IVIg therapy. Lack of Tregs among KD patients was also 
confirmed in another clinical study with a higher number of patients (n=18) and similarly Tregs 
were back to normal ranges after IVIg treatment (Hirabayashi et al., 2013). Importantly, this 
study highlighted that patients with a more severe reduction in the number of Tregs (25-fold 
lower compared to IVIg-sensitive patients) were associated with resistance to IVIg therapy. 
Thus, the ability of IVIg to influence Treg induction has been shown both in animal models 
and in human diseases and several potential mechanisms have been proposed (Kaufman et al., 
2015; Maddur et al., 2010). For example, Kaveri and colleagues demonstrated that the 
mechanism by which IVIg induces Treg cells was by the induction of cyclo-oxygenase dependent 
prostaglandin E2 (PGE2) from human dendritic cells (Trinath et al., 2013b). In their model 
system already mentioned in section 3.1.4 Massoud et al. reported that sIgGs induced Treg cells 
and attenuated airway hyperresponsiveness after binding to DCIR (Massoud et al., 2013). 
Interestingly, transfer of IVIg treated DCs from FcγRs KO mice still increased Treg cells and 
abrogated inflammation, suggesting that in this asthma model the effects of IVIg on Tregs were 
independent of FcγRs. The importance of Treg cells in the immune modulation induced by IVIg 
is also underlined by the studies of De Groot et al. (De Groot et al., 2008), who identified in 
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silico conserved Tregs epitopes named Tregitopes in both the IgG Fc and F(ab’)2 regions that 
bind to multiple MHC Class II determinants. When co-incubated with a specific antigen, 
Tregitopes suppressed immune response in vivo in mice and in vitro in human PBMCs toward 
this antigen, and resulted in the expansion of Tregs together with upregulation of IL-10 secretion. 
Although not studied directly in their model, they presumed that APCs play an important role in 
this pathway and by presenting Tregitopes on their surface they directly activate natural Tregs 
which in turn convert effector T cells in adaptive Tregs, therefore shifting the balance to immune 
tolerance. However, an independent study demonstrated that Tregitopes didn’t prevent or reverse 
type 1 diabetes in NOD mice (Grant et al., 2013). Therefore, more investigation is still required 
to elucidate the beneficial effects of IVIg in modulation of Tregs.  
  
 40 
 
Although a lot of studies emphasize the role of the IgG Fc-portion, it has also been reported 
that in several murine and in vitro human models the F(ab’)2 fragment of IVIg is involved in the 
immune modulation of the disease process.  
3.2.1.  Neutralization of autoantibodies 
Considering that IVIg preparations are generated from adults who have been vaccinated 
and have encountered a multitude of pathogens throughout their life, it is not surprising that IVIg 
contains IgG molecules specific for foreign antigens that account for its beneficial effect in 
replacement therapy for immunodeficiencies. On the other hand, one of the first explanations for 
its anti-inflammatory effect in autoimmune diseases was that there are anti-idiotypic antibodies 
present in IVIg preparations that neutralize the pathogenic auto-antibodies.  Indeed serum from 
healthy people contains natural antibodies of the IgG, IgM, and IgA isotypes, mostly 
autoantibodies generated in the absence of foreign antigens and selected by self-antigenic 
structures in the body. Therefore, these antibodies do not undergo affinity maturation and remain 
conserved throughout life in normal individuals. Natural autoantibodies are more polyreactive 
than immune antibodies, in the sense that they can often bind to different antigens (Coutinho et 
al., 1995). Thus, a considerable fraction of IVIg consists of antibodies capable of interacting with 
idiotypes (constituents of the variable region) of other antibodies.  
Affinity purified disease-specific anti-idiotypic antibodies from IVIg showed good 
therapeutical effects, as highlighted in several reviews (Seite et al., 2008; Svetlicky et al., 2013; 
Vani et al., 2008). For instance, the beneficial effect of target-specific IVIg has been proven in 
animal models of SLE (anti-dsDNA anti-idiotypes) (Shoenfeld et al., 2002), EAMG (anti- 
acetylcholine receptor anti- idiotypes) (Fuchs et al., 2008), or Pemphigus vulgaris (anti-
desmoglein 1+3 anti-idiotypes) (Mimouni et al., 2010). Others showed that pathogenic antibodies 
from patients’ serum could be neutralized by anti-idiotypes antibodies in IVIg preparations, such 
as anti-factor VIII (hemophilia) (Sultan et al., 1984), anti-GM1 (Guillain-Barré syndrome) (Yuki 
and Miyagi, 1996), or anti-thyroglobulin (thyroiditis) (Dietrich and Kazatchkine, 1990). These 
studies indicate that IVIg could be effective through anti-idiotypic antibodies, and the small 
proportion being specific for the disease of interest might explain the requirement of high doses 
of IVIg. 
3.2. Fab-dependent mechanisms 
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Efficacy of anti-pathogenic autoantigen antibodies present in IVIg preparation is largely 
disease-specific and might vary from batch to batch. Since IVIg have demonstrated beneficial 
effects in the treatment of a various range of diseases, it is more likely that some additional 
mechanisms play a role at the same time as well. 
3.2.2. Neutralization of various self-proteins 
Natural autoantibodies are reactive with a variety of serum and cells self-proteins. It has 
been demonstrated that IVIg contains low levels of autoreactive IgG antibodies that recognize a 
wide array of self-antigens. Direct binding of IVIg to some pro-inflammatory proteins will 
neutralize them, or in some cases it can promote cell death via activation of pro-apoptosis 
receptors. This includes: pro-inflammatory cytokines such as BAFF and APRIL, two potent B 
cells activators (Le Pottier et al., 2007) or GM-CSF, IFN-α, IL-1α (Wadhwa et al., 2000); pro-
apoptosis cell surface receptor such as Fas (induction of apotosis) (Prasad et al., 1998) or 
SIGLEC-9 and SIGLEC-8 (von Gunten et al., 2006; von Gunten et al., 2007); adhesion 
molecules involved in leukocyte trafficking (Vassilev et al., 1999); αβ T-cell receptor 
(Marchalonis et al., 1992); or against FcγRs (Bouhlal et al., 2014).  
3.2.3. Scavenging of complement components 
Given the potent pro-inflammatory activity of the complement components, this has been 
suggested in several studies as a potential pathway by which IVIg is able to block tissue 
inflammation. IVIg was shown to bind in an anti-idiotypic manner to several activated 
complement components such as C3a, C3b and C5a via its F(ab′)2 fragments, thereby attenuating 
complement-mediated tissue damage (Arumugam et al., 2007; Basta and Dalakas, 1994; Basta et 
al., 2003; Berger et al., 1985). 
In summary, various IgG molecules reactive against self pro-inflammatory proteins are 
present in IVIg preparations, but more work needs to be done to elucidate their contributions to 
IVIg beneficial properties in patients. 
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Immune cells are involved at several stages in the pathogenesis of autoimmune diseases 
and inflammatory disorders, therefore many studies were aimed at investigating whether IVIg has 
a direct effect on cells from the innate as well as the adaptive immune system. 
3.3.1.  Effects of IVIg on innate cellular immunity 
F(ab′)2 fragments of IVIg were shown to expand Tregs via induction of cyclooxygenase 
(COX)-2-dependent prostaglandin E2 (PGE2) in both human DCs and murine DCs in a model of 
EAE (Trinath et al., 2013b). It was shown that PGE2 may have a net inhibitory effect on the 
functional activity of maturing DCs by decreasing their ability to attract T cells (Kalinski, 2012). 
Another study underlined the role of IVIg in inhibiting TLR-mediated activation in human DCs 
(Bayry et al., 2009). Massoud et al. showed that IVIg binds directly to DCs via DCIR to be 
internalized, and that DCs were directly involved in the disease recovery since DCs cultured IVIg 
adoptively transferred to mice before OVA challenge induced Treg cells and inhibited AHR 
(Massoud et al., 2013). IVIg has been shown to inhibit the maturation of human DCs in vitro by 
downregulating expression of co-stimulatory molecules (Bayry et al., 2003; Qian et al., 2014). 
However, Tjon et al. observed the contrary effect in their experiments on human DCS: IVIg did 
not inhibit, but instead stimulated spontaneous maturation and increased sensitivity of human 
DCs to T-cell stimulation in a FcγRIIa dependent manner (Tjon et al., 2014). Similarly, the 
clinical effects of IVIg in ameliorating ITP involved interaction of IVIg with activating FcγRs on 
mouse DCs, and in contrast to the prevailing theories IVIg did not interact with the inhibitory 
FcγRIIB (Siragam et al., 2006). Masoud et al. showed that pulmonary DCs from IVIg-treated 
mice express altered Notch-ligand, including increased Delta-4 and reduced Jagged-1 levels 
(Massoud et al., 2012). However, another study indicated that IVIg does not modulate the 
expression of Notch ligands on activated human DCs (Trinath et al., 2013a).  
IVIg mediated neutrophils as well as eosinophil death in vitro by naturally occurring anti-
SIGLEC-9 and anti-SIGLEC-8 autoantibodies, respectively, present in IVIg preparations (von 
Gunten et al., 2006; von Gunten et al., 2007). In contrast, it was shown that human neutrophils 
exposed to IVIg showed increased levels of bacterial cell killing, phagocytosis, and autophagy 
(Itoh et al., 2015).  
3.3.  Modulation of immune cells 
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Tha-In et al. identified a pathway in which IVIg induced maturation of DCs, which 
activated NK cells, which in their turn mediated apoptosis of the IVIg-DCs by ADCC (Tha-In et 
al., 2007). They hypothesized that this mechanism downsized the antigen-presenting pool and 
therefore inhibited T-cell priming. Moreover, beneficial effects of IVIg treatment in patients with 
Kawasaki disease have been shown to be accompanied by increased NK cell activity in 
peripheral blood (Finberg et al., 1992). 
3.3.2.  Effects of IVIg on adaptive cellular immunity 
Results of in vitro and in vivo studies have shown diverse and sometimes contradictory 
effects of IVIg on B cells. Data obtained with purified human B cells showed that IVIg was not 
capable of directly inhibiting B cell proliferative responses, unlike T cell responses (Heidt et al., 
2009). In line, a recent study demonstrated that inhibitory effect of IVIg on T cells activation in 
vitro was not dependent on B cells (Issekutz et al., 2015). However, some other data indicated 
that human B cells are resistant to immunomodulation by IVIg-treated DCs, but that IVIg directly 
inhibited B cell activation and proliferation (Maddur et al., 2011). A direct interaction of IVIg 
with B cells was shown to occur through CD22, resulting in BCR modulation and induction of 
apoptosis in mature human B cells in vitro (Seite et al., 2010). The apoptosis theory was also 
supported by a study in patients suggesting that IVIg therapy may constrain antibody responses 
by inducing B cell depletion through differentiation into CD21-low B cells that undergo 
accelerated apoptosis (Mitrevski et al., 2014). Opposing results were found when using mice 
deficient in B cells or CD22, showing that neither B cells nor CD22 are critical for the anti-
inflammatory activity of IVIg in mouse models of rheumatoid arthritis and ITP (Schwab et al., 
2012b). Another theory arose regarding IVIg effect on B cells, suggesting that it induces a 
silencing program similar to anergy rather than apotosis (Seite et al., 2013; Seite et al., 2011). In 
contrast, some other data provided evidence for stimulation of both splenic B and CD4+ T 
lymphocytes after i.v. administration of IVIg at high dose in BALB/c mice (Sundblad et al., 
1991). 
In an EAE model, both IVIg and its F(ab′)2 fragments accounted equally well to the 
beneficial effect of the therapy, by modulating the polarization of CD4+ T cells towards Tregs 
and decreasing infiltration of effector T cells in the CNS by sequestering them in lymph nodes 
(Othy et al., 2013). Addition of IVIg to human T cells in vitro inhibited anti-CD3 and tetanus 
induced proliferation in a dose dependent manner and also prevented IL-2 secretion (Amran et 
 44 
 
al., 1994). Further investigations indicated that the inhibition of IL-2 production by IVIg occurred 
post-transcriptionally and had no effect on the levels of IL-2 mRNA. (Modiano et al., 1997). A 
more recent study confirmed these findings, showing that IVIg dose-dependently inhibited T cell 
proliferation to anti-CD3 stimulation on human PBMCs as well as a broad range of cytokines 
secretion (Issekutz et al., 2015). However, in rat models of EAE and AIA, administration of IVIg 
lead to intact or enhanced T-cell proliferative responses to antigens specific to the disease but led 
to decreased production of the inflammatory cytokine TNF-α (Achiron et al., 1994). Some studies 
claim that  IVIg exerts its anti-inflammatory effects by acting directly on T cells  in the absence 
of accessory cells (MacMillan et al., 2009; Tawfik et al., 2012), whereas others challenged this 
notion suggesting that T cell modulation is the indirect consequence of a direct effect of IVIg on 
APCs (Padet and Bazin, 2013; Padet et al., 2011). Thus, the mode of action by which IVIg 
inhibits adaptive immune cell activation is, so far, not completely elucidated and probably 
involves multiple pathways. 
As discussed above it was shown that IVIg inhibited both the in vivo and in vitro antigen-
specific T-cell responses but whether this effect is a consequence of a direct interaction or not 
remains unclear. Some recent evidences indicated that the suppressive effect of IVIg of T cells 
might be an indirect consequence of a reduction in the antigen presentation ability of APCs. 
Aubin and colleagues demonstrated that DO-11.10 cells (TCR transgenic T cells for OVA) 
incubated together with P388D1 cells (macrophage-like cell line) and OVA decreased their IL-2 
secretion in the presence of IVIg (Aubin et al., 2011). Using flow cytometry, they observed that 
IVIg inhibited the uptake of OVA-immune complexes by P388D1 cells but not the uptake of 
native OVA. With the same method they showed that IVIg decreased the amount of MHC: 
peptide complexes presented on the APC surface. They demonstrated that the overall inhibitory 
effect was FcγR independent. In another study, CD40-activated B cells were co-cultured DO-
11.10 cells in presence of native OVA and IVIg (Paquin Proulx et al., 2010). They showed that 
IVIg inhibited IL-2 secretion, and since IVIg didn’t affect the level of MHC-II expression on B 
cells, they deduced that IVIg inhibited antigen presentation. Addition of HSA to activated B cells 
did not significantly decrease IL-2 secretion, and flow cytometry showed that IVIg bound to the 
B cell surface more efficiently than HSA. Therefore the authors suggested a positive relationship 
between the extent of IVIg internalization and inhibition of antigen presentation. Further studies 
3.4. Inhibition of antigen presentation 
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reported that IVIg-mediated inhibition of uptake and processing of antigens was associated with 
an increased accumulation of lipid in DCs, suggested to promote tolerogenic properties (Othy et 
al., 2012). Additional data supported the notion that such high IVIg doses suggest that only a 
small fraction of IgG is responsible for the anti-inflammatory effects, and underlined the role of 
naturally occurring cationic IgGs. Indeed they demonstrated by intracellular fluorescence staining 
followed by flow cytometry that highly cationic IgG molecules present in IVIg are internalized 
more efficiently than IVIg in mouse P388D1 cells. These highly cationic IgG also showed 
improved inhibition of OVA presentation by APCs as determined by the reduction in IL-2 
secretion by T cells (Trepanier et al., 2012). 
 
4. Aim of the thesis 
We have seen that there is an increasing number of studies examining the potential mode of 
action of IVIg as an anti-inflammatory agent, but the majority of them leads to contradictory 
results.  Such disparities could be attributed to differences in experimental approaches, animal 
models, IVIg source, route and timing of IVIg administration, mouse strain and other variables 
such as the involvement of different anti-inflammatory pathways in humans and mice. The 
difficulties that emerge to establish a common mechanism may also account from the fact that 
IVIg therapy targets a broad range of inflammatory diseases with etiologic and pathologic 
profiles that largely differ from one another. There have been many pathways published from the 
innate and adaptive immune systems to be potentially targeted by IVIg, but to date there is no 
convincing evidence that any of these postulated mechanisms account for all its therapeutic 
benefits. In light of these results, the mechanism by which IVIg mediates its anti-inflammatory 
activity remains an open question. 
The aim of the thesis was to investigate whether IVIg has a direct impact on immune cell 
populations in vivo in mice. More specifically, we wanted to characterize the cells that are 
affected by IVIg treatment, to understand how this effect could explain the immunomodulatory 
properties of IVIg. The first part of the thesis aimed at establishing a quick but robust 
immunization model in mice with ovalbumin (OVA), and to see whether IVIg can efficiently 
downregulate the antibody response against OVA. Since this model appeared to be suitable to 
reproduce the inhibitory effects of IVIg on the OVA-specific response, we next determined 
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which cell populations were affected by IVIg injection by examining various cell surface 
markers. Size of the lymphoid organs and formation of germinal centers were also compared 
between animal groups treated with or without IVIg. Of specific interest, comparison with a 
human monoclonal IgG antibody, adjuvant dependency and IVIg dose dependency were 
investigated. Moreover, effects of IVIg in TI antigen-immunized mice were studied to clarify 
T cell involvement in the mediation of IVIg effects. In the second part of the thesis, we addressed 
the question whether mice were able to mount an efficient antibody response against IVIg and on 
which IgG regions this response was focused. It was also investigated whether IVIg had an effect 
on the total IgG present in mouse serum. Additional analyses were conducted on the bone 
marrow to examine the number of Ig-secreting cells (ISC), as well as to explore any changes in 
the different B cell populations upon IVIg administration. These studies were performed to 
understand if IVIg might act by inhibiting the differentiation of OVA-activated B cells into 
plasma cells. The last part of the thesis includes a series of key control experiments that were 
conducted to exclude any other parameter that could interfere with the interpretation of the 
results, such as the formulation of IVIg, the use of the antigen or the adjuvant. Finally, we 
propose a model in line with the data obtained, that describes the likely sequence of events that 
may be responsible for the inhibitory properties of IVIg in an antigen-specific antibody response. 
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 Material and Methods 
 
1. Mouse experiments 
All animal experiments were performed in accordance with the Federal and Cantonal laws of 
Switzerland. Animal protocols were approved by the Cantonal Veterinary Office of Baselstadt, 
Switzerland 
Mice C57Bl/6NCrl were obtained from Charles River, France. All mice were used at an 
age of 7-11 weeks. Mice were immunized 3 times once a week s.c in the neck with 50μg 
OVA/mouse (Invivogen; ref. vac-efova) together with adjuvant as described on Figure 13. The 
following adjuvants were tested: AddaVax™ (MF59) at 1:5 v/v in 600 μL (Invivogen; ref. vac-
adx-10), Aluminum Alhydrogel® 2 % at 1:5 v/v in 600 μL (Invivogen; ref. vac-alu-250), 
LT (R192G/L211A) at 5 μg/mouse in 500 μL, a double mutant heat-labile toxin from Escherichia 
coli, (kindly provided by Prof. J. D. Clements, Tulane University School of Medicine, USA), 
CpG ODN 2395 VacciGrade™ (unmethylated CpG motifs oligodeoxynucleotides) at 50 
μg/mouse in 500 μL (Invivogen; ref. vac-2395-1), MPLA-SM VacciGrade™ (Monophosphoryl 
Lipid A from Salmonella minnesota R595) at 20 μg/mouse in 500 μL (Invivogen; ref. vac-mpla). 
Eventually the following compounds were co-injected in the same solution to be tested 
individually: IVIg (Octagam 10 %; Octapharma), Avastin (Bevacizumab; Roche) or Vectibix 
(Panitumumab; Amgen) at 50mg/mouse, and Tregitope peptides published by De Groot (De 
Groot et al., 2008) or peptides identified with the in-house MAPPs assay (see section 2.5) at 25 or 
50 μg/mouse each as indicated. All injections volumes were completed to 500 μL or 600 μL as 
indicated above with DPBS (Gibco Invitrogen; ref. 14190-094). In the context of control 
experiments, we tested injection of BSA (50 μg/mouse; Sigma ref. A7979) or LPS (25 μg/mouse; 
Invivogen ref. vac-3pelps). Also as control, IVIg was centrifuged on an Amicon® Ultra 
centrifugal filter with a 30kDa cut-off (Merck Millipore; ref UFC903024), and flow-through was 
injected to mice (same volume as IVIg). Injections were performed with BD Microlance Needles 
26G x 0.5''/13mm ref. 3038009 and Primo syringes (1mL, ref. 62.1002). Mice were marked and 
their weight was controlled twice per week. Mice were terminated 24h after the last injection. 
1.1. Mice immunization 
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Figure 13: Mouse immunization protocol. 
 
On the day of termination mice were anesthetized with Isoflurane (AbbVie; ref. B506) 4 % 
inhalation (supporting gas: O2). Blood was collected via the retro-orbital path using 20 μL 
minicaps
®
 disposable capillary pipettes (Hirschmann®; ref. 9000120) and placed in Micro tubes 
containing serum gel with clotting activator (1.1 mL Z-Gel; Sarstedt; ref. 41.1500.005). Animals 
were sacrificed by CO2 inhalation. Death was confirmed by palpation of the heart and dim eyes. 
Spleen and lymph nodes as well as bone-marrow were dissected out and immediately placed on 
ice in a 12-well plate (Corning; ref. 3513) containing 2 mL of complete Iscove’s media (Iscove`s 
Modified Dulbecco's Medium (IMDM) Invitrogen ref. 12440046; 1X Glutamax Invitrogen ref. 
31980048; 10 % FCS Invitrogen ref. 161140071; 1 % penicillin/streptomycin Invitrogen ref. 
15140122;  50 µM Beta-mercaptoethanol Invitrogen ref. 31350; 1x MEM non-essential amino 
acids Invitrogen ref. 11140; 1 mM sodium-pyruvate Invitrogen ref. 11360). Micro tubes 
containing blood were centrifuged at 2500 x g (model 5810R, rotor A-4-62; Eppendorf) for 15 
min at 10 °C, and serum was placed into a fresh 1.5 mL Eppendorf tube (ref) to be conserved 
at -20 °C. 
For spleen and lymph nodes cell suspension was obtained by disrupting organs through a 
40 μm nylon cell strainer (BD ref. 352340) thanks to the bottom of piston needle, and washed 
with 10 mL of media on top of a 50mL Falcon tube (BD ref. 352070). Bone- marrow was 
extracted by applying 1 mL of media inside the femur bone using a 27G needle on top of a nylon 
1.2. Necropsy 
1.3. Cells isolation from mouse organs 
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cell strainer. Cells were then disrupted as described above for spleen and lymph nodes. All 
samples were centrifuged at 350 x g (Eppendorf 5810R, rotor A-4-62) for 5 min at RT (room 
temperature). For spleen-derived cells, 1mL of red blood cells lysing buffer (Sigma ref. R7757) 
was apply and lysis was performed 5 min at RT upon agitation. 20 mL of media was added on 
top of the spleen cells and they were centrifuged at 350 x g for 5 min. Spleen cells were 
resuspended in 4 mL of media and lymph nodes or bone-marrow cells in 1 mL, diluted 1:10 in 
media and counted with the Vi-cell
TM
 XR (Beckman-Coulter).  
2E6 cells were transferred in a 96-well V-bottom plate (Corning ref. 3894) and centrifuged 
2 min at 2000 rpm at 4 °C (Eppendorf 5810R, rotor A-4-62). Cells were washed twice with 200 
μL of FACS Buffer (DPBS Gibco Invitrogen ref. 14190-094; 2 % FCS Invitrogen ref. 
161140071; 2 μM ETDA Gibco Invitrogen ref. 15575-038). FcγRs were blocked by resuspending 
cells in 25 μl of rat anti-mouse CD16/CD32 antibodies (BD clone 2.4G2 ref. 553141) diluted 
1:100 in FACS Buffer and incubating 5 min at 4 °C. Surface staining was performed by adding 
on top 25 μl of FACS Buffer containing a combination of the following antibodies (final 
concentration in the well is indicated for each antibody): CD3-Brilliant violet 510 1:50 
(BioLegend clone 17A2 ref. 100233), CD4-APC-Cy7 1:100 (BD Pharmingen clon GK1.5 ref. 
552051), CD8α-PE-Cy7 1:100 (eBioscience clone 53-6.7 ref. 25-0081-82), CD25-PercP Cy5.5 
1:100 (BioLegend clone 3C7 ref. 101912), CTLA-4-APC 1:50 (BioLegend clone C10-4B9 ref. 
106310), CD69-PE 1:50 (BD Pharmingen clone H1.2F3 ref. 553237), CD11c-PercP Cy5.5 1:50 
(BD Pharmingen clone HL3 ref. 560584), CD19-APC-CY7 1:100 (BD Pharmingen clone 1D3 
ref. 557655), I-A/I-E-Brilliant violet 510 1:500 (BioLegend clone M5/114.15.2 ref. 107635), 
CD86-APC 1:100 (eBioscience clone GL1 ref. 17-0862-81), CD83-FITC 1:100 (eBioscience 
clone HB15 ref. 11-0832-82), CD80-PE-Cy7 1:100 (eBioscience clone 16-10A1 ref. 25-0801-
82), CD45R/B220-PE-Cy7 1:100 (BioLegend clone RA3-6B2 ref. 03222), CD40-FITC 1:50 (BD 
Pharmingen clone Mrz 23 ref. 561845), CD43-APC 1:50 (BioLegend clone S11 ref. 143208), 
IgD-APC-efluor 780 1:100 (eBioscience clone 11-26c ref. 47-5993-82), CD21-PE 1:100 
(BioLegend clone 7E9 ref. 123410), CD23-FITC 1:100 (BD Pharmingen clone B3B4  ref. 
553138), CD19-Brilliant violet 510 1:100 (BD Pharmingen clone 1D3 ref. 562956), IgM-PercP-
eFluor 710 1:100 (eBioscience clone II/41 ref. 46-5790-82), fixable viability dye-efluor 450 
1:1000 (eBioscience ref. 65-0866-14). All antibodies were incubated 30 min or overnight at 4 °C.  
1.4. Antibody staining and flow cytometry 
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Cells were then washed twice with 200 μL FACS Buffer, resuspended in 100 μL of 
Fixation/Permeabilization concentrate (eBioscience ref. 00-5123-43) at 1:4 in diluent 
(eBioscience ref. 00-5223-56), and incubated at 4 °C for 30 min. Cells were washed twice with 
200 μL FACS Buffer and resuspended in 150 μL of FACS Buffer. For intracellular staining, after 
the fixation/permeabilization incubation, cells were washed twice with 200 μL of 1X 
permeabilization buffer (eBioscience ref. 00-8333-56), resuspended in 25 μL of 1X 
permeabilization buffer and incubated with 25 μL of FoxP3-FITC 1:50 final (eBioscience clone 
FJK-16s ref.72-5775-40) diluted in permeabilization buffer for 30 min at 4 °C. Cells were 
washed twice with 200 μL permeabilization buffer and resuspended in 150 μL of FACS Buffer. 
Flow cytometry measurements were performed on a FACS Canto II instrument (BD) and 
the data were analyzed with FlowJo software (Tree Star).  
After necropsy organs were frozen in biopsy holders (Cryomold®; Medite; ref. 81-0785-
00) containing OCT compound (Tissue-Tek®; Sakura; ref. 4583) by being placed directly on dry 
ice and later on transferred to a -80 °C deep freezer. Sections of 5 μm were cut using a cryostat 
(Hyrax C50; Zeiss) and applied on slides (SuperFrost® Plus; VWR ref. 631-0108). Slides were 
air-dried 1 h at RT before being kept at -80 °C.  
Prior to staining, slides were thawed 1 h at RT to avoid water condensation on tissues. The 
tissue zone was delimited on the slide using the ImmEdge hydrophobic barrier pen (Vector Lab; 
ref. H-4000). Tissues were fixed 10 min in PFA 4 % (Sigma; ref. 16005; diluted in DBPS), rinsed 
5 min under tap water, and washed in PBS-Tween 0.05 % (Calbiochem; ref. 524653; 1 tablet for 
1L ddH2O) twice 5 min. Blocking was performed by covering the slide with drops of Image-IT 
FX Signal Enhancer (Life Technologies; ref. I36933). After 30 min incubation at RT, slides were 
washed twice 5 min in PBS-Tween 0.05 %. Primary anti-mouse antibodies were diluted in IHC 
diluent (Enzo; ref. 950-244-0250) as follows: rat anti-mouse T- and B-cell activation antigen-
FITC at 10 μg/mL (BD; clone GL7 ref. 562080), PNA-biotin from Arachis hypogaea at 
10 μg/mL (Sigma; ref. L6135-1MG) polyclonal rabbit CD3ε at 10 μg/mL (Abcam; ref. ab49943), 
rat CD45R at 1 μg/mL (Serotec; clone RA3-6B2 ref. MCA1258GT), Armenian hamster CD11c-
biotin at 10 μg/mL (BioLegend; clone N418 ref. 117304), OVA-FITC at 10 μg/mL (Molecular 
Probes; ref. O23020), rabbit polyclonal anti-human IgGs at 10 μg/mL (Jackson; ref. 309-005-
1.5. Immunofluorescence 
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082), goat polyclonal anti-mouse IgGs at 10 μg/mL (LifeSpan; ref. LS-C60700-2000). 400 µl of 
primary antibodies mixture were applied per slide and incubated overnight at 4 °C.  
Slides were washed twice for 5 min in PBS-Tween 0.05 %. Secondary antibodies were all 
diluted 1:200 in IHC diluent (Enzo; ref. 950-245-0100) and were the following: mouse anti-
FITC-Alexa Fluor® 488 (Jackson; ref. 200-542-037), streptavidin-Alexa Fluor® 647 (Life 
Technologies; ref. S21374), donkey anti-rabbit-Alexa Fluor® 594 (Jackson; ref. 711-585-152), 
donkey anti-rat-Cy3 (Jacskon; ref. 712-165-150), streptavidin-Alexa Fluor® 594 (Life 
Technologies; ref. S11227), donkey anti-goat-Alexa Fluor® 647 (Jacskon; ref. 705-605-147), 
donkey anti-rabbit-Alexa Fluor® 488 (Jacskon; ref. 711-545-152). 400 μl of secondary 
antibodies mixture were applied per slide and incubated 30 min at RT. Slides were washed twice 
for 5 min in PBS-Tween 0.05 %.  
For counterstaining DAPI (Molecular Probes; ref. D1306) was diluted to 2 ug/ml in DPBS 
and 400 μl were applied per slide for 15 min at RT. Slides were washed twice for 5 min in PBS-
Tween 0.05 % and once for 5 min under tap water. Slides were subsequently mounted in 
Fluoromount™ Aqueous Mounting Medium (Sigma; ref. F4680) with coverslips (24 mm x 50 
mm; VWR; ref. 631-1574), air-dried at RT and cleaned with ethanol before being kept at 4 °C in 
the dark. 
Images were acquired with NanoZoomer 2.0 HT (Hamamatsu) and analyzed with 
NDP.view2 software (Hamamatsu). 
1.6.1. Mouse anti-OVA Ig 
Mouse OVA-specific IgG1 antibodies were measured using the kit from Cayman; ref. 
500830 and the instructions provided by the manufacturer were followed. Briefly, standard 
(mouse anti-OVA IgG1 provided in the kit) was serially diluted 1:2 in assay buffer to get a range 
of 8 standard points from 1.56 ng/mL to 200 ng/mL. Mouse serum samples were thawed and 
diluted in assay buffer as follows: 1:10 000 for mice terminated 2 weeks after the first bolus of 
immunization with adjuvant LT (R192G/L211A) or Aluminum, 1:50 000 with adjuvant MF59, 
1:2000 with adjuvant MPLA-SM and 1:500 with adjuvant CpG ODN 2395. 100 μL of standard 
and samples were applied on OVA precoated 96-well strip plate and incubated 2h at RT on an 
1.6. ELISA 
 52 
 
orbital shaker (Titramax 1000; Heidolph). Plates were washed three times with the plate washer 
BioTek ELx 405RS and 100 μL of goat anti-mouse IgG1 polyclonal antibody conjugated to HRP 
were added to each well for 1 h at RT with shaking. Plates were washed and 100 μL of TMB 
substrate solution per well were added for 15 min at RT with shaking, followed by 100 μL of 
HRP Stop solution. OD was acquired at a wavelength of 450 nm on a Versa max reader 
(Molecular Devices). Results were analyzed on the Softmax® Pro software (Molecular Devices) 
and data expressed as relative units compared to standard.  
Mouse OVA-specific total IgG antibodies were measured using the kit from Chondrex ref. 
3011, and the instructions provided by the manufacturer were followed. Briefly, plates were 
coated with 100 μL of OVA per well at 10 μg/mL and incubated at 4 °C overnight. Plates were 
washed three times with the plate washer BioTek ELx 405RS and 100 μL of blocking buffer 
were added to each well for 1 h at RT. Standard (mouse IgG, clone L-71 - Dr. Shin Yoshino of 
Kobe Pharmaceutical University) was serially diluted 1:2 in Solution C from 12.5 ng/mL to 
0.098 ng/mL. Mouse serum samples were thawed and diluted 1:10 000 in Solution C. After 
washing, 100 μL of standards and serum samples were added to each well and incubated 2 h at 
RT on an orbital shaker (Titramax 1000; Heidolph). Plates were washed, 100 μL/well of 
detection antibody (HRP-conjugated goat Anti-Mouse IgG polyclonal antibody at 100 ng/mL) 
was added for 1 h at RT. After washing, 100 μL/well of TMB solution was applied for 20 min at 
RT, followed by 50 μL of Stop Soltion (2N sulfuric acid). OD was acquired at a wavelength of 
450 nm on a Versa max reader (Molecular Devices). Results were analyzed on the Softmax® Pro 
software (Molecular Devices) and data expressed as relative units compared to standard. 
Mouse OVA-specific IgM antibodies were detected as follows. OVA (Invivogen; ref. vac-
efova) was diluted to 10 μg/mL in DPBS and plates (Greiner; medium binding, ref. 655001) were 
coated with 70 μL/well overnight at 4 °C. Plates were washed three times with the plate washer 
BioTek ELx 405RS with 300 μL/well of PBS-Tween 0.05 % (Calbiochem; ref. 524653; 1 tablet 
for 1 L ∆H2O), and blocked for 2 h at RT with 200 μL/well of FCS 10 % in DBPS. Mouse serum 
samples were thawed and diluted 1:100 in blocking buffer. Standard (mouse IgM anti-OVA; 
Chondrex Clone 2H11A8, ref. 7097) was serially diluted 1:2 in blocking buffer from 125 ng/mL 
to 0.12 ng/ml. 50 μL of serum and standards samples were added into each well and incubated 
overnight at 4 °C. Plates were washed and 50 μL/well of detection antibody (polyclonal goat anti-
mouse IgM coupled to Alcaline Phosphatase; Southern ref. 1021-04) diluted 1:500 in blocking 
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buffer were added for 2 h at RT under shaking (Titramax 1000; Heidolph). After washing, 
100 μL/well of substrate were added (p-Nitrophenyl Phosphate from Sigma; ref. N2765; add 1 
tablet of 20 mg for 20 mL of developing buffer prepared with Na2CO3 15 mM; NaHCO3 35 mM, 
NaN3 3 mM at pH 9.6) for 15 min at RT under shaking. OD was acquired at a wavelength of 405 
nm on a Versa max reader (Molecular Devices). Results were analyzed on the Softmax® Pro 
software (Molecular Devices) and data expressed as relative units compared to standard. 
1.6.2. Mouse anti-NP IgG and IgM 
Capture antigen, NP-BSA (ratio 41, Biosearch Technologies; ref. N-5050H-10) was diluted 
to 10 μg/mL in DPBS, and plates (Greiner; medium binding, ref. 655001) were coated with 
70 μL/well overnight at 4 °C. Plates were washed three times with the plate washer BioTek ELx 
405RS with 300 μL/well of PBS-Tween 0.05 % (Calbiochem; ref. 524653; 1 tablet for 1 L 
∆H2O), and blocked for 1 h at RT with 200 μL/well of FCS 10 % in DBPS. Mouse serum 
samples were thawed, diluted 1:500 in blocking buffer and added at 50 μL/well for 2 h at RT on 
an orbital shaker (Titramax 1000; Heidolph). After washing, 50 μL/well of detection antibody 
(polyclonal goat anti-mouse IgM coupled to Alcaline Phosphatase; SouthernBiotech ref. 1021-04 
or polyclonal goat anti-mouse IgG coupled to Alcaline Phosphatase; SouthernBiotech ref. 1030-
04) diluted 1:500 in blocking buffer were added for 1 h at RT with shaking. After washing 
100 μL/well of substrate were added (p-Nitrophenyl Phosphate from Sigma; ref. N2765; add 
1 tablet of 20 mg for 20 ml of developing buffer prepared with Na2CO3 15 mM; NaHCO3 35 
mM, NaN3 3 mM at pH 9.6) for 15 min at RT with shaking. OD was acquired at a wavelength of 
405 nm on a Versa max reader (Molecular Devices). 
1.6.3. Mouse total Ig 
Capture antibodies were polyclonal goat anti-mouse IgM (SouthernBiotech; ref. 1021-01), 
anti-mouse IgG adsorbed against human sera (SouthernBiotech; ref. 1030-01) or anti-mouse IgA 
(SouthernBiotech; ref. 1040-01). They were diluted to 10 μg/mL in DPBS and plates (Greiner; 
medium binding, ref. 655001) were coated with 70 μL/well overnight at 4 °C. Plates were 
washed three times with the plate washer BioTek ELx 405RS with 300 μL/well of PBS-Tween 
0.05 % (Calbiochem; ref. 524653; 1 tablet for 1 L ∆H2O), and blocked for 1 h at RT with 200 
μL/well of FCS 10 % in DBPS. Mouse serum samples were thawed and diluted in blocking 
buffer as follows: 1:20 for IgG2a detection, 1:2500 for IgG2b, 1:800 for IgG3, 1:15 000 for IgG1, 
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1:25 000 for IgG, 1:3500 for IgM and 1:600 for IgA. Mouse Ig isotypes standards 
(SouthernBiotech; ref. 5300-01) were serially diluted 1:2 from 1000 ng/mL to 0.98 ng/mL in 
blocking buffer. Serum samples and standards were added at 50 μL/well for 2 h at RT on an 
orbital shaker (Titramax 1000; Heidolph). After washing, 50 μL/well of the corresponding 
detection antibody diluted 1:500 in blocking buffer were added: polyclonal goat anti-mouse IgM 
coupled to alkaline-phosphatase (SouthernBiotech; ref. 1021-04), anti-mouse IgG adsorbed 
against human sera (SouthernBiotech; ref. 1030-04), anti-mouse IgG1 adsorbed against human 
sera (SouthernBiotech; ref. 1070-04), anti-mouse IgG2a adsorbed against human sera 
(SouthernBiotech; ref. 1080-04), anti-mouse IgG2b adsorbed against human sera 
(SouthernBiotech; ref. 1090-04), anti-mouse IgG3 adsorbed against human sera 
(SouthernBiotech; ref. 1100-04), anti-mouse IgA (SouthernBiotech; ref. 1040-04). Plates were 
incubated 1 h at RT with shaking. After washing 100 μL/well of substrate were added (p-
Nitrophenyl Phosphate from Sigma; ref. N2765; add 1 tablet of 20 mg for 20 mL of developing 
buffer prepared with Na2CO3 15 mM; NaHCO3 35 mM, NaN3 3 mM at pH 9.6) for 15 min at RT 
with shaking. OD was acquired at a wavelength of 405 nm on a Versa max reader (Molecular 
Devices). Results were analyzed on the Softmax® Pro software (Molecular Devices) and data 
expressed as relative units compared to standard. 
1.6.4. Mouse anti-IVIg Ig and anti-Avastin Ig 
IVIg (Octagam 10 %; Octapharma), Avastin (Roche), Avastin-Fc and IVIg-Fc (both 
internally produced, see section 5.6) were diluted to 1 μg/mL in DPBS and coated with 
70 μL/well in Greiner plates medium binding (ref. 655001).  IVIg-Fab and IVIg-(Fab’2) 
fragments  were diluted to 10 μg/mL in DPBS and coated with 70 μL/well in Costar plates high 
binding (ref. 9018). Coating occurred overnight at 4 °C. Plates were washed three times with the 
plate washer BioTek ELx 405RS with 300 μL/well of PBS-Tween 0.05 % (Calbiochem; ref. 
524653; 1 tablet for 1 L ∆H2O), and blocked for 1 h at RT with 200 μL/well of FCS 10 % in 
DBPS. Mouse serum samples were thawed and diluted in blocking buffer as follows: 1:500 to 
measure mouse anti-IVIg and anti-Avastin antibodies, 1:100 for anti-IVIg-Fc and 1:50 for anti-
IVIg-Fab or anti-IVIg-(Fab’2). Standard (mouse polyclonal IgG anti-human IgG (H+L), Jackson 
Immunoresearch; ref. 209-005-082) was serially diluted 1:2 from 125 ng/mL to 0.12 ng/mL in 
blocking buffer. Serum samples and standards were added at 50 μL/well for 2 h at RT on an 
orbital shaker (Titramax 1000; Heidolph). After washing, 50 μL/well of the corresponding 
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detection antibody diluted 1:500 in blocking buffer were added: polyclonal goat coupled to 
alkaline-phosphatase anti-mouse IgM (SouthernBiotech; ref. 1021-04), anti-mouse IgG adsorbed 
against human sera (SouthernBiotech; ref. 1030-04), anti-mouse IgG1 adsorbed against human 
sera (SouthernBiotech; ref. 1070-04), anti-mouse IgG2a adsorbed against human sera 
(SouthernBiotech; ref. 1080-04), anti-mouse IgG2b adsorbed against human sera 
(SouthernBiotech; ref. 1090-04), anti-mouse IgG3 adsorbed against human sera 
(SouthernBiotech; ref. 1100-04), anti-mouse IgA (SouthernBiotech; ref. 1040-04). Plates were 
incubated 1 h at RT with shaking. After washing 100 μL/well of substrate were added (p-
Nitrophenyl Phosphate from Sigma; ref. N2765; add 1 tablet of 20 mg for 20 ml of developing 
buffer prepared with Na2CO3 15 mM; NaHCO3 35 mM, NaN3 3 mM at pH 9.6) for 15 min at RT 
with shaking. OD was acquired at a wavelength of 405 nm on a Versa max reader (Molecular 
Devices). Results were analyzed on the Softmax® Pro software (Molecular Devices) and data 
expressed as relative units compared to standard. 
1.6.5. Competition assay 
Serum from mice injected 3 times weekly with 1mg/mL of IVIg was incubated with 10, 20 
or 50 mg/mL of IVIg or Avastin in a final volume of 20 uL. Samples were incubated 1 h at 37°C. 
IVIg-specific IgG and total mouse IgG were measured by ELISA as previously described. 
1.6.6. ELISPOT 
Capture antibodies (polyclonal goat anti-mouse IgG adsorbed against human sera, 
SoutherBiotech, ref. 1030-01; or polyclonal goat anti-mouse IgM, SoutherBiotech, ref. 1021-01) 
were diluted to 10 μg/mL in coating buffer (45.2 mM of NaHCO3 and 18 mM of Na2CO3). 
Capture antigen (OVA, Invivogen; ref. vac-efova) was diluted to 5 μg/mL in coating buffer. 
Nitrocellulose membrane plates (Millipore; ref. MAHA S4510 were coated with 70 μL/well, and 
incubated overnight at 4 °C. Plates were washed 3 times with 1X PBS by inverting the plates and 
eliminating carefully the wash solution by flicking the plates firmly several times face down onto 
a sheet of paper tissue. For blocking, 200 μL/well of PBS + 1 % BSA were added and incubated 
30 min at 37 °C. Blocking solution was eliminated carefully by flicking the plates firmly several 
times face down. Plates were then pre-incubated with 100 μL/well of complete B cell medium 
(RPMI, Invitrogen ref. 21875034; 1X MEM non-essential amino acids, Invitrogen ref. 11140; 1X 
Sodium Pyruvate, Invitrogen ref. 11360070; 50 µM Beta mercaptoethanol, Invitrogen ref. 1350; 
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1X Kanamycin, Invitrogen ref. 15160-047; 1X penicillin/streptomycin, Sigma ref. P4333; 10 % 
FCS Hyclone, Invitrogen ref. 10100-147), the same medium used to plate cells later. For 
measuring mouse total IgG and IgM secreting cells, cells obtained after mouse necropsy (see 
section 1.3 for cells isolation from mouse organs) were applied on the plate at 200 000, 40 000, 
8000, or 1600 cells/well in 100 μL of B cell medium. To measure the specific anti-OVA IgG 
secreting cells, cells obtained after mouse necropsy were plated at 200 000 cells/well in 100 μL 
of B cell medium, and half a plate was covered for each sample to increase the chances of 
detection of these very specific cells. Plates were incubated overnight at 37 °C. 
Plates were manually washed 4 times with PBS 0.25 % Tween 20 and 3 times with 1X 
PBS, before being rinsed once with distilled water (200 μL/well) for 5 minutes. Detection 
antibodies (polyclonal goat biotinylated anti-mouse IgG, SouthernBiotech, ref. 1030-08 or 
polyclonal goat biotinylated anti-mouse IgM, SouthernBiotech, ref. 1020-08) were diluted 1:2000 
in PBS + 1 % BSA, added at 70 μL/well and incubated 2 h at RT. Plates were washed 4 times 
with PBS 0.25 % Tween 20 and 3 times with 1X PBS. Streptavidin-HRP (SouthernBiotech, ref. 
7100-05) was diluted 1:400 in PBS + 1 % BSA, added at 70 μL/well and incubated 1 h at RT. 
Plates were washed as described above. The developing solution was prepared just before use by 
dissolving one tablet of AEC dye (Sigma; ref. A6926) in 1,6 mL of dimethylformamide (Sigma; 
ref. D4551). 200 μL of this AEC solution were then added to 9 mL of sodium acetate buffer (30 
mM of glacial acetic acid + 70 mM of sodium acetate hydrate) and filtered on a 0,45 nm filter 
(Corning; ref. 431220) before adding 4 μL of H2O2 (Sigma; ref. H1009). 70 μL of the developing 
solution were added into each well and plates were incubated in the dark at RT until individual 
spots could be visualized (approximately 10 min). Finally, plates were extensively washed with 
tap water and air-dried at RT. Plates were read on a CTL-ImmunoSpot® Analyzer (Cellular 
Technology Ltd) with the ImmunoCapture
TM
 Version 6.1 Software and spots were counted with 
ImmunoSpot® Professional Version 4.0. 
Balb/cByJ mice were purchased from Charles River (France) and used at the age of 8 weeks. 
Mice were sensitized on day-21 with a solution homogenate containing 2 mg/mL of methylated 
BSA (mBSA) (Sigma ref. A1009) in 5% glucose solution (B.Braun Medical; ref. 395147) + 1mL 
of Complete Freund Adjuvant (DIFCO Laboratories; ref. H37 Ra). Twice, 50 μl of this solution 
were injected intra-dermally in the back of the animal, once on each side respectively (these 
1.7. AIA model 
 57 
 
injections were kindly performed by Bernhard Jost, Novartis Institute for Biomedical Research, 
ATI, IPH). Mice were sensitized a second time on day-14 as described above. On day 0, mice 
were injected intra-articularly with 10 μl of mBSA 10 mg/mL with 5 % glucose in the right knee 
or with 10 μl of glucose 5%. Intra-articular injections were performed with the help of a stepper 
(Tridak; ref. 4001.010) (kindly done by Janet Dawson, Novartis Institute for Biomedical 
Research, ATI, IPH). In the prophylactic model, IVIg (Octagam 10 %; Octapharma) was injected 
at 50 mg/mouse sub-cutaneously in the neck on days -21, -14 and day 0, whereas for the 
therapeutic model, IVIg was injected at 50 mg/mouse sub-cutaneous in the neck on day 0 only. 
DBPS (Gibco Invitrogen; ref. 14190-094) was injected as control. Swelling of the knee was 
measured every 2-3 days as indicated with a digimatic caliper (Mitutoyo; ref. CD-15CP) (kindly 
done by Bernhard Jost).  
2. MAPPs assay 
MAPPs stands for MHC-II associated peptides proteomics and enables isolating and 
identifying naturally presented MHC-II associated peptides directly from human DCs or mouse 
PBMCs. MAPPs assay has been described by (Rombach-Riegraf et al., 2014), as illustrated on 
Figure 14. 
 
Figure 14: Illustration of MAPPs 
assay procedure for human DCs. 
“Monocytes are isolated from human 
buffy coats and differentiated to 
immature DCs in the presence of 
cytokines. Immature DCs are loaded 
with human IgGs and induced to 
maturation with LPS. After 24 hours, 
mature DCs are frozen. After lysis of  
mature DCs, HLA-DR:peptide 
complexes are isolated via 
immunoprecipitation using anti-HLA-
DR coated beads. After several wash 
steps, peptides are eluted from HLA-DR 
complexes by pH shift and analysed by 
nano LC-MS with subsequent sequence 
identification via SEQUEST database 
search.” (Rombach-Riegraf et al., 2014). 
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PBMCs were isolated from human buffy coats sampled from consented healthy donors 
(Swiss Red Cross, Bern) according to local ethical practice. Blood from one buffy coat was added 
to 160 mL of pre-warmed RPMI (Gibco Invitrogen ref. 31870-074) with 1000 units of Liquemine 
(Drossapharm) before being distributed in Leucosep® tubes (Greiner Bio One; ref. 227290) that 
have been pre-centrifuged quickly with 15.5 ml Ficoll Paque Plus (GE Healthcare ref. 17-1440-
03). Blood was centrifuged at 1000 x g for 10 min at 18 °C (Thermo Scientific™ Sorvall Legend 
XTR, rotor 75003667). Supernatant above the interphase was removed by aspiration and the 
PBMCs layer above the filter was recovered and washed several times with warm RPMI (340 x 
g, 5 min). Erythrocytes were lysed by adding 50 mL of pre-warmed ammonium chloride buffer to 
the cell pellet previously re-suspended (144 mM of NH4Cl + 18 mM of Tris at pH 7.2, sterile 
filtered). Cells were washed twice with RPMI and counted with the Vi-cell
TM
 XR (Beckman-
Coulter). 
The isolated PBMCs were washed and resupended in 600 μL of EDTA buffer per 1 E8 cells 
(0.5 % HSA Sigma; ref. A-3782-1G + 1 mM EDTA Gibco; ref.15575, in DPBS; Gibco ref. 
14190094). PBMCs were labeled with 50 μL/1E8 cells of human anti-CD14 microbeads (Milteny 
Biotech, MACS®, ref. 130-050-201) for 15 min at 4 °C.  After filtration of labeled cells through 
pre-separation filters (Miltenyi Biotech, ref. 130-041-407), CD14
+
 cells were magnetically 
separated with LS MACS® (Miltenyi Biotech, ref. 130-042-401) columns in a magnetic field. 
Cells were counted with the Vi-cell
TM
 XR (Beckman-Coulter) and resuspended to a concentration 
of 3 E
5
 cells/mL in DC medium (RPMI 1640, Gibco ref. 31870-025; 10 % FCS, Invitrogen ref. 
161140071; 1X Glutamax, Gibco ref. 35050-038; 1X non-essential amino acids, Gibco ref. 
11140-035; 1X Na-Pyruvate, Gibco ref. 11360-039; 1X Kanamycine, Gibco ref. 15160-047; 3 
ng/ml IL-4, R&D ref. 204-IL-050; 33 ng/mL GM-CSF, R&D ref. 215-GM-050). Monocytes 
were plates in cell culture dishes (Corning; ref. 430167) at 5.4 E
6
cells/plate and differentiated to 
immature DCs for 5 days at 37 °C and 5 % CO2.      
Immature DCs were induced to maturation by adding LPS at 1 µg/mL (Sigma, ref. 5886). 
For identifying well-presented peptides derived from IVIg, DCs were simultaneously loaded with 
IVIg (Octagam; Octapharma) at 2.5 nmol/mL. In the context of a competition assay for peptides 
2.1. Isolation of human monocytes 
2.2. Differentiation to human DCs and loading 
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presentation, DCs were simultaneously loaded with OVA at 14 nmol/mL and IVIg either at 14 
nmol/mL or at 117 nmol/mL (DCs stimulation for the competition MAPPs assay were kindly 
performed by Sascha Gottlieb, Novartis Pharma AG; TD NBEs; IBP). Unloaded DCs served as 
negative control. After incubation for 24 hours at 37 °C and 5 % CO2, DCs were harvested, 
washed in PBS, and cell pellets were frozen at -80 °C. 
Monoclonal antibodies specific for human HLA-DR molecules were generated in-house 
using the mouse hybridoma cell line L243. Protein A purified anti-HLA-DR antibody was 
immobilized on NHS-Mag Sepharose activated beads (GE Healthcare; ref. 28-9811-57) 
according to the manufacturer’s protocol and stored at 4 °C in DPBS containing 0.02 % sodium 
azide. For confirmation of HLA-DR depletion efficiency of the L243-conjugated beads, cell 
lysates before and after immunoprecipitation with the beads were analyzed by Western Blotting 
using the HLA-DR-specific mAb 1B5 (Lifespan Biosciences, ref. LS-B2858-50). 
For isolation of HLA-DR associated peptides, DC pellets were lysed 200 μL of hypotonic 
buffer containing 1 % Triton X-100 (Roche; ref. 11332481001) and protease inhibitor tablets 
(Roche; ref. 11836153001) for 1 hour at 4 °C on a horizontal shaker at 1100 rpm. After 
centrifugation, the lysate was incubated over night at 4 °C with L243-conjugated beads for 
immunoprecipitation. After washing with wash buffer (PBS containing  0.5 % Zwittergent) and 
several wash steps with distilled water, peptides were eluted from HLA-DR molecules by adding 
0.1 % trifluoracetic acid (Sigma; ref. 40967) at 37 °C, lyophilized using an Eppendorf 
Concentrator 5301 and stored at 4 °C. 
2.4. MHC-II peptides isolation from mouse lymphoid organs 
Monoclonal antibodies specific for mouse I-A molecules were generated in-house using the 
mouse hybridoma cell line Y-3P. Protein A purified anti-I-A antibody was immobilized on NHS-
Mag Sepharose activated beads (GE Healthcare; ref. 28-9811-57) according to the 
manufacturer’s protocol and stored at 4 °C in DPBS containing 0.02 % sodium azide. For 
confirmation of I-Ab depletion efficiency of the Y-3P-conjugated beads, cell lysates before and 
after immunoprecipitation with the beads were analyzed by Western Blotting using the I-A 
specific mAb generated in-house using the mouse hybridoma cell line KL295. 
2.3. MHC-II peptide isolation from human DCs 
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For isolation of I-Ab associated peptides, lymphoid organs from untreated C57Bl/6NCrl 
mice (Charles River) mice were smashed with a polytron (Kinematica PT 1600 E) in 500 μL of 
hypotonic buffer containing 1 % Triton X-100 (Roche; ref. 11332481001) and protease inhibitor 
tablets (Roche; ref. 11836153001) and lysed for 1 hour at 4 °C on a horizontal shaker at 1100 
rpm. After centrifugation, the lysate was incubated overnight at 4 °C with Y-3P-conjugated beads 
for immunoprecipitation. After washing with wash buffer (PBS containing  0.5 % Zwittergent) 
and several wash steps with distilled water, peptides were eluted from I-A  molecules by adding 
0.1 % trifluoracetic acid (Sigma; ref. 40967) at 37 °C, lyophilized using an Eppendorf 
Concentrator 5301 and stored at 4 °C. 
Lyophilized peptides were resuspended in hydrophilic buffer containing 5 % acetonitrile, and 
1.1 % formic acid and injected onto a self-packed fused-silica C18 reversed phase nano-HPLC 
column. Peptide identification was performed using liquid chromatography (nano capillary 
system, Dionex Corporation) on a reversed phase column connected to a mass spectrometer 
(LTQ Velos Orbitrap) via electrospray ionization (LC-ESI-MS/MS) (measurements kindly 
performed by Stephan Koepke, Novartis Pharma AG; TD NBEs; IBP). A database was created by 
combining either the human IPI (International Protein Index) v3.70 or the mouse IPI v3.87 with 
the NCBI Ig sequences (NCBI IgBLAST- retrieve Ig sequences). Peptides were identified using a 
database search approach with the SEQUEST algorithm. Peptides with a delta mass of <10 ppm 
to the expected mass, cross correlation values of XCorr > 1.8 for singly charged ions, > 2.3 for 
doubly charged ions, >2.8 for triply charged ions and > 3.3 for quadruply charged ions and a 
delta cross correlation (dCn) > 0.1 were considered as true hits. Peptides were aligned against a 
human or a mouse antibody sequence, respectively, using an in-house sequence alignment tool. 
Selected peptides as well as published peptides 289 and 167 (De Groot et al., 2008) were 
synthesized by ProImmune with a purity >90%. Lyophilized peptides were all dissolved in 
DMSO at 10 mg/mL followed by sonication for 20 min, and stored at -80 °C. 
  
2.5. Peptides identification and synthesis 
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3. Human T cell proliferation assays 
PBMCs were isolated as described in section 2.1. PBMCs were labelled with 1 μM CFSE 
(Invitrogen, ref. C34554) at a concentration of 1 E
6
 cells/mL in pre-warmed RPMI (Gibco 
Invitrogen ref. 31870-074) for 10 min at 37 °C in a 250 mL flask (Corning; ref. 734-1713) held 
vertically. Cells were then distributed in Falcon tubes (BD; ref. 352070) for being washed twice 
with 50 mL of warm RPMI (centrifugation 350 x g, 5 min, Thermo Scientific™ Sorvall Legend 
XTR, rotor 75003667). PBMCs were resuspended in X-Vivo 15 medium (Lonza; ref. BE04-
418F) supplemented with 10 % FCS (Invitrogen; ref. 161140071) and 1X Glutamax (Invitrogen; 
ref. 35050038), and counted with the Vi-cell
TM
 XR (Beckman-Coulter). Cell concentration was 
adjusted to 5E
6
 cells/mL and 1 mL/well were distributed in a 12-well plate (Corning; ref. 3513). 
Unlabelled cells were also prepared and plated at the same concentration to serve as 
compensation control for flow-cytometry. 
In order to induce T-cell proliferation, Tetanus Toxoid (TT) (Novartis Marburg; lot 
317705010) was added to a final concentration of 6 μg/mL per well. Potential inhibitors of TT-
induced T-cell proliferation were tested individually at the following final concentration in the 
well: IVIg (Octagam 10 %; Octapharma) at 6 mg/mL or 0.6 mg/mL; human Tregitopes 289 or 
167 (De Groot et al., 2008) or selected in-house identified peptides (MAPPs assay as described in 
section 2.5) at 10 μg/mL. The allergen birch pollen Betv1a peptide 
(TPDGGSILKISNKYHTKGDH; ProImmune) was used as a control peptide at 10 μg/mL. Since 
all peptides tested were dissolved in DMSO, TT with DMSO 0.1 % v/v served as a control. PHA 
(Sigma; ref. L1668) was used as a positive control for T-cell proliferation and was added to a 
final concentration of 1 μg/mL per well. Unstimulated cells served as negative control. Cells 
were incubated at 37 °C and 24 h later 1 ml of fresh complete X-Vivo 15 medium was added on 
top of each well. Cells were harvested on day 7. 
  
3.1. CFSE labelling  
3.2. Cell stimulation 
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On day 7, plates were centrifuged at 2000 rpm for 5 min (Eppendorf 5810R, rotor A-4-62). 
1 mL/well of supernatant was harvested and placed at -20 °C for ELISA measurement. Cells 
were resuspended by pipetting up and down and transported into a 96-deep well plate (Corning; 
ref. 3960),  centrifuged at 2000 rpm for 5 min, washed once with 300 μL of FACS Buffer (DPBS 
Gibco Invitrogen ref. 14190-094; 2 % FCS Invitrogen ref. 161140071; 2μM ETDA Gibco 
Invitrogen ref. 15575-038), and resuspended in 200 μL of FACS Buffer. 100 μL of this cell 
suspension were transferred to a V-bottom 96-well plate (Corning ref. 3894) and centrifuged 
2 min at 2000 rpm at 4 °C (Eppendorf 5810R, rotor A-4-62). Cells were washed twice with 
200 μL of FACS Buffer (DPBS Gibco Invitrogen ref. 14190-094; 2 % FCS Invitrogen ref. 
161140071; 2 μM ETDA Gibco Invitrogen ref. 15575-038). FcγRs were blocked by resuspending 
cells in 100 μL of 200 μg/mL of IVIg (Octagam; Octapharma) and incubating for 20 min at 4 °C. 
Cells were centrifuged and resuspended in 25 μL of FACS Buffer. Surface staining was 
performed by adding 25 μl of FACS Buffer containing a combination of the following antibodies 
(final concentration in the well is indicated for each antibody): CD3-Brilliant Violet 510 1:100 
(BioLegend clone OKT3; ref. 317331), CD4-APC-CY7 1:100 (BD Pharmingen clone RPA-T4; 
ref. 557871), CD25-APC 1:100 (BD Pharmingen clone 2A3; ref. 340907), fixable viability dye-
efluor 450 1:1000 (eBioscience; ref. 65-0863). All antibodies were incubated 30 min at 4 °C.  
Cells were then washed twice with 200 μL FACS Buffer, resuspended in 100 μL of 
Fixation/Permeabilization concentrate (eBioscience ref. 00-5123-43) at 1:4 in diluent 
(eBioscience ref. 00-5223-56), and incubated at 4 °C for 30 min. For intracellular staining, cells 
were washed twice with 200 μL of 1X permeabilization buffer (eBioscience ref. 00-8333-56), 
resuspended in 25 μL of 1X permeabilization buffer and incubated with 25 μL of Foxp3-PE 1:50 
(eBioscience clone 236A/E7; ref. 72-5774-40) diluted in permeabilization buffer for 30 min at 
4 °C. Cells were washed twice with 200 μL permeabilization buffer and resuspended in 150 μL 
of FACS Buffer. Flow cytometry measurements were performed on a FACS Canto II instrument 
(BD) with and the data were analyzed with FlowJo software (Tree Star). 
  
3.3. Antibody staining and flow cytometry 
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4. Data analyses 
Graphs and statistics were generated with GraphPad Prism software. 
5. IVIg versus Avastin and Vectibix analytics 
The analyses described below required specific technologies and have therefore all been 
performed in dedicated labs by a third party. Analyses were performed on IVIg (Octagam 10 %; 
Octapharma), Avastin (Roche) and eventually on Vectibix (Amgen). 
These measurements were kindly performed by Olivia Rossberg (Novartis Pharma AG; TD 
NBEs; IBP). Bacterial endotoxins were measured using the LAL test (Limulus Amebocyte 
Lysate). This assay is based on the biology of the horseshoe crab (Limulous), which produces 
LAL enzymes in blood cells (amoebocytes) to bind and inactivate endotoxin from invading 
bacteria by forming a clot. Here, a kinetic chromogenic assay was used in which a synthetic 
analog to coagulogen, the natural substrate, is used to measure the endotoxin mediated activation 
of the serine protease enzyme. The cleavage of this synthetic substrate by the activated pro-
clotting enzyme results in the release of the chromophore p-nitroaniline (pNA) that can be 
measured photometrically at a wavelength of 385 nm - 410 nm. Samples were diluted to 
1 mg/mL using endotoxin free ddH2O. For each measurement 4 x 25 µL of the diluted sample 
were loaded on a LAL test cartridge (Charles River Laboratories; ref. PTS2005) and measured on 
an Endosafe Portable Test System (Charles River Laboratories) according to the manufacturer 
instructions.  
These measurements were kindly performed by Jasmin Widmer (Novartis Pharma AG; TD 
NBEs; IBP). The LabChip GXII Electrophoresis Systems (Caliper LifeSciences) uses a single 
sipper microfluidic chip to aspirate protein samples directly from 96-well plates. Reduced as well 
as non-denaturated proteins are stained with a fluorescent dye and separated by gel 
electrophoresis directly on a chip. The protein is detected via its fluorescent label by laser-
induced fluorescence. The protein size and purity based on relative area percentage are compared 
to a ladder and marker calibration standard. Samples were diluted to a final concentration of 
1 mg/mL and if not possible, 5 μg of samples were analysed. The measurements were performed 
5.1. Endotoxin measurements 
5.2. Integrity of heavy and light chains in preparations 
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on the HT Protein Express LabChip (Caliper LifeSciences; ref. P/N 760499) and the chip was 
read on the LabChip GXII instrument (Caliper LifeSciences) following the manufacturer’s 
procedure.  
These measurements were kindly performed by Patrick Favrod (Novartis Pharma AG; 
TRD; PCA. The technique used to characterize aggregates in the samples was the micro-flow 
imaging (MFI), that is flow microscopy applied to sub-visible particulate analysis in protein 
formulations. The samples have been degassed prior to measurement to avoid the presence of air 
bubbles. After illumination has been optimized on 0.4 mL of sample, 0.9 mL of undiluted sample 
has been analyzed with MFI instrument (Brightwell Technologies Inc., ref. DPA4100) following 
the instructions of the manufacturer. For correct size and concentration determination, NIST 
(National Institute of Standards and Technology) traceable particle concentration standards were 
used (Duke Scientific Corporation, ref. CC25-PK). The concentration of the detected beads 
needed to be within 10 % of the declared concentration (3000 mL
-1
) for size ranges 4.5-5.5 μm 
and 9.0-11.0 μm and within 20% for size ranges 2-2.2 μm and 22.5-27.5 μm. 
These measurements were kindly performed by Christian Graf and Alicia Burr (Novartis 
Pharma AG; TD NBEsv; IBP). Briefly, 50 µg of protein were digested with 50 units of the 
Fabricator IdeS enzyme (immunoglobulin-degrading enzyme from Streptococcus pyogenes; 
Genovis), in digestion buffer (sodium phosphate pH 6.6) for 1 h at 37 °C.  Fabricator is a unique 
enzyme that specifically digests the hinge region of IgG, producing a F(ab')2 fragment and two Fc 
fragments. Digested fragments were then denatured and reduced by adding 5 M Guanidine 
hydrochloride and 40 mM TCEP and incubated for 1 h at 37 °C. Reduced antibody fragments 
were measured by LC-ESI-MS (H-Class UPLC, BEH C4 column, SYNAPT G2 Q-TOF) on a 
70 % Isopropanol/ 20 % acetonitrile/ 9.9 % water/ 0.1 % TFA gradient. For determination of the 
Fc-glycan profile, the obtained mass spectrum of the Fc/2 fragment was deconvoluted using the 
MaxEnt1 algorithm (MassLynx 4.1 or UNIFI 1.6 software). The intensity of the different Fc-
glycoform mass peaks (identity determined by exact mass) was taken for relative quantification 
of the main glycans. 
  
5.3. Measure of aggregates in preparations 
5.4. Fc-Glycan Profiling  
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These measurements were kindly performed by Simon Mittermeier and Torsten Kuiper 
(Novartis Pharma AG; TD NBEs; IBP). Cross-reactivity of the tested antibodies was assessed on 
a ProtoArray
®
 v5.1 (Life Technologie; ref. PAH05251020) coated with more than 9000 full-
length human proteins. Each tested antibody was incubated at 5 mg/mL and detection of binding 
was achieved by using a DyLight649 conjugated F(ab’)2 -goat anti-human IgG F(ab’)2 fragment 
specific (Jackson ImmunoResearch; ref. 109-496-006) following the manufacturer’s instruction. 
The different steps were performed on the HS 4800™ Pro Hybridization Station (Tecan) and the 
protein array was read on a PowerScanner™ (Tecan). Data were analysed with the GenePix® 
Pro 7 software (Molecular Devices). 
These experiments were kindly performed by Tina Buch, Yasmin Widmer, Dennis Ungan, 
and Paulina Baczyk (Novartis Pharma AG; TD NBEs; IBP). Fc and Fab fragments were 
generated from IVIg and Avastin by papain digestion (Roche). Briefly, IVIg or Avastin were 
added to a 20 mM succinic acid /35.1 mM NaOH, pH 6.0 solution in a 50 mL Falcon tube, 
together with an EDTA / L-cysteine solution at a final concentration of 1 mM. The papain was 
added to the reaction and the falcon tubes were placed in a water bath at 37 °C with shaking. 
After digestion, the reaction was stopped by adding an iodacetamide solution at a final 
concentration of 1.2 mM.  In order to separate the Fab and Fc fragments an affinity 
chromatography step was performed directly after the papain digest (Column: Atoll GmbH; 
Resin: MabSelect SuRe from GE Healthcare; System: ÄKTA Explorer from GE Healthcare). The 
column was equilibrated with 20 mM NaH2PO4/Na2HPO4, pH 7.0 and sample was loaded. 
Column was then washed with the same equilibration buffer and elution was performed with 
50 mM Acetic acid. After capturing the pH of the eluate was adjusted to pH ~5.0 with 1 M Tris 
right after elution from the column. Flow troughs containing the Fab fragments and eluates 
containing the Fc parts with potential undigested IVIg or Avastin were further polished by size 
exclusion chromatography. About 12 mg of each flow trough/eluate were concentrated to about 
0.5 mL using Amicon® Ultra Centrifugal filters (10 kDa cut-off; Merck Millipore) and loaded on 
a column Superdex™ 200 100/300 GL (GE Healthcare) with the ÄKTA Explorer system from 
GE Healthcare. Column was equilibrated with 50 mM NaH2PO4/NaOH, 150 mM NaCl, pH 7.0, 
5.5. Human protein chip 
5.6. Generation of Fc, Fab and (Fab’2) fragments 
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samples were loaded and elution was performed with the same equilibration buffer. 1 mL 
fractions were collected.  
F(ab’)2 fragments were generated from IVIg and Avastin by FabRICATOR® digestion 
(Genovis). 80 μg of antibodies (at 1 mg/mL) were digested in 50 mM NaH2PO4/NaOH, 150 mM 
NaCl, pH 7.0 in a 50 mL Falcon tube together with 268 units of FabRICATOR®. The Falcon 
tubes were placed in a water bath at 37 °C for 36 h with shaking. F(ab’)2 fragments were 
collected in the flow-through after an affinity chromatography step and further polished by size 
exclusion chromatography as described above.   
Purity of the different fragments generated was determined by the LabChip GXII 
Electrophoresis system (see method in section 5.2) and concentration was assessed by reversed 
phase chromatography. Identification of the various fragments was confirmed by mass check by 
LC-MS (kindly performed by Bjoern Hueber, Coralie Etter and reviewed by Christian Graf; 
Novartis Pharma AG; TD NBEs; IBP). 
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 Results  
 
1. IVIg effect on T and B cell populations in vivo in mice 
Mice were injected s.c with OVA together with adjuvant MF59, and IVIg doses ranging 
from 1 mg to 50 mg were injected simultaneously on the same site.  Mouse IgG response against 
OVA was measured by ELISA and results are shown in Figure 15.  
 
  
These results show that OVA immunization was efficient and an IgG response could be 
detected in mouse serum 15 days after the first injection (red bar in the graph).  IVIg lead to 
decreased amount of OVA-specific mouse IgG, and importantly this reduction was proportional 
to the dose of IVIg that was injected. The maximum tested dose of 50 mg of IVIg lead to a a 
reduction of 70% of the OVA-IgG antibodies. These data hereby demonstrate that a simple 
immunization mouse model could mimic in vivo the IVIg immunomodulation properties in a 
dose-dependent way, as reported in the clinic with patients affected with autoimmune diseases.   
1.1. IVIg inhibits anti-OVA response in vivo in a dose-dependent manner 
Figure 15: IVIg inhibits anti-OVA IgG response in 
vivo in a dose-dependent manner. C57Bl/6NCrl 
mice were injected 3 times weekly s.c in the neck with 
50 μg OVA and Adjuvant AddaVax® MF59 (red bar) 
and terminated 24h after last injection (15 days after 
the 1
st
 injection). IVIg doses ranging from 1 mg to 50 
mg were injected simultaneously as indicated and IgG 
mouse response against OVA was measured by 
ELISA performed on mouse serum. Values are 
expressed as relative units to standard. Results pool 
data from 2 independent experiments (n=6). Bars 
represent mean ± SD. n.d: not detected. Statistical 
significance was tested using one-way ANOVA with 
Dunnett’s correction. Each group was compared to the 
control group “Adj+OVA”. Star maker significant 
difference *: p < 0.05; **p<0 0.01; ***: p<0.001; 
****: p<0.0001.  
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Despite the inhibition of the OVA-specific humoral response, treatment with 50 mg of IVIg 
together with adjuvant surprisingly lead to an obvious increase in the size of secondary lymphoid 
organs such as spleen and draining lymph nodes (Figure 16A). This observation was further 
confirmed by the increase of weight that have been measured (Figure 16B). Spleen weight was 
slightly increased upon IVIg treatment, whereas brachial, axillary and cervical lymph nodes were 
2-fold larger.  
To determine whether this was accompanied by an increase in the B and T-cell number, B 
and T cell populations were characterized by flow cytometry. Absolute cell numbers were back 
calculated according to the cell count established after processing the organs. The number of B 
cells was consistently higher in mice treated with IVIg (Figure 16B). This was reflected by an 
increase of 10.1 E
6
 cells in the spleen, 6 E
6
 cells in the axillary and brachial lymph nodes and 
3.6 E
6
 cells in the cervical lymph nodes, compared to the OVA-treated group. The number of 
T cells was not increased in the spleen of IVIg-treated animals, but in lymph nodes both, the 
number of CD4 and CD8 T cells were elevated upon IVIg administration (2.3 E
6
 or 3.1 E
6
 cells 
more in the cervical lymph nodes and 1.4 E
6
 or 1.8 E
6
 cells more in the brachial/axillary lymph 
nodes for CD4 and CD8 T cells, respectively). The reason for CD8 T cells mobilization with 
IVIg is unknown, but most likely it could be attributed to cross-presentation by certain APCs, 
which are able to process and present extracellular antigens on MHC class I molecules. It has 
been shown that limited antigen degradation correlates with efficient cross-presentation (Joffre et 
al., 2012). Limited proteolysis could occur in APCs due to the high dose of IVIg that might be 
present in the endocytic compartments, thereby favoring the presentation of IVIg-derived 
epitopes on MHC class I and promoting CD8 T cell activation.  Taken together these data suggest 
a prominent activation of the immune system by IVIg, as indicated by T and B cell proliferation. 
Such effect was less pronounced upon OVA immunization, since a single protein will only elicit 
a very low number of epitope-specific immune cells, whose expansion is more difficult to detect 
in vivo. 
1.2. IVIg increases T and B-cell numbers in secondary lymphoid organs 
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Figure 16: IVIg increases the weight of lymphoid organs as well as B and T-cell number. (A) Pictures of spleen 
and draining lymph nodes from one representative animal in each group of treatment. (B) Spleen and lymph nodes 
were collected, weighed, and flow cytometry was performed on isolated cells (Adj MF59 was used for experiments). 
For weight, values are expressed as ratio to the “OVA+Adj” treated group. For cell numbers, values are expressed as 
absolute cell numbers. Cells were gated on lymphocytes. Dead cells were excluded using a viability fluorescent dye. 
B cells were gated on CD19+ cells and T cells on CD4+ or CD8+ cells. Bars represent mean ± SD. Data pool 4 
independent experiments (n=12). Statistical significance was tested using one-way ANOVA with Dunnett’s 
correction. Each group was compared to the control group “Adj+OVA”. Star maker significant difference *: p< 0.05; 
**p<0.01; ***: p<0.001; ****: p<0.0001.  
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As data reported above revealed that the weight of the lymphoid organs was increased and 
the number of B cells was elevated upon IVIg administration, the effect of IVIg on various B cell 
markers was specifically investigated. Increasing doses of IVIg ranging from 1 mg to 50 mg were 
administered to mice immunized with OVA 
IVIg increased the expression of co-stimulatory markers CD86 and CD83 on CD19+ B 
cells, as well the expression of the early activation molecule CD69, in both the spleen and 
draining lymph nodes (Figure 17). These effects occurred proportionally to the IVIg dose 
administered, with an increase of CD86, CD83 and CD69 of respectively 2.5, 1.7 and 1.6-fold, in 
cervical lymph nodes upon administration of 50 mg of IVIg. The weight of axillary/brachial and 
cervical lymph nodes was increased when mice received IVIg, and this effect was more 
significant with high doses of IVIg (up to 2-fold), whereas weight of the spleen only slightly 
varied with IVIg treatment. In the next step, expression of the MHC class II molecules (here the 
subclass I-A) as well as the co-stimulatory molecules CD80 and CD40 was examined on B cells. 
Although some statistically significant increase in expression for CD40 and I-A was observed, 
the effect of IVIg on these markers was considered overall as minor (Figure 18A). When gated on 
CD11c+ I-A+, a small percentage of DCs could be detected in the spleen, whereas the DC 
population was not detectable in the lymph nodes (Figure 18B). IVIg had no effect on CD86, 
CD83 and I-A expression on spleen DCs. 
The results are in line with literature showing that peripheral blood lymphocytes have little 
basal expression of CD69, but their stimulation causes rapid induction of this marker on T, B and 
NK cells surface within a few hours (Reddy et al., 2004). Therefore analysis of CD69 expression 
is an approach commonly used to follow B-cell activation (Borges et al., 2007; Purtha et al., 
2008). Although B cells express very low levels of co-stimulatory molecules on their surface, 
some studies revealed that CD86 surface expression is rapidly up-regulated following BCR or 
LPS induced B-cell activation both in vitro and in vivo, while CD80 remains poorly expressed 
after stimulation (Constant et al., 1995; Kohm et al., 2002; Lenschow et al., 1994), which is 
consistent with the observations presented here. Although CD83 is predominantly expressed on 
mature DCs, it has also been shown to be up-regulated on activated B cells in vivo (Breloer et al., 
2007; Prazma et al., 2007). Thus, our results demonstrate that IVIg induced B cell activation in a 
dose-dependent manner.   
1.3. IVIg activates B cells in a dose-dependent manner 
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Figure 17: IVIg increased weight of the draining lymph nodes and activated B cells in a dose-dependent 
manner. C57Bl/6NCrl mice were injected 3 times weekly s.c in the neck with 50 μg OVA and Adjuvant AddaVax® 
MF59 (red bar) and terminated 24h after last injection. IVIg doses ranging from 1 mg to 50 mg were injected 
simultaneously. Draining lymph nodes and spleen were harvested, weighed and flow cytometry was performed on 
isolated cells. (A) Results pool data from 2 independent experiments (n=6). Values are expressed as ratio to the 
“Adj+OVA” group values. Bars represent mean ± SD. Median of fluorescence intensity (MFI) was measured on 
CD19+ B cells. Statistical significance was tested using one-way ANOVA with Dunnett’s correction. Each group 
was compared to the control group “Adj+OVA”. Star maker significance *: p < 0.05; **p<0.01; ***: p<0.001; 
****: p<0.0001. (B) Gating strategy for B cells. (C) Flow cytometry histograms from one representative animal. 
A 
B 
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Figure 18: IVIg has a minor effect on CD40, MHC class II (subclass I-A) and CD80 expression on B cells and 
no effect on the expression of co-stimulatory molecules on DCs. C57Bl/6NCrl mice were injected 3 times weekly 
s.c in the neck with 50 μg OVA and Adjuvant AddaVax® MF59 (red bar) and terminated 24h after last injection. 50 
mg of IVIg were injected simultaneously as indicated. Draining lymph nodes and spleen were harvested, and flow 
cytometry was performed on isolated cells. (A) CD40, I-A and CD80 expression on B cells. Results pool data from 4 
independent experiments (n=12). Values are expressed as ratio to the “Adj+OVA” group values. Bars represent 
mean ± SD. Median of fluorescence intensity (MFI) was measured on CD19+ B cells. Statistical significance was 
tested using one-way ANOVA with Dunnett’s correction. Each group was compared to the control group 
“Adj+OVA”. Star maker significant difference *: p < 0.05; **p<0.01; ***: p<0.001; ****: p<0.0001. (B) Gating 
strategy for DCs and expression of CD86, CD83 I-A on surface of spleen DCs.  
A 
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 To assess whether IVIg effect was depending on the presence of adjuvant or Ova, mice 
were treated with different combinations of IVIg, OVA and adjuvant as described below (Figure 
19). Weight of lymph nodes was increased to 2 to 2.5 fold and weight of the spleen was increased 
to 1.5 fold in mice treated with IVIg together with adjuvant or with IVIg plus OVA and adjuvant. 
 
Figure 19: Presence of adjuvant is required together with IVIg to mediate increase of weight in lymphoid 
organs and B cells activation. C57Bl/6NCrl mice were injected 3 times weekly s.c in the neck with 50 μg OVA and 
Adjuvant AddaVax® MF59 (red bar) and terminated 24h after last injection. 50 mg of IVIg was injected alone or in 
combination to OVA and/or Adjuvant, as indicated. Draining lymph nodes and spleen were harvested, weighed and 
flow cytometry was performed on isolated cells. Results pool data from 2 independent experiments (n=6). Values are 
expressed as ratio to the “Adj+OVA” group values. Bars represent mean ± SD. Median of fluorescence intensity 
(MFI) was measured on CD19+ B cells. Statistical significance was tested using one-way ANOVA with Tukey’s 
correction. Star maker significant difference *: p <0.05; **p<0.01; ***: p<0.001; ****: p<0.0001.  
1.4. Adjuvant is required to mediate IVIg effect 
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When mice received IVIg in combination with adjuvant with or without OVA, the 
expression of CD86 and CD83 on B cells was 2 to 3 fold higher in spleen and lymph nodes 
compared to the group treated with OVA and adjuvant. In contrast, mice treated with IVIg alone, 
adjuvant alone, or IVIg in combination with OVA exhibited no such effect neither on the weight 
of lymphoid organs nor on the expression of co-stimulatory molecules on B cells. These data 
indicate that the presence of adjuvant is required to mediate B cell activation and increase the 
weight of lymphoid organs upon IVIg injection. 
Downregulation of the anti-OVA IgG response observed upon IVIg treatment as well as B 
cell activation may be dependent on the Fc-region of IVIg, or mediated by its high sequence 
diversity in the variable regions. This was addressed by testing a human monoclonal antibody, to 
see if it was able to inhibit the OVA-specific IgG response, as observed upon IVIg injection. For 
this purpose, two marketed monoclonal antibodies were carefully selected regarding their target 
species-specificity, to prevent cross-reactivity in mice and to exclude potential interference with 
the immune system that could impair the interpretation of the data. Avastin (a humanized IgG1κ) 
has been shown to possess an extremely weak interaction with mouse VEGF-A, which fails to 
result in immunoneutralization (Yu et al., 2008). Similarly, Vectibix (a human IgG2κ), does not 
cross-react with mouse EGFR (Tabrizi et al., 2006). IVIg, Avastin or Vectibix were injected 
together with OVA and adjuvant in mice. Anti-OVA IgG response was measured by ELISA and 
expression of B cell stimulation markers were assessed by flow cytometry. Avastin applied at 50 
mg/mouse had no effect on the anti-OVA IgG titer when given together with MF59. Avastin 
given together with adjuvant LT (R192G/L211A) significantly increased the OVA-specific IgG 
response in mice. However, IVIg injected at the same dose consistently lead to a significant 
decrease of about 3.4-fold when adjuvant MF59 was used, and of 6.5-fold with adjuvant 
LT (R192G/L211A) (Figure 20A). Both adjuvants mediate a balanced Th1/Th2 response. Avastin 
administration slightly increased the weight of the spleen and the cervical lymph nodes but did 
not result in a significant gain in weight in axillary and brachial lymph nodes. Avastin also didn’t 
increase expression of CD86, CD83 and CD69 on B cells as shown in Figure 20B and C. In 
contrast, IVIg triggered a 2- to 3-fold up-regulation of CD86 on B cells, and a 1.5-2-fold up-
regulation for CD83 and CD69, in both the spleen and the corresponding draining lymph nodes.  
  
1.5. A human monoclonal antibody can’t reproduce IVIg effects 
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Figure 20: Avastin, a humanized monoclonal IgG1κ antibody, doesn’t inhibit the anti-OVA IgG response in 
vivo in mice and doesn’t promote B cell activation compared to IVIg. C57Bl/6NCrl mice were injected 3 times 
weekly s.c in the neck with 50 μg OVA and adjuvant (Adj) (red bar) and terminated 24h after last injection. IVIg or 
Avastin were injected simultaneously to OVA and Adj as indicated. (A) Anti-OVA IgGs in mouse serum were 
measured by ELISA. For Adj MF59, results pool data from 4 independent experiments (n=12) and for Adj 
LT(R192G/L211A) results are from one experiment (n=3). (B) Flow cytometry histograms are shown for one 
representative animal (Adj MF59 was used). (C) Draining lymph nodes and spleen were harvested, weighed and 
flow cytometry was performed on isolated cells (Adj MF59 was used). Results pool data from 2 independent 
experiments (n=6), except for CD69 for which data are derived from one experiment (n=3). Values are expressed as 
ratio to the “Adj+OVA” group values. Median of fluorescence intensity (MFI) was measured on CD19+ B cells. 
Bars represent mean ± SD. n.d: not detected. Statistical significance was tested using one-way ANOVA with 
Dunnett’s correction. Each group was compared to the control group “Adj+OVA”. Star maker significant difference 
*: p < 0.05; **p<0.01; ***: p<0.001; ****: p<0.0001.   
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Consistent with the observations made with Avastin, anti-OVA IgG response was not 
affected by the injection of Vectibix (Figure 21A and B). This was confirmed with the use of two 
different adjuvants, the MF59 or LT (R192G/L211A). Vectibix induced a minor increase in weight of 
the spleen and axillary/brachial lymph nodes, but did not augment CD86 expression on B cells in 
these organs, as observed in a substantial way with IVIg (Figure 21C).  
Figure 21: Vectibix, a human monoclonal IgG2κ antibody, doesn’t inhibit the anti-OVA IgG response in vivo 
in mice and doesn’t promote B cell activation compared to IVIg. C57Bl/6NCrl mice were injected 3 times 
weekly s.c in the neck with 50 μg OVA and adjuvant (Adj) (red bar), and terminated 24h after last injection. IVIg or 
Vectibix were injected simultaneously to OVA and Adj as indicated. (A) Anti-OVA IgG1 in mouse serum as 
measured by ELISA upon use of Adj LT (n=3). (B) Anti-OVA IgG in mouse serum as measured by ELISA upon use 
of Adj MF59 (n=3). (C) Draining lymph nodes and spleen were harvested, weighed and flow cytometry was 
performed on isolated cells (Adj LT was used). Values are expressed as ratio to the “Adj+OVA” group values. 
Median of fluorescence intensity (MFI) was measured on CD19+ B cells. Bars represent mean ± SD with n=3. n.d: 
not detected. Statistical significance was tested using one-way ANOVA with Dunnett’s correction. Each group was 
compared to the control group “Adj+OVA”. Star maker significant difference *: p < 0.05; **p<0.01; ***: p<0.001; 
****: p<0.0001.  
n.d n.d 
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Taken together, these data indicate that a monoclonal IgG antibody injected at high dose 
cannot impair an antigen-specific humoral response, thus ruling out FcRn saturation as the main 
driver of the inhibitory effects of IVIg in this mouse modelThese results are in line with studies 
showing that IVIg therapeutic effects still occurred although mice were deficient for FcRn (Crow 
et al., 2011; Li et al., 2005).Notably, the composition of IVIg differs from a human mAb by the 
presence of many different IgG-variable regions. Therefore these results also point to the 
direction that this high sequence diversity in IVIg preparations may be relevant in decreasing the 
formation of antigen-specific antibodies.  
Having proven the effect of IVIg in up-regulating some activation markers on B-cells, we 
next examined by flow cytometry whether IVIg has an effect on the T-cell population. IVIg has 
been reported in some clinical studies to promote expansion of Tregs in patients (Bayry et al., 
2012). Our data demonstrate that the percentage of CD4+CD25+Foxp3+ Tregs in lymphoid 
organs from IVIg-treated mice remains unchanged (Figure 22B). Since the total number of CD4+ 
T cells significantly increased in the draining lymph nodes (Figure 16B), the absolute number of 
Tregs increased as well in presence of IVIg.  
To investigate whether IVIg promotes activation of Tregs, the expression of Foxp3, CD25 
and CTLA-4 was assessed. Data revealed that IVIg didn’t affect the level of expression of any of 
these markers (Figure 22D), which is in line with a pro-inflammatory context. These results are 
contradicting a study showing that IVIg treatment in patients enhanced the activation status of 
circulating Tregs while numbers remained unchanged (Tjon et al., 2013). 
 
  
1.6. IVIg doesn’t induce activation of Tregs but increases the proportion of CD69+ 
CD4 T cells. 
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Figure 22: IVIg doesn’t activate the Tregs population but triggers CD69 expression on CD4+ T cells. 
C57Bl/6NCrl mice were injected 3 times weekly s.c in the neck with 50 μg OVA and adjuvant (Adj MF59) (red bar), 
and terminated 24h after last injection. IVIg or Avastin were injected simultaneously to OVA and Adj as indicated. 
(A) Gating strategy for Tregs (B) Draining lymph nodes and spleen were harvested, weighed and flow cytometry 
was performed on isolated cells. Bars represent mean ± SD. For % CD25+ and % CD25+Foxp3+ data pool 5 
independent experiments (n=15), except for Avastin group n=6 (from 2 independent experiments). For % CD69+ 
data pool 4 independent experiments (n=12), except for Avastin group n=3. Statistical significance was tested using 
one-way ANOVA with Dunnett’s correction. Each group was compared to the control group “Adj+OVA”. Star 
maker significant difference *: p < 0.05; **p< 0.01; ***: p<0.001; ****: p<0.0001. (C) Flow cytometry dot plots 
showing CD69+ cells among CD4+ T cells from one representative animal for each group of treatment. (D) MFI of 
Foxp3, CTLA-4 and CD25 on Tregs expressed as MFI ratio of “Adj+OVA+IVIg” over the “Adj+OVA” group (data 
pool 4 independent experiments; n=12). 
 
 
 
 
 
 
Interestingly, the percentage of CD69+ cells among CD4+ T cells increased in IVIg-treated 
mice: 3.8 % more in the spleen, 4.8 % in the axillary and brachial lymph nodes and 6.2 % in the 
cervical lymph nodes (Figure 22C). CD69 is the earliest cell surface antigen expressed by T cells 
following activation and thus the increased CD69 expression indicated an inflammatory response 
(Caruso et al., 1997). Avastin mediated a small but significant increase of CD69+ cells within 
CD4+ T cells in the spleen, but had no effect in the lymph nodes, however this result was derived 
from only one experiment with n=3 mice, unlike the other groups of treatment which comprised 4 
independent experiments with n=12 mice. Consistent with the observation that IVIg induced T 
cell proliferation in the lymph nodes, the data presented here demonstrates that CD4+ T cells are 
being activated as indicated by the expression of CD69. Overall, data suggest an inflammation 
rather than increased suppressive capacities of the immune system. Therefore, it is unlikely that 
the increased number of Tregs is the main driver of the inhibitory effect of IVIg on the anti-OVA 
antibody response. 
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To further confirm the triggering the immune system by IVIg, the formation of germinal 
centers in the spleen and lymph nodes was evaluated by immunofluorescence. The activated B 
cells during the germinal center reaction can be probed with either the rat monoclonal GL7 
antibody or the PNA (Peanut agglutinin). First, the specificity of the immunofluorescence 
staining was assessed by overlaying both stainings as illustrated in Figure 23A. GL7 antibody 
was used later on to specifically stain germinal centers by immunofluorescence. As expected, 
injection of adjuvant alone produced no germinal centers, whereas addition of OVA triggered the 
formation of very few and small germinal centers. Mice that have received IVIg together with 
OVA and adjuvant exhibited a striking number of germinal centers in their spleen and draining 
lymph node sections, with a markedly enlarged size in the lymph nodes (Figure 23B). This is in 
line with previous data presented here showing that IVIg induced B cell activation. GL7 antigen 
is selectively expressed on activated but not on mature B cells, and GL7
high
 B cells have been 
shown to have higher functional activity for producing antibodies and presenting antigens (Naito 
et al., 2007). In the case of a thymus-dependent antigen, formation of a germinal center involves 
that B cells receive an input signal from a cognate helper T cell. The data presented here thus 
imply that IVIg not only activated B cells but might also have mobilized many diverse T cells. 
Notably, mice that have been treated with Avastin together with OVA and adjuvant presented the 
same number and size of germinal centers compared to mice immunized with OVA and adjuvant. 
This supports the ELISA and FACS results showing that a monoclonal human antibody is not 
able to trigger the same effects as IVIg.    
In line with the data reviewed previously in section 1.4, the number of germinal centers is 
strongly augmented in spleen as well as in lymph nodes when mice were administered with IVIg 
together with adjuvant, but not when mice received IVIg or adjuvant alone Figure 24. These 
results highlight once again the initiation of a strong immune response in mice when IVIg is 
injected, and – as any immune response – it can’t be initiated without triggering the pattern 
recognition receptors on immune cells, which is mediated by the adjuvant in our model.  
  
1.7. IVIg induces the formation of numerous germinal centers 
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Figure 23: IVIg induces the formation of large and numerous germinal centers in vivo in the mouse. 
C57Bl/6NCrl mice were immunized 3 times weekly s.c in the neck with 50 μg OVA and adjuvant (Adj MF59), 
50 mg of IVIg or Avastin were injected simultaneously to OVA and Adj as indicated, and mice were terminated 24h 
after last injection. (A) Spleen sections of mice were co-stained with PNA (red) and GL7 (green). (B) Spleen and 
draining lymph nodes were probed for germinal centers with the rat monoclonal GL7 antibody (green). Each picture 
is from one representative animal.  
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Figure 24: IVIg required the presence of adjuvant to induce the formation of numerous germinal centers in 
vivo in the mouse. C57Bl/6NCrl mice were immunized 3 times weekly s.c in the neck with 50 mg of IVIg, 
simultaneously or not with adjuvant (MF59). Mice were terminated 24h after last injection. Spleen and draining 
lymph nodes were probed for germinal centers with the rat monoclonal GL7 antibody (green). Each picture is from 
one representative animal. 
 
Of specific interest, the effect of IVIg in the distribution of some specific B-cell 
populations in the spleen and bone marrow was investigated. Newly immature formed B cells 
leave the bone marrow to home in the spleen where they mature as either follicular (FO) B cells 
(B220+CD23
high
CD21
low
IgD
high
) or marginal zone (MZ) B cells (B220+CD23
low
CD21
high
IgD
low
). 
Mature naïve follicular B cells, that comprise more than 95 % of the B cells in peripheral lymph 
nodes, have the ability to freely recirculate, entering and exiting follicular niches in secondary 
lymphoid organs in search of antigen, and to mediate T-dependent immune responses (Pillai and 
Cariappa, 2009). In contrast, MZ B cells are non-recirculating cells which line the marginal sinus 
in the spleen and respond to blood-borne pathogens to provide T-independent immune 
1.8. IVIg impacts the number of re-circulating mature B cells in bone-marrow  
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responsiveness. The bone marrow also constitute an alternative perisinusoidal niche for 
recirculating mature B cells with a follicular phenotype wherein they have immediate access to 
blood-borne pathogens and can be activated in a T cell-independent manner, similarly to MZ B 
cells. The different B cells compartments in the spleen and bone marrow were assessed by flow 
cytometry and the gating strategy is presented in Figure 25A. The proportion of re-circulating 
mature B cells in the bone-marrow was reduced in mice which were administered with IVIg 
together with OVA and adjuvant (Figure 25B). In fact, once they have bound antigen, B cells 
activate their adhesion molecules (ex: LFA-1) to get trapped at the border of the T-cell and B-cell 
zones of peripheral lymphoid tissues, and thus their re-circulation is prevented. This is can be 
observed by immunization with OVA, which reduces the proportion of mature B cells re-
circulating in the bone-marrow compared to mice injected with adjuvant alone. Since IVIg 
amplified this effect, this may indicate that the highly diverse IVIg-epitopes increases the chance 
to encounter epitope-specific B cells, so that a larger number of responding mature B cells gets 
arrested in the peripheral lymphoid tissues and don’t show-up anymore in the bone-marrow. This 
observation is in correlation with the increased number of B cells in these tissues upon IVIg 
treatment shown in section 1.2. In addition, IVIg seems also to further increase the proportion of 
pre-B cells in the bone-marrow significantly, compared to OVA immunization. Both effects on 
pre-B and recirculating mature B cells in the bone-marrow couldn’t be reproduced with Avastin, 
which indicates that these effects are specifically linked to the high diversity of IVIg. Regarding 
the spleen compartments, IVIg affected neither the percentage of FO nor the MZ B cells. All 
results were similar when plotting number of cells instead of percentage (data not shown). 
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Figure 25: IVIg doesn’t affect B-cell compartment in the spleen but reduces the proportion of mature re-
circulating B cells in the bone-marrow and promotes pre-B cells formation. (A) Gating strategy for assessing the 
different B-cell compartments in the spleen and bone-marrow by flow-cytometry. (B) C57Bl/6NCrl mice were 
injected 3 times weekly s.c in the neck with 50 μg OVA and adjuvant (Adj MF59) (red bar), and terminated 24h after 
last injection. IVIg or Avastin were injected simultaneously to OVA and Adj as indicated. Bars represent mean ± SD 
(n=6; except for Avastin group n=3). Statistical significance was tested using two-way ANOVA with Dunnett’s 
correction. Each group was compared to the control group “Adj+OVA”. Star maker significant difference *: p < 
0.05; **p<0.01; ***: p<0.001; ****: p<0.0001. 
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In order to understand the timing of the IVIg mediated effects,  mice were injected once with 
IVIg and adjuvant and readouts were performed after 16h, 24h, 48h, 72h and 7 days, and 
compared with the OVA and adjuvant treated groups. Strikingly, some IVIg effects were already 
visible after only 48h (Figure 26A), such as increased weight in lymph nodes of about 1.5 to 
2-fold. Similarly, CD86 expression on B cells in axillary lymph nodes was upregulated of more 
than 1.5-fold, and expression of CD69 of 5-fold. B and T-cell numbers were also increased of 
about 2-fold after 48h (Figure 26B). The peak of the effects in IVIg-treated mice appeared at day 
3 in lymph nodes, with a weight increase of 2 fold in axillary lymph nodes and about 4 fold in 
cervical lymph nodes. On day 3 CD86 on B cells was up-regulated up to 2 fold, CD83 up-
regulated to 1.5-2 fold and CD69 up-regulated to 3 fold. Increase in T and B-cell numbers, 
compared to the OVA immunized group, also appeared to be maximal at day 3. B-cell numbers 
increased up to 6 to 7-fold in lymph nodes, together with both CD4+ and CD8+ T-cell number 
which were 2 to 3-fold higher. These effects tend to decrease after day 3 until day 7. All together 
these data indicate that IVIg mediates an activation of the immune system visible as early as 2 
days after injection and reaching a maximum after 3 days. Moreover, all readouts were performed 
after a single IVIg injection, so the effects observed here are likely to appear even earlier and/or 
to be more pronounced when measurements would be performed after several boosting 
injections. 
  
1.9. IVIg effects appear early 
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Figure 26: IVIg-mediated effects on immune cell populations appear early after injection. C57Bl/6NCrl mice 
were injected once s.c in the neck with 50 μg OVA and adjuvant MF59 (red lines), and with/without 50mg of IVIg in 
addition (blue lines). Mice were terminated 16h, 24h, 48h, 72h and 7 days after the injection. (A) Weight and 
expression of CD86, CD83 and CD69 on CD19+ B cells. (B) Number of B CD19+ B cells, CD4+ T cells and CD8+ 
T cells. Data show ratio compared to “OVA+Adj” group. Lines represent mean. Statistical significance was tested 
using two-way ANOVA with Sidak’s correction. Star maker significant difference *: p < 0.05; **p<0.01; 
***: p<0.001; ****: p<0.0001. 
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To investigate whether IVIg was able to promote immune tolerance against a specific 
antigen, a group of mice was injected once with OVA, adjuvant aluminum and IVIg. The 
following weeks mice were then challenged with OVA and adjuvant only. Anti-OVA IgG1 titers 
were measured 2, 3 and 4 weeks after the first injection (Figure 27). Sustained IVIg injections 
together with OVA and adjuvant efficiently reduced the level of anti-OVA antibodies as 
measured in week 2 and week 3. However, this effect was lost in week 4 for 2 animals out of 3. 
This can be due to the weekly repeated OVA-adjuvant injections which might have finally 
overcome the inhibition mediated by IVIg. This could also be due to inter-animal variability and 
low number of tested animals. Interestingly, the group which received one shot of IVIg followed 
by weekly OVA-adjuvant challenges showed no decrease in the OVA–specific antibodies titer 
for all time-points. This suggests that a single dose of IVIg is not able to promote immune 
tolerance against a specific antigen.   
 
 
Figure 27: Single shot of IVIg followed by OVA challenges doesn’t promote tolerance. ELISA measuring anti-
OVA IgG1 at 2, 3 and 4 weeks after first injection. C57Bl/6NCrl mice were injected once a week s.c in the neck with 
50 μg OVA and adjuvant aluminum, and where indicated with 50 mg of IVIg in addition. In one group mice were 
administered once with OVA- alum- IVIg the first week whereas the following challenges consisted in OVA and 
aluminum only. Lines represent mean. Statistical significance was tested using two-way ANOVA with Dunnett’s 
correction. Star maker significant difference *: p < 0.05; **p<0.01; ***: p<0.001; ****: p<0.0001. 
  
1.10. Single shot of IVIg followed by OVA challenges doesn’t promote tolerance 
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2. Characterization of the humoral immune response in mice 
Data presented here collectively suggest that IVIg strongly triggers the mouse immune 
system. To investigate whether mice mounted a substantial immune response directed against 
IVIg, IVIg-specific antibodies were measured in mouse serum by ELISA. In addition, the level of 
total mouse antibodies in serum was studied to assess whether it was affected by IVIg . For all 
the data presented in this section, it is of importance to notice that the antibody titers can’t be 
directly compared between the different ELISA formats. Although they are expressed in relative 
units as compared to a standard or in OD units, antibodies used in the capture or detection steps 
all differ in their format, affinity and avidity between the different assays and therefore the titers 
obtained are not comparable on the same scale. 
2.1.1. Anti-IVIg mouse IgG 
Different doses of IVIg ranging from 1 mg up to 50 mg per animal were tested to explore 
the effect on the formation of anti-OVA antibodies in mice. As already described in section 1.1, 
inhibition of the OVA-specific humoral response was proportional to the dose of IVIg injected 
(Figure 28A). A prominent IVIg-specific immune response was raised in mice when 1 mg of 
IVIg was injected (Figure 28B). Surprisingly, less IVIg-specific mouse IgG were detected in 
mouse serum when the dose of IVIg administered was increased, in an inversely proportional 
manner. FcRn saturation might not be the major factor accounting for the observed inverse 
correlation. FcRn saturation is a non-selective process that will accelerate the degradation of all 
antibodies present in mouse serum, regardless of their antigen specificity. Indeed, previous data 
(Figure 20A) presented here demonstrated that Avastin given at high dose didn’t decrease the 
anti-OVA IgG in mouse serum. Titration curves measuring anti-OVA IgG nicely show that the 
ratio of the inhibitory effect from IVIg remains similar upon different dilutions of the samples, 
since the two curves are parallel in the linear range (Figure 28C). Despite a possible interference 
in the assay, titration of samples to measure anti-IVIg IgG is parallel to titration of the standard 
(Figure 28D). This means that back-calculation of the sample titer according to standard provided 
the same results across the different dilutions of the samples within the linear range, with a 
variability of ±20 %. Thus, the decrease in signal with the increase in IVIg dose can’t be 
attributed to unspecific binding in the assay. To investigate whether this effect could be explained 
2.1. IVIg raises a specific antibody response in mice 
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by interference in the ELISA assay, a competition assay was performed by spiking IVIg into the 
serum of 1 mg IVIg-treated mice (Figure 29A). Indeed sera from low dose IVIg treatment still 
contain a high proportion of mouse anti-IVIg not complexed that could be detected by ELISA. 
Addition of IVIg inhibited the detection of anti-IVIg mouse IgG, with a 71 % signal inhibition at 
the dose of 50 mg/mL of IVIg, 49 % at 20 mg/mL and 42 % at 10 mg/mL. This demonstrates that 
reduction in signal observed when IVIg dose increases can most likely be explained by 
interference in the ELISA assay, as illustrated in Figure 29B. When mice raise an anti-IVIg IgG 
response, the higher the dose of IVIg present in the serum, the more IVIg-specific mouse 
antibodies will be complexed with IVIg. Considering their antigen-binding part being already 
occupied, these IVIg-specific mouse IgG are not able to bind to IVIg coated on the assay plate. In 
consequence of this assay interference, injection of high dose of IVIg lead to a low detection 
signal in the ELISA measuring IVIg-specific mouse IgG, whereas injection of low dose of IVIg 
lead to a high detection signal, as shown with serum from the 1 mg-treated group (Figure 28B).  
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Figure 28: IVIg raises a specific antibody response in mice. C57Bl/6NCrl mice were injected 3 times weekly s.c 
in the neck with 50 μg OVA and adjuvant MF59 (red bar), and terminated 24h after last injection. IVIg was injected 
simultaneously to OVA and Adj as indicated at different doses (A) OVA-specific mouse IgG measured by ELISA. 
(B) IVIg-specific mouse IgG measured by ELISA. Bars represent mean ± SD. Values as expressed as relative units 
to standard. Data pool 2 independent experiments (n=6). (C,D) ELISA titration curves on serum from mice treated 
with OVA+Adj±IVIg at 50 mg. Dots represent mean ± SD (n=3). Statistical significance was tested using one-way 
ANOVA with Dunnett’s correction. Each group was compared to the control group “Adj+OVA”. Star maker 
significant difference *: p < 0.05; **p<0.01; ***: p<0.001; ****: p<0.0001. 
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Figure 29: IVIg present in mouse serum can lead to interference in ELISA assay. (A) Addition of IVIg in vitro 
in mouse serum inhibits the detection of IVIg-specific mouse IgG by ELISA in a dose-dependent manner. Blocking 
Buffer or IVIg were added at 10, 20 or 50 mg/mL in serum from mice treated 3 times weekly with 1mg of IVIg 
(n=3). (B) Schematic representation of the ELISA assay to measure IVIg-specific mouse IgG and how IVIg can lead 
to interference in this assay.  
 
B 
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2.1.2. High dose IVIg reduces total mouse IgG  
Different doses of IVIg ranging from 1 mg up to 50 mg per animal were tested to explore 
the effect on the formation of total IgG antibodies in mice (Figure 30A). OVA immunization 
enhanced the total mouse IgG titer of about 0.8 relative unit compared to the adjuvant group. 
Injection of 1mg of IVIg led to an increase of the total mouse IgG titer of about 2 relative units 
compared to the OVA-immunized group. Surprisingly, less total mouse IgG were detected in 
mouse serum when the dose of IVIg administered was increased, in an inversely proportional 
manner. To investigate whether IVIg complexed with specific mouse antibodies interferes with 
the detection of total mouse IgG in serum, a control ELISA assay has been performed in which 
total mouse IgG are captured via a Fc-specific polyclonal goat anti-mouse IgG. Results obtained 
were identical to the results obtained with a non Fc-specific capture antibody (Figure 30C). Thus, 
these data rule out that steric hindrance around the CDR regions of mouse IgG could interfere 
with binding of the capture antibody and explain reduction in signal. In addition, these data show 
good reproducibility of the assay. However, steric hindrance may still occur around the Fc 
regions of the mouse IgG, that could potentially inhibit their capture via Fc-specific antibodies. 
To confirm the assumption that there is no interference in the detection of total mouse IgG due to 
steric hindrance, a competition ELISA was performed. 
To determine if the formation of immune complexes between IVIg and mouse anti-IVIg 
antibodies can lead to interference in the detection of total mouse IgG antibodies, different 
concentrations of IVIg were spiked in vitro into the serum of 1mg IVIg-treated mice. Indeed sera 
from low dose IVIg treatment still contain a high proportion of mouse IgG not complexed that 
could be detected by ELISA (as shown in Figure 30A). The results depicted in Figure 30D 
revealed no inhibition in the detection signal of total mouse IgG following IVIg or Avastin 
spiking into mouse serum compared to buffer spiking, for all the three different concentrations 
tested.  This indicates that IVIg doesn’t lead to a detectable interference in this assay. The totality 
of mouse IgG present in mouse serum could be detected in this assay, regardless of the treatment 
applied. 
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Figure 30: Detection of total mouse IgG in serum by ELISA. C57Bl/6NCrl mice were injected 3 times weekly s.c 
in the neck with 50 μg OVA and adjuvant MF59 (red bar), and terminated 24h after last injection. IVIg was injected 
simultaneously to OVA and Adj as indicated at different doses. (A)  Total mouse IgG captured via a goat polyclonal 
anti-mouse IgG antibody (n=6 from 2 independent experiments). (B) Total mouse IgG detected in serum after IVIg 
or Avastin treatment. Total mouse IgG were captured via a goat polyclonal anti-mouse IgG antibody. Data pool 4 
independent experiments (n=12). (C) Total mouse IgG captured via a goat polyclonal anti-mouse IgG Fc-specific 
antibody. (n=6 from 2 independent experiments). (D) Competition ELISA. Blocking Buffer, IVIg or Avastin were 
added in vitro at 10, 20 or 50 mg/mL in serum from mice treated 3 times weekly with 1mg of IVIg. Total mouse IgG 
were captured using a goat polyclonal anti-mouse IgG antibody (n=3). For (A), (B) and (C), statistical significance 
was tested using one-way ANOVA with Dunnett’s correction. Each group was compared to the control group 
“Adj+OVA”. For (D), statistical significance was tested using two-way ANOVA with Dunnett’s correction. Each 
group was compared to the control group “Spiked Buffer”. In all graphs bars represent mean ± SD. Values as 
expressed as relative units to standard. Star maker significant difference *: p < 0.05; **p<0.01; ***: p<0.001; 
****: p<0.0001. 
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In a separated experiment we measured the titer of total mouse IgG in serum samples from 
mice treated with high dose of IVIg or Avastin (Figure 30B). When mice were administered with 
50 mg of IVIg, the titer of total mouse IgG was comparable to the one obtained in OVA 
immunized mice, in line with what was already depicted in Figure 30A and C. Strikingly, 
treatment with the same dose of Avastin lead to the same effect.This suggests that both IVIg and 
Avastin induced an homeostatic effect most likely via FcRn saturation, which led to a reduction 
of total mouse IgG. This is in line with previous studies showing that FcRn saturation accelerates 
the clearance of mouse antibodies present in serum (Bleeker et al., 2001). However, data in 
section 1.5 demonstrated that Avastin didn’t lead to a decrease of the OVA-specific IgG. This 
ruled out FcRn saturation as the main driver of the inhibitory effects of IVIg in the OVA-specific 
response in this mouse model. Schemata that illustrate the different antibodies present in mouse 
serum before and after clearance are depicted in Figure 31. Basically, OVA-IgG are decreased 
when IVIg doses are increased (Figure 31A). When IVIg doses increase, all types of IgG will 
decrease proportionally, due to increased clearance mechanisms (Figure 31B).   
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Figure 31: Schematic of how high doses of IVIg could promote total mouse IgG clearance via FcRn saturation. 
(A) Increasing doses of IVIg lead to the formation of mouse anti-IVIg (in blue) antibodies and decreasing levels of 
anti-OVA mouse IgG (in red). (B) In parallel, increasing doses of IVIg augment clearance via FcRn saturation, thus 
leading to decreased levels of total mouse IgG.  
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2.1.3. Mouse antibody response against IVIg is mostly directed towards Fab 
To investigate whether the mouse anti- IVIg-IgG were mostly directed towards the Fc or 
the Fab part of IVIg, a competition experiment was performed- IVIg or the control mAb Avastin 
were spiked in vitro into the serum of 1mg IVIg-treated mice. As already described previously,   
addition of IVIg inhibited the detection of anti-IVIg mouse IgG, with a 71 % signal inhibition at 
the dose of 50 mg/mL of IVIg (Figure 32A).  Interestingly, addition of Avastin in 1 mg IVIg-
treated mouse serum only lead to a significant signal interference of 30 % at the highest dose of 
50 mg/mL. The most plausible explanation for such inhibition following spiking of Avastin is 
that a small fraction of mouse antibodies directed against IVIg recognized some common 
epitopes shared between IVIg and Avastin, most likely in the Fc-part of human IgG. These data 
thereby confirm that mice develop antibodies targeting both Fc and Fab regions of IVIg. 
However, since the signal inhibition following Avastin spiking was much lower as compared to 
IVIg spiking, we can conclude that mouse IgG are mostly directed against the variable parts of 
IgG which are part of the Fab region of IVIg Fab  
To assess the IgG response against Avastin, serum from mice treated with 50 mg of 
Avastin was applied on an Avastin-coated plate and specific mouse IgG were detected. As 
illustrated in Figure 32B, mice elicited an IgG response against Avastin. Interestingly, serum 
from IVIg-treated mice contained IgG that were able to bind to Avastin and lead to a higher 
detection signal in the assay. ELISA with coating of Avastin-Fc further confirmed that this signal 
comes from antibodies directed against Avastin Fc parts. These data show that antibodies 
directed towards IVIg Fc parts also react with the Fc part of Avastin, which share some common 
epitopes since both comprise human antibodies. Very importantly, when detecting IVIg-specific 
mouse IgG, a part of the antibodies generated upon 50 mg of Avastin administration can bind to 
IVIg coated on the plate and lead to 27% of detection signal compared to mice treated with IVIg 
(Figure 32B). This therefore suggests that 27% of anti-IVIg IgG is directed to its Fc region.   
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Figure 32: Mouse IgG response against IVIg is mostly directed against IVIg-Fab region. (A) Addition of IVIg 
in vitro in mouse serum inhibits the detection of IVIg-specific mouse IgG by ELISA in a dose-dependent manner. 
Blocking Buffer, IVIg or Avastin were added at 10, 20 or 50 mg/mL in serum from mice treated 3 times weekly with 
1mg of IVIg (n=3). (B) Detection of mouse IgG specific for Avastin (n=6), Avastin-Fc (n=9) and IVIg (n=12) by 
ELISA. (C) ELISA measuring mouse IgG anti-IVIg-Fc, Fab or (Fab)’2 fragments (n=6). In all graphs bars represent 
mean ± SD. Statistical significance was tested using two-way ANOVA with Dunnett’s correction for (A) and with 
two-tailed unpaired t-test for (B). Each group was compared to the control group “Buffer”. Star maker significant 
difference *: p < 0.05; **p<0.01; ***: p<0.001; ****: p<0.0001. n.d: not detected.  
A 
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To further confirm the specificity of anti-IVIg mouse IgG, ELISA measurements were 
performed after coating purified IVIg-Fc, Fab or (Fab’)2 fragments. Titers of mouse IgG 
recognizing the Fab or (Fab’)2 fragments from IVIg were decreased while IVIg doses injected in 
mice were increased (Figure 32C). This inverse correlation might likely be due to the interference 
in the assay described in Figure 29. This suggests that mice build a humoral response mainly 
directed against the variable parts of IVIg. In contrast, mouse antibodies directed towards IVIg 
Fc-region were more or less equally well detected in ELISA, suggesting in that the signal was not 
inhibited in a dose-dependent manner by IVIg present in mouse serum. This could imply that the 
anti-Fc mouse IgG might not be the highest in affinity, and/or the highest in number in regards to 
the immune response generated and thus are less sensitive to IVIg high dose interference in the 
serum. These results suggest that anti-IVIg mouse antibodies might be mostly directly against the 
IVIg-Fab region (Figure 32 A and B). This is consistent with previous data showing that IVIg 
spiking in serum led to 71 % of signal inhibition whereas Avastin spiking to 30 % inhibition 
only. Ideally these data should have been confirmed by a competition ELISA assay spiking high 
concentrations of IVIg-Fab or Fc molecules into 1 mg IVIg-treated mouse serum. Unfortunately, 
with regards to the high concentrations needed for such a competition, this experiment couldn’t 
be performed.  
Taken together these results reveal that IVIg raises an antibody response in mice mainly 
directed towards the Fab region. This suggests that the highly diverse variable regions present in 
IVIg are the cause of the massive immune response we observed following IVIg injection.  In 
line with our previous data showing that a human mAb was not able to reproduce the effect of 
IVIg, it seems that the highly diverse variable regions present in IVIg are responsible to some 
extend for the reduced  anti-OVA antibody response. 
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ELISA data showed that the total IgG in mice treated with IVIg together with adjuvant was 
increased to the same level as in mice treated with adjuvant and OVA (Figure 33A). We can 
expect the total IgG titer to be much higher in IVIg-adj-treated mice compared to OVA-adj-
treated mice, but due to the homeostatic effect via FcRn saturation (described in section 2.1.2), 
such difference couldn’t be measured when high dose of IVIg was administered Mice treated 
with IVIg alone or IVIg and OVA but in the absence of adjuvant presented a titer of total IgG 
similar to non-immunized mice injected with adjuvant alone (Figure 33A, light blue bars). This is 
line with the fact that adjuvant is usually required to mount a proper antibody response. 
Regarding anti-OVA-specific mouse IgG, mice treated with IVIg plus OVA and adjuvant 
consistently showed significant lower titers (about 4.4-fold lower) compared to mice treated with 
OVA and adjuvant only (Figure 33B). As expected, anti-OVA antibodies could not be detected in 
serum from mice treated with adjuvant only or without OVA. In correlation with the data 
outlined in section 1.4 and 1.7 showing that presence of adjuvant was required together with IVIg 
to induce B cell activation and formation of numerous germinal centers, an anti-IVIg IgG 
response occurred only significantly when adjuvant was co-injected with IVIg (figure 33C). 
Figure 33: Co-injection of adjuvant is required to induce a mouse IgG response against IVIg. C57Bl/6NCrl 
mice were injected 3 times weekly s.c in the neck with 50 mg IVIg in combination with OVA and/or adjuvant MF59 
as indicated. Mice were terminated 24h after last injection. ELISA to measure total mouse IgG, OVA-specific and 
IVIg-specific mouse IgG were performed on mouse serum. Bars represent mean ± SD. Values as expressed as 
relative units to standard. Data pool 3 independent experiments (n=9). Statistical significance was tested using one-
way ANOVA with Tukey’s correction for total IgG and anti-IVIg IgG data, and with Dunnett’s correction for anti-
OVA IgG data. Star maker significant difference *: p < 0.05; **p<0.01; ***: p<0.001; ****: p<0.0001. n.d: not 
detected.  
2.2. Effect of adjuvant on the antibody response 
n.d n.d n.d 
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After showing that IVIg injection together with adjuvant lead to the production of IVIg-
specific IgG in mice, it was determined which isotypes of the IVIg-specific antibody response 
were produced. Figure 34A shows that IVIg-specific IgG1, IgG2a and IgG2b titers were inversley 
correlated to the IVIg dose administered to mice, due to ELISA assay interference as explained in 
section 2.1. Importantly, titers can’t be compared between the different istypes due to different 
assay formats. In contrast, more IgM antibodies were detected as the IVIg dose was increased. 
This might be due to anti-IVIg mouse IgM not being sensitive to IVIg high dose interference in 
the serum. Indeed, IgM antibodies are of low affinity, and might likely not be the dominant 
isotype produced, as for a TD antigen. IgA and IgG3 isotypes could not be detected in serum 
diluted in 1/100. Consistent with ELISA data shown in Figure 33, we observed a highly 
significant increase in anti-IVIg IgG1, IgG2a, IgG2b and IgM levels in mice treated simultaneously 
with IVIg and adjuvant compared to mice treated without adjuvant (Figure 34B), thus confirming 
the necessity of adjuvant co-administration to mount an immune response against IVIg. Here we 
therefore demonstrated that IgG1, IgG2a and IgG2b appear to be the main isotypes of the anti-IVIg 
antibody response.  
2.3. Isotypes of the anti-IVIg response 
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Figure 34: IgG1, IgG2a and IgG2b appear to be the main isotypes of the anti-IVIg antibody response. 
C57Bl/6NCrl mice were injected 3 times weekly s.c in the neck with different doses IVIg in combination with OVA 
and/or adjuvant MF59 as indicated. Mice were terminated 24h after last injection. ELISA assays were performed on 
mouse serum. (A) IVIg-specific mouse IgG isotypes upon IVIg dosing. Data are from one experiment (n=3). 
(B) IVIg-specific mouse IgG isotypes with and without adjuvant administration. Data are from 2 independent 
experiments (n=6). For (A) and (B) bars represent mean ± SD. Values as expressed as O.D. measured at 405 nm.. 
Serum dilutions were the following: IgG1 1/1600; IgG2a 1/100; IgG2b 1/100; IgM 1/100. Statistical significance was 
tested using one-way ANOVA with Tukey’s correction. Star maker significant difference *: p < 0.05; **p<0.01; 
***: p<0.001; ****: p<0.0001. n.d: not detected. ns: not significant. 
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After it has been demonstrated that IVIg reduced the OVA-antibodies titer, it was assessed 
whether IVIg can inhibit the differentiation of B cells into plasma cells, or if it might impair their 
immunoglobulin secretion ELISPOT appeared to be the best functional assay to evaluate the 
frequency of immunoglobulin-secreting cells or ISC.  
As illustrated in Figure 35A and B, IVIg significantly increased the number of total IgG 
ISC in both axillary/brachial lymph nodes and cervical lymph nodes, of about 15- and 6.5-fold 
respectively, compared to OVA-immunized mice. These results reveal the strong formation and 
activation of plasma cells in the presence of IVIg rather than exhaustion or an inhibitory effect. 
There was no change in the frequency of IgG-ISC in bone-marrow and spleen upon IVIg 
treatment. This is most likely due to the fact that these lymph nodes are the primary draining 
organ after IVIg injection, whereas spleen re-circulation is more systemic. These results are in 
line with the data reported in sections 1.3, 1.4 and 1.5 showing more prominent effects of IVIg on 
B cell activation in draining lymph nodes compared to the spleen. In agreement with the 
formation of numerous germinal centers (GC) in the spleen upon IVIg and adjuvant injection (as 
seen in section 1.7), it could be expected an increase in total IgG-ISC in the spleen as well. 
However, it is important to note that this increase in GC formation in the spleen was not 
systematic since it could not be observed in all experiments, whereas the effect of IVIg on GC in 
lymph nodes was very consistent thoughout all experiments.  In addition, the ELISPOT data are 
derived from a single experiment with n=3. Therefore, the IgG-ISC in the spleen may have been 
missed in that experiment.  
OVA-specific IgG antibody-secreting cells (ASC) frequency was also assessed by 
ELISPOT (Figure 35C). Consistent with the observation that IVIg reduced the production of 
OVA- specific IgG, IVIg reduced the proportion of OVA-IgG ASC relative to the total IgG ISC. 
These data reflect a massive recruitment of IVIg-specific B cells and their further differentiation 
into plasma cells, which as a consequence may reduce efficient mobilization of OVA-specific 
immune cells. We observed no effect of IVIg administration on total IgM-ISC (Figure 35D). 
Taken together these results are in line with ELISA data showing that IVIg consistently induced a 
strong antibody response in mice, mainly formed by IgG isotypes. 
2.4. IVIg increases IgG-Immunoglobulin secreting cells as measured by ELISPOT 
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Figure 35: IVIg administration in mice increases the number of IgG-secreting cells in lymph nodes while 
reducing the proportion of OVA-specific IgG secreting cells.  C57Bl/6NCrl mice were injected 3 times weekly s.c 
in the neck with 50 mg of IVIg in combination with OVA and adjuvant MF59 as indicated. Mice were terminated 
24h after last injection, cells were processed from lymphoid organs and plated for ELISPOT assay. (A) Total IgG 
Immunoglobulin-secreting cells (ISC). (B) ELISPOT showing total IgG-ISC for one representative animal (n=3). 
The number of spots was counted and reported in graph (A). (C) Proportion of OVA-specific IgG antibody secreting 
cells (ASC) relative to total IgG ISC. (D) Total IgM ISC. Bars represent mean ± SD. Data are from one experiment 
(n=3). Statistical significance was tested using two-way ANOVA with Dunnett’s correction. Star maker significant 
difference *: p < 0.05; **p<0.01; ***: p<0.001; ****: p<0.0001. 
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Overall our data suggest that IVIg strongly triggers the mouse immune system, including the 
secretion of IVIg-specific IgG antibodies as discussed above. This points towards a massive 
T-cell dependent antibody response against IVIg, which might compete out the T-cell dependent 
antibody response against OVA. To address whether IVIg is able to downregulate the antibody 
response against a thymus-independent antigen (TI-Ag), the TI-Ag NP-Ficoll was co-
administered together with IVIg. NP (4-Hydroxy-3-nitrophenylacetic) is a hapten, a small non-
immunogenic molecule that is conjugated to Ficoll, a high molecular weight polysaccharide that 
is highly immunogenic. As control, a group of mice were co-injected with IVIg and NP-OVA as 
a thymus-dependent antigen (TD-Ag).  
 
Figure 36: IVIg doesn’t decrease the NP-antibody response when mice are immunized with NP-Ficoll, a TI 
antigen. C57Bl/6NCrl mice were injected 3 times weekly s.c in the neck with 50 μg of NP-OVA or NP-Ficoll 
together with adjuvant MF59, with or without IVIg as indicated. Mice were terminated 24h after last injection and 
serum was collected. (A) ELISA for NP-specific mouse IgG were on serum diluted 1:500.  (B) ELISA for NP-
specific mouse IgM on serum diluted 1:50. Bars represent mean ± SD. Data are from one experiment (n=6). 
Statistical significance was tested using two-tailed unpaired t-test. Star maker significant difference *: p < 0.05; 
**p<0.01; ***: p<0.001; ****: p<0.0001. ns: not significant. 
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IVIg administration efficiently decreased the production of NP-specific IgG in mice 
immunized with NP-OVA, with a reduction of 88% in the antibody titer (Figure 36A). This 
shows good reproducibility with the data obtained in OVA-immunized mice. The NP-antibody 
response in NP-Ficoll immunized mice was mainly of IgM isotype (Figure 36B), with almost no 
IgG detected (Figure 36A). This is in line with the fact that T cells are needed to mediate isotype 
switching from IgM to IgG. IVIg significantly reduced the NP-specific IgM titer in NP-OVA 
immunized mice (51% of reduction), although the inhibition was stronger in the NP-IgG titer, as 
expected for a TD antigen. IVIg injections didn’t significantly reduce the NP-specific IgM titer in 
NP-Ficoll immunized mice (Figure 36B). These results demonstrate that IVIg can significantly 
inhibit an antibody response targeted against a TD antigen, but has no effect on the antibody 
response towards a TI antigen. Therefore, this suggests that T cells are essential for IVIg to exert 
its inhibitory effect on the antibody production.  
 
3. Additional control experiments  
Intrinsic factors in the IVIg product could have possibly induced a strong activation of the 
immune system in vivo in mice. Indeed, presence of endotoxins in the formulation could be 
responsible for such activation, as well as the presence of degraded products such as free heavy 
or light chains, that could potentially constitute a source of new epitopes that are normally hidden 
in an intact IgG molecule. In addition, aggregation of recombinant proteins has been shown to 
enhance activation of both innate and adaptive immunity (Joubert et al., 2012; Rombach-Riegraf 
et al., 2014), and to ultimately lead to the formation of anti-drug antibodies (van Beers et al., 
2010).  
Therefore, to rule out such possible implications in the IVIg effects observed on immune 
cells, endotoxin measurements, electrophoresis and sub-visible particles count were performed on 
the IVIg preparation which was used for the experiments reported here (Octagam; Octapharma), 
as well as on the human monoclonal IgG control antibody Avastin and for some analyses the 
second human monoclonal IgG control antibody Vectibix. Both antibodies and IVIg were free of 
endotoxin as the levels obtained were below the detection limit (Figure 37A). Results from 
capillary electrophoresis show one main peak for both, IVIg and Avastin with high purity (Figure 
3.1. Analytics on IVIg preparation versus human mAb preparations 
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37B), thus excluding a significant amount of -degradation products in both, IVIg and Avastin. 
Sub-visible particle analyses demonstrated that the tested IVIg preparation overall contains less 
aggregates compared to the reference antibody Avastin (Figure 37C). This indicates that 
aggregates are unlikely to play a major role in IVIg-specific effects. As an additional control, Fc-
glycan profile was analyzed on the human monoclonal IgG antibodies Avastin and Vectibix. 
Indeed, as reviewed in the introduction part (section 3.1.4), the role of Fc-sialylation in the anti-
inflammatory properties of IVIg remains unclear and highly controversial. Since we observed no 
anti-inflammatory effects in our experiments with both Avastin and Vectibix (see results part 
section 1.5), presence of sialic acids on the Fc part of these two antibodies would have ruled out 
the role of Fc-sialylation involvement in IVIg inhibitory effect in the OVA-antibodies response. 
Results of glycoprofiling show that neither Avastin nor Vectibix contain sialylation on their Fc-
part (indicated as S1 and S2 in Figure 37D, for glycan structures explanations please refer to 
figure 12 in the introduction part section 3.1.4).  These data could therefore not exclude a 
possible role of Fc-sialylation in the anti-inflammatory properties of IVIg. Due to the complexity 
of IgG molecules present in IVIg, the glycan profile of IVIg couldn’t be measured.  
IVIg and Avastin were applied on a chip coated with more than 9000 human proteins to 
study potential binding interactions. Figure 38 illustrates a magnified section of each array, with 
each spot representing a specific coated human protein. Intense red spots seen identical on both 
arrays represent positive controls. IVIg bound to a lot of different human proteins as compared to 
Avastin, but with low signal intensity. This low signal might be explained by either a low affinity 
and/or unspecific polyreactive binding. Specific-antibodies present at low concentration in the 
IVIg preparation might also result in a low-intensity signal. These data thereby provide insights 
in IVIg polyspecificity for human self-proteins. This is in line with several studies showing that 
IVIg reacted with several human self-proteins, as reviewed in introduction section 3.2.2. 
Moreover, we demonstrated in a competition assay that mouse antibodies specific for IVIg are 
mainly directed towards its Fab region (section 2.1.3). All together this supports the notion that 
IVIg might likely react with B cell receptor through anti-idiotypic binding.   
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Figure 37: Various analytics performed on IVIg and Avastin preparations. (A) Endotoxin measurments. 
(B) Capillary electrophoresis to determine the purity and integrity of IgG molecules (Caliper LifeSciences 
technology). (C) Sub-visible particles count by MFI. (D) Fc-Glycan profiling by LC-MS. 
Figure 38: Evaluation of IVIg and Avastin binding to human proteins. The picture illustrates magnified section 
of the same region of both arrays.  Antibodies were applied at 5 μg/mL each on a Invitrogen ProtoArray®  5.1 coated 
with a panel of human proteins. Intense red spots seen identical on both arrays represent positive controls. 
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In order to eliminate potential bias in the experimental outcomes due to the use of a single 
adjuvant, various adjuvants were tested in vivo under the same OVA immunization procedure, 
and effects of IVIg were investigated. LT (R192G/L211A) and MF59 (AddaVax®) stimulate a 
balanced Th1/Th2 immune response, whereas CpG (ODN 2395) and MPLA-SM stimulate a Th1 
response and Aluminum a Th2 response. MF59 (AddaVax®) was the adjuvant which was the 
most potent as it raised the highest titer of mouse IgG1 anti-OVA (Figure 39A). Very 
interestingly, administration of IVIg significantly downregulated the production of IgG1 anti-
OVA in mouse serum by about 5-fold for all the five different adjuvant tested, irrespective of the 
potency of the adjuvant (Figure 39B). Similarly, IVIg significantly increased the weight of 
draining lymph nodes (2 to 3-fold). Weight of the spleen was not consistently increased upon the 
different adjuvants, which is in line with data showing that the IVIg effect in the spleen is not 
strong and consistent. The expression of CD86 and CD83 on B cells was augmented (2 to 3-fold 
and 1.5 to 2-fold, respectively) when co-injected with each of the five different adjuvants (Figure 
39C). This data thereby demonstrate the robustness of the mouse in vivo model used in these 
studies and provide great confidence in the reproducibility of the experiments. 
  
3.2. Testing of various adjuvants 
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Figure 39: IVIg inhibits the formation of OVA-specific IgG1 and activates B cells when administered with 
different adjuvants. C57Bl/6NCrl mice were injected 3 times weekly s.c in the neck with 50 mg of IVIg in 
combination with OVA and different adjuvants as indicated. Mice were terminated 24h after last injection. 
(A) ELISA to measure OVA-specific mouse IgG1. (B) ELISA data of figure (A) presented as ratio to “OVA+Adj” 
group. (C) Results from weight measurement and flow cytometry analyses. Bars represent mean ± SD. Data are from 
one experiment (n=3). For figures (A) and (B) n=12 for Adjuvant LT(R192G/L211A) (3 independent experiments);  n=3 
for CpG; n=3 for MPLA-SM; n=6 for Aluminum (2 independent experiments); n=9 for MF59 (3 independent 
experiments). For figures (C) n=12 for Adjuvant LT(R192G/L211A) (3 independent experiments);  n=3 for CpG; n=3 for 
MPLA-SM; n=6 for Aluminum (2 independent experiments) for spleen and axillary/brachial LN; n=3 for Aluminum 
for cervical LN; n=12 for MF59 (4 independent experiments). Statistical significance was tested using two-way 
ANOVA with Dunnett’s correction. Star maker significant difference *: p < 0.05; **p<0.01; ***: p<0.001; 
****: p<0.0001. 
A B 
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To further evaluate the robustness of the data obtained with the OVA-immunization in an 
in vivo model, the ability of IVIg to inhibit the production of antibodies against an alternative 
antigen was assessed. To this purpose mice were immunized with BSA and in a separate group 
IVIg was co-administered, respecting the same injection scheme as in the OVA immunization 
model.  Consistent with the observation that IVIg downregulated the humoral response against 
OVA, the titer of anti-BSA IgG was significantly lower upon IVIg administration (Figure 40A). 
Effects of IVIg on the weight of lymphoid organs as well as on CD86 and CD83 expression on B 
cells were even more pronounced as compared to OVA experiments (Figure 40B). For instance in 
the draining lymph nodes, the weight was increased of about 3-fold  and CD86/CD83 expression 
on B cells up to 4-5-fold. These results therefore indicate that IVIg effects could be reproduced in 
the in vivo mouse model upon immunization with a different antigen, thus confirming the 
robustness of the results. 
  
3.3. BSA immunization 
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Figure 40: IVIg inhibits IgG response against BSA while activating B cells in vivo. C57Bl/6NCrl mice were 
injected 3 times weekly s.c in the neck with 50 mg of IVIg in combination with 50 μg BSA and adjuvant as 
indicated. Mice were terminated 24h after last injection. (A) ELISA to measure BSA-specific IgG antibodies. Values 
as expressed as relative units to standard. (B) Results from weight measurement and flow cytometry performed on 
lymphoid organs. Values as expressed as ratio to “OVA+Adj” group. Bars represent mean ± SD. Data are from one 
experiment (n=3). Statistical significance was tested using one-way ANOVA with Dunnett’s correction. Star maker 
significant difference *: p < 0.05; **p<0.01; ***: p<0.001; ****: p<0.0001. n.d: not detected.  
A 
B 
 112 
 
In order to rule out any involvement of IVIg formulation in impairing the anti-OVA 
response, or in the marked activation of the mouse immune system, the buffer contained in IVIg 
preparation was injected in mice. After centrifugation of IVIg on a 30 kDa filter, flow-through 
was administered to mice at the same volume as IVIg. As expected, injection of IVIg formulation 
buffer was not able to diminish the titer of anti-OVA IgG produced in immunized mice, in 
contrast to IVIg, which reduced it 4.9-fold (Figure 41A). In a similar way, injection of IVIg 
formulation buffer didn’t lead to an increase in the weight of draining lymph nodes or up-
regulation of CD83 expression on B cells (Figure 41B), unlike IVIg which mediated these effects 
in a very reproducible manner.  
  
3.4. Injection of IVIg formulation buffer 
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Figure 41: Formulation buffer of IVIg is not able to reproduce IVIg effects. C57Bl/6NCrl mice were injected 3 
times weekly s.c in the neck with 50 μg OVA and adjuvant, and IVIg or its formulation buffer was eventually co-
injected as indicated. Mice were terminated 24h after last injection. (A) ELISA to measure OVA-specific IgG 
antibodies. (B) Results from weight measurement and flow cytometry performed on lymphoid organs. Values as 
expressed as ratio to “OVA+Adj” group. Bars represent mean ± SD. Data are from one experiment (n=3). Statistical 
significance was tested using one-way ANOVA with Dunnett’s correction. Star maker significant difference *: p < 
0.05; **p<0.01; ***: p<0.001; ****: p<0.0001. n.d: not detected. ns: not significant. 
 
B 
n.d 
A 
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As a massive and polyclonal B cells activation was associated with IVIg administration, 
mice were injected with LPS to test if this could mimic some or all IVIg effects. LPS is a TI 
antigen that is known to be a potent B-cell mitogen. Following the usual procedure, mice were 
immunized with OVA and adjuvant, and LPS was optionally co-injected. Administration of LPS 
did not result in a reduction of the anti-OVA IgG titer as it was observed in previous experiments 
with IVIg, but instead lead to an increased antibody response against OVA (Figure 42A).  This 
can most likely be explained by the fact that LPS potentiated the effect of the MF59 adjuvant by 
acting synergistically. Despite a number of studies have reported that LPS induced up-regulation 
of co-stimulatory molecules on murine B cells in vitro (Xu et al., 2008), no such effect could be 
observed in vivo as measured by flow cytometry (Figure 42B). LPS treatment also had no 
influence on the weight of secondary lymphoid organs. 
  
3.5. Injection of LPS 
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Figure 42: LPS did not mediate same effects as IVIg in vivo. C57Bl/6NCrl mice were injected 3 times weekly s.c 
in the neck with 50 μg OVA and adjuvant, and with or without LPS co-injected as indicated. Mice were terminated 
24h after last injection. (A) ELISA to measure OVA-specific IgG antibodies. Values as expressed as relative units to 
standard. (B) Results from weight measurement and flow cytometry performed on lymphoid organs. Values as 
expressed as ratio to “OVA+Adj” group. Bars represent mean ± SD. Data are from one experiment (n=3). Statistical 
significance was tested using one-way ANOVA with Dunnett’s correction. Star maker significant difference 
*: p< 0.05; **p<0.01; ***: p<0.001; ****: p<0.0001. n.d: not detected.  
A 
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Data presented here demonstrated that IVIg reduced the OVA-specific antibody response 
in vivo, while at the same time inducing a massive activation of the immune system mostly 
against IVIg-Fab regions. To assess whether these effects could be reproduced in the context of 
an autoimmune disease mouse model, the antigen-induced arthritis model was chosen. This is a 
well-established model that is widely used to study the mode of action of IVIg. When 
administered in a prophylactic regimen (Figure 43A), IVIg efficiently reduced the severity of the 
induced disease as measured by the swelling of the knees in two independent experiments (Figure 
43B and C), thus validating this mouse model for studying IVIg mechanisms. However, the ratio 
of the weight of right and left axillary/brachial and inguinal lymph nodes revealed no difference 
upon IVIg treatment on day 3 (data not shown). There were also no differences in the expression 
of B cell activation markers as measured by flow cytometry (data not shown). Because of results 
obtained with the OVA-immunization model, massive immune cell activation in lymph nodes 
and increased weight were expected to be observed on day 3 when IVIg effects have been found 
to be maximal (see section 1.9). The inflammatory signals generated upon BSA challenge in the 
knee were expected to mediate adjuvant-like effects and thus induce weight increase and B cell 
activation by IVIg, that might account for its effect in disease amelioration. However, these 
inflammatory signals were too weak, most likely because the immunization against BSA was 
inhibited already at the beginning of the experiment on Day -21 thanks to the co-administration 
of IVIg.  Thus, BSA re-call in the knee didn’t provoke significant inflammatory signals and 
couldn’t allow IVIg to trigger a massive immune response. Therefore, the prophylactic regimen 
of IVIg was not designed for the purpose of seeing a potential B cell activation. In a follow up 
experiment the IVIg effect could be studied in a therapeutic setting where IVIg is injected on 
day 0 only. This wuld maximize the chances to observe IVIg effects on day 3. Moreover, a 
therapeutic regimen is closer to the clinical situation where patients are treated with IVIg after the 
onset of the inflammatory disease.   
3.6. AIA mouse model 
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Figure 43: Prophylactic administration of IVIg ameliorates knee swelling in an AIA mouse model. (A) Scheme 
of the injections. Balb/cByJ mice were immunized intra-dermally (i.d) on day -21 and day -14 with 2x50 μL of 
homogenate containing 2 mg/mL of methylated BSA. On day 0 mice were challenged with 10 μL of BSA at 
10mg/mL injected intra-articularly (i.a) in the right knee and with 10 μL of vehicle in the left knee. 50 mg of IVIg or 
PBS was given sub-cutaneously (s.c) on days -21, -14 and 0. Knee swelling was measured as indicated by green 
arrows. On day 3 half of the group was terminated and flow cytometry measurements were performed on cell 
suspension from spleen and lymph nodes. (B) Knee swelling curves. Triangles represent mean ± SD (n=6). (C) Knee 
swelling curves of a repetition experiment. Triangles represent mean ± SD (n=5). Statistical significance was tested 
using two-way ANOVA with Sidak’s correction. Star maker significant difference *: p <0.05; **p<0.01; 
***: p<0.001; ****: p<0.0001.  
B C 
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4. Tregitopes as a potential mechanism in IVIg anti-inflammatory effects? 
De Groot and colleagues (De Groot et al., 2008) have identified in silico conserved 
peptides named Tregitopes in both the IgG Fc and F(ab’)2 regions that bind to multiple MHC 
ClassII determinants. They have published a series of experiment that demonstrate that 
Tregitopes, can provide immunomodulatory effects both in vitro and in vivo, and can thereby 
account for the therapeutic effects of IVIg. They hypothesized that these Tregitopes, once 
presented by APCs, activate Tregs which in turn lead to the suppression of bystander effector T 
cells that recognize effector epitopes. Thus, they claimed that Tregitopes lead to the suppression 
of antigen-specific immunogenicity by tipping the balance toward tolerance rather than effector 
immune response. Here we attempted to reproduce the work they published to assess if 
Tregitopes could indeed constitute one potential mechanism by which IVIg promotes its 
immunomodulatory effects. De Groot and colleagues identified two IgG Fc-derived Tregitopes, 
namely 167 and 289, using in silico screening based on their likelihood to bind to the 8 most 
common human HLA-DRB1 alleles.  
For evaluation of the published Tregitopes in human in vitro assays and mouse in vivo 
assays, suitable peptide controls had to be identified, which were well presented by HLA class II 
or MHC class II molecules. Some control peptides should be derived from the constant region, 
similar to the published Tregitopes but more importantly, peptides from non-conserved regions 
had to be selected which should not act as Tregitopes, based on de Groot’s model.   By applying 
MHC-II associated peptides proteomics (MAPPs) on IVIg-loaded human DCs, IVIg-derived 
peptides were identified, and they clustered in several regions along the sequence of the reference 
antibody (Figure 44A). These peptides were detected multiple times and in several different 
lengths, thus increasing the confidence in the peptide identification method and serving as the 
basis to identify sequence regions that were strongly presented by DCs. Several sequence regions 
showed promiscuous binding to different HLA alleles, since they occurred across several donors. 
In total, four strongly and commonly presented sequence regions were selected: two in the 
variable region and one in the constant region of the light chain as well as one in the variable 
region of the heavy chain. Due to the high diversity in the sequences of IgGs contained in IVIg, 
the presented regions showed some diversity regarding their sequence in the variable domains. 
This shows that several slightly different peptides are able to bind to the same HLA class II 
4.1. Identification of Ig-derived MHC-II peptides in human and mouse 
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molecule thanks to conserved binding residues. Since the number of test sequences had to be 
limited, we chose the corresponding sequences of well-characterized marketed mAbs, either 
Humira a fully human antibody or Remicade a chimeric antibody which are both immunogenic in 
the clinic. Moreover, additional peptides were tested that represented the consensus sequence of 
the different peptides identified within a sequence region. To this end, the amino acid with the 
highest occurrence per position was used for the consensus. Interestingly, some but not all donors 
tested in the MAPPs assay presented the published Tregitope 167. Notably, the published 
Tregitope 289 was never detected in the MAPPs assay. Finally, a total of 7 human peptides were 
synthesized and tested in both, in vitro and in vivo (Figure 44B). 
In order to identify I-A associated IgG-derived peptides naturally presented in the mouse, 
we applied the MAPPs assay to cell suspensions obtained from spleen or lymph nodes collected 
in C57Bl/6NCrl naïve mice. In total we could identify 4 clusters, located in the constant region of 
the heavy chain or in the variable region of the light chain. Two additional peptides bearing the 
mouse equivalent sequence of human peptides HC-76 and LC-167 were also synthesized to be 
tested in the assays (Figure 44B). 
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Figure 44: Identification of IgG-derived naturally presented MHC-II associated mouse and HLA-II associated 
human peptides by MAPPs assay. (A) Identification of main peptide-clusters from IVIg-loaded human DCs from 
one blood donor. The sequence of the reference antibody used for alignment is depicted in grey. Peptides were 
detected by LC-MS multiple times and in several different lengths, forming clusters in several regions along the 
sequence of the reference antibody. CDR regions are depicted in red. (B) List and sequences of IgG-derived human 
and mouse peptides identified, from IVIg-loaded human DCS or from mouse spleen and LN respectively. Peptides 
were numbered according their position in the sequence and named as follows: first letter H=heavy chain/ L=light 
chain; second letter H=Humira antibody sequence; R= Remicade antibody sequence; C= Consensus peptide (amino 
acid with the highest occurrence per position was used). human-equivalent means this sequence was not identified by 
MAPPs performed on mouse cells but still was synthesized to be further tested in the different assays.  
A 
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Each tested peptide was added simultaneously with tetanus toxoid (TT) to human PBMCs 
in vitro, and CD4+ T-cell proliferation was assessed by flow cytometry via CFSE staining. PHA 
positive control led to a high response in all donors with a proliferation rate from 50 % up to 
80 %. TT stimulation led to proliferation rate between 5 and 50 % and was very donor dependent, 
likely due to their vaccination status. Proliferation results were calculated as stimulation index 
(S.I.) and normalized against the group stimulated with tetanus toxoid alone (Figure 45A). 
Addition of a control peptide, Betv1a (major birch pollen allergen), led to a small but not 
significant reduction in T-cell proliferation. This might be due to the fact that all peptides are 
dissolved in DMSO, with a final volume in the well of 0.1 %.  DMSO is known to be toxic for 
cells and thus even small doses may interfere with the proliferation of T cells. Therefore, baseline 
for reference was not set-up at 1 (TT group) but at the mean of the Betv1a group. Unlike what 
has been published by De Groot et al., addition of human Tregitopes 167 and 289 had no effect 
on T-cell proliferation induced by TT stimulation, and neither had any of the other tested human 
peptides. In addition, Tregitopes 167 and 289 bearing acetylation on their N-terminus and 
amidation on their C-terminus were also tested, as these modifications were also used in the work 
published by De Groot et al. None of these modified two Tregitopes was able to reduce T-cell 
proliferation upon TT stimulus. Interestingly, IVIg used at 6 mg/mL led to a significant reduction 
of T-cell proliferation of about 50 % in average, therefore constituting a nice positive control to 
the experiment. When used at a dose 10 times lower, IVIg inhibition effect was lost. These data 
are in line with the data obtained in vivo with the OVA-immunization mouse model. Thus, this 
validates the relevance of the mouse model used here to study IVIg effects, since it nicely makes 
the analogy to findings in humans.  
4.2. In vitro human T cell proliferation assay 
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Figure 45: Published Tregitopes and peptides from diverse IgG sequence regions have no effect on human T-
cell proliferation and % Tregs upon stimulation with tetanus toxoid. (A) Proliferation of CD4+ T cells. Human 
PBMCs were stimulated with 6 μg/mL of tetanus toxoid (TT) and peptides (10 μg/mL) were co-incubated at the 
same time as indicated. After 7 days proliferation of CD4+ T cells was assessed by flow cytometry via CFSE 
staining. Stimulation index (S.I) was calculated by dividing the % proliferation obtained by which obtained with the 
negative control (no stimulation, medium only). Values are expressed as S.I. ratio to the TT group. n= 11 to 26 
donors. (B) % Tregs (CD4+CD25+Foxp3+) after 7 days. n= 15 donors. (C) Gating strategy for flow cytometry. For 
both graphs lines represent mean.  Statistical significance was tested using one-way ANOVA with Dunnett’s 
correction. Star maker significant difference *: p < 0.05; **p<0.01; ***: p<0.001; ****: p<0.0001. 
aa
: acetylated and 
amidated peptide.  
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In the same set of experiments the Tregs population was investigated, which was expanding 
upon addition of Tregitopes ex vivo in the experiments published by De Groot et al... In contrast 
to their results, co-incubation with Tregitopes 167 and 289 (both chemically modified and non-
modified) did not lead to expansion of CD4+CD25+Foxp3+ Tregs 7 days after stimulation 
(Figure 45B). Intriguingly, IVIg high dose led to a decrease in the percentage of Tregs, although 
not significant. These data are in contrast to a study published by Kessel and colleagues, showing 
that in vitro culture of IVIg with peripheral human T cells led to increase in % Foxp3 expressing 
cells among CD4+CD25
high
 T cells (Kessel et al., 2007). However, this decrease in Tregs upon 
IVIg addition is in correlation with the data obtained in vivo that show overall an immune 
activation. 
The ability of Tregitopes to suppress in vivo an immune response to a specific antigen was 
next examined, as it has been demonstrated by De Groot and colleagues in HLA-DR4 transgenic 
mice immunized with house dust mite lysate (De Groot et al., 2008). For this purpose the 
standard OVA immunization protocol was used in wild-type Bl6 mice, as described in the 
material and methods section 1.1. Consistent with human in vitro data obtained above, neither 
mouse Tregitopes 167 and 289 nor the other tested peptides were able to downregulate the 
production of OVA-specific antibodies in mouse serum (Figure 46A and B). Importantly, the 
same adjuvant LT (R192G/L211A) employed by De Groot and colleagues was used (not published, 
personal communication), as well as the standard adjuvant MF59 (AddaVax®) used in most of 
the experiments presented here, and the results obtained were similar. In addition, co-
administration of OVA together with human Tregitopes 289 and 167 was tested, but similarly to 
their mouse counterparts they did not suppress the antibody response against OVA (Figure 46C). 
However, in all experiments high dose IVIg injections led to a strong and significant reduction in 
OVA-specific antibodies. This validates the use of this in vivo model for studying the potential of 
Tregitopes, since they are supposed to mimic the effects attributed to IVIg. Moreover, it 
demonstrates once again the robustness of the data obtained with IVIg. 
Taken together, results from a human in vitro T-cell assay and a mouse in vivo experiment 
indicate that published as well other tested IgG-derived potential Tregitopes had no effect on 
Tregs and showed no immunosuppressive activity. This therefore challenges the concept of 
Tregitopes elaborated by De Groot et al.  
4.3. In vivo OVA immune response 
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Figure 46: Published human and mouse Tregitopes as well as other test peptides were not able to reduce the 
titer of OVA-specific IgG in OVA immunized mice. C57Bl/6NCrl mice were injected 3 times weekly s.c in the 
neck with 50 μg OVA and adjuvant, with or without peptides (50 μg each) or IVIg (50 mg) co-injected as indicated. 
Mice were terminated 24h after last injection (A) ELISA anti-OVA IgG1 upon use of Adj LT(R192G/L211A) (n=6). (B)  
ELISA anti-OVA IgG1 upon use of Adj MF59 (n=6 except for tested peptides n=3). (C) ELISA anti-OVA IgG upon 
use of Adj MF59 (n=3). mo: mouse. hu: human. mo 1- to 6: mouse peptides identified in vitro via MAPPs assay. 
[ace, amid]: acetylated and amidated peptide. For all graphs bars represent mean ± SD. Statistical significance was 
tested using one-way ANOVA with Dunnett’s correction. Star maker significant difference *: p<0.05; **p<0.01; 
***: p<0.001; ****: p<0.0001. 
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5. IVIg doesn’t compete with presentation of OVA-derived peptides on MHC 
Class-II on human DCs in vitro 
 
To investigate whether IVIg could impair the presentation of OVA-derived peptides on HLA 
Class II molecules, human DCs were matured with LPS and simultaneously loaded with OVA 
and IVIg in vitro. IVIg and OVA-derived HLA Class II peptides were identified via the MAPPs 
technique. MAPPs uses liquid chromatography to separate the different peptide species in the 
mixture and the eluted peptides are measured by mass spectrometry. When a peptide peak is 
eluted from the chromatography column, the mass spectrometer will trigger multiple mass 
spectra. Two approaches were selected to evaluate the impact of IVIg on the presentation of 
OVA peptides. In the first approach, peptides were identified via database search which compares 
the measured spectra with theoretical spectra from a protein database. This method is only semi-
quantitative since the chromatographic co-elution of several peptide species at the same time will 
compete with the detection in the mass spectrometer. Moreover, only high quality mass spectra 
are identifiable by database search. Thus, the number of peptides identified from the number of 
detected mass spectra is only a semi-quantitative method. For each identified peptide, the number 
of repeated identifications was counted (Figure 47A). The number of OVA-derived peptides 
presented on HLA Class II determined by this method on 5 different donors (3 low dose, 2 high 
dose), was similar in samples loaded with and without IVIg. Exemplarily, data for two donors are 
shown in Figure 47A. Similarly, IVIg didn’t impair the presentation of peptides derived from two 
proteins, ANXA2 and MAN2B1 which are naturally presented in many donors. In the second 
approach, several well-presented OVA-peptides identified via the semi-quantitative approach 
were selected for a more robust quantification based on the integration of the area under the 
peptide elution peak from the extracted ion chromatograms. This allows for determination of the 
amount of peptide present in the DCs sample that was eluted from the LC column. The results 
revealed that the presentation of OVA-derived peptides on MHC Class II was not affected by 
IVIg. Exemplarily, data for two donors are shown in (Figure 47B).  
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Figure 47: IVIg doesn’t impair the presentation of OVA-derived peptides on MHC Class II when loaded 
simultaneously with OVA on human DCs in vitro. (A) Semi-quantitative number of identical peptides derived 
from OVA and two other well-presented proteins, ANXA2 and MAN2B1. (B) Quantification of the area under curve 
from the extracted ion chromatograms of selected OVA-peptides. Human DCs isolated from different donors were 
loaded in vitro with OVA at 14 nmol/mL, with or without IVIg either at 14 nmol/mL or at 117 nmol/mL. Exemplary 
data from 2 donors are shown.   
A 
B 
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 Discussion and Conclusion  
 
IVIg is a natural blood product, purified from several thousand donors and therefore 
constituted of a pool of highly polyclonal IgG. IVIg was initially used as a replacement therapy 
in patients with primary immune deficiencies to supply them with immunoglobulins. Since IVIg 
has been shown in 1981 to ameliorate ITP in patients, IVIg is increasingly being used in the 
clinic for the treatment of a wide range of autoimmune and severe inflammatory diseases, mostly 
as off-labeled use. Due to its elevated cost and an inevitable upcoming shortage, attention has 
been drawn to try to understand its therapeutic mode of action. Indeed identifying the active 
ingredients in IVIg would allow the development of IVIg-derived substitutes which would reduce 
the use of plasma-derived IVIg and thereby secure its supply for patients for which there are no 
alternative treatments. Despite an increasing number of studies providing new insights, they have 
shown a lot of discrepancies in their outcomes and thus IVIg mechanisms of action still remain 
poorly understood to date.  The aim of this PhD project was to provide a better comprehension of 
the disease ameliorating mechanisms of IVIg. 
First of all the OVA immunization model in Bl6 mice has been proven to be suitable to study 
IVIg effects. IVIg subcutaneous administration reduced immunogenicity against OVA in a dose-
dependent manner and this effect was significant only for doses not lower than 1 g/kg. A high 
dose of IVIg led to a reduction in OVA-specific antibodies of about 70 % within 2 weeks. These 
results nicely reflect what has been observed in the clinical setting in pemphigus vulgaris 
patients, where pathogenic autoantibodies rapidly declined by an average of 59 % within 1 week 
after initiating IVIg treatment and by 70 % within 2 weeks (Bystryn and Jiao, 2006). Moreover, 
this mouse model is simple, quick, has the advantage to use wild-type mice, and provided very 
reproducible data throughout the different experiments. Although this model does not account for 
the use of intravenous Ig, subcutaneous Ig (SCIg) has been reported in several recent clinical 
studies as a convenient alternative to IVIg with less adverse events, most likely due to different 
kinetics and distribution (Danieli et al., 2014). SCIg provides ease of self-administration and a 
similar efficacy as IVIg (Hadden and Marreno, 2015).  Even though more clinical trials are 
needed for all indications, the several benefits associated with SCIg make it an emerging 
therapeutic approach, therefore rationalizing the choice of the applied mouse model. 
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To summarize the findings presented here, OVA immunization consistently led to a robust 
OVA-specific IgG response in mice.  As expected in such a context of inflammation, this leads to 
a small increase in the weight of the draining lymph nodes as well as in T and B cell numbers. 
OVA injection together with adjuvant up-regulated the expression of co-stimulatory molecules 
on B cells to some extent and induced the formation of a few and small germinal centers (GC), as 
compared to adjuvant alone. In line with this immune activation, OVA immunization decreased 
the number of mature re-circulating B cells in the bone-marrow. In comparison, when high dose 
IVIg was injected in addition to OVA and adjuvant, this led to a considerable gain in weight in 
the corresponding draining lymph nodes, associated with an increased number of both B and T 
cells. Co-stimulatory molecules CD86 and CD83 as well as the early lymphocyte activation 
marker CD69 were found to be strongly up-regulated on the surface of B-cells upon IVIg 
treatment, as compared to treatment with OVA and adjuvant. CD80 expression on B cells 
remained unchanged after IVIg treatment, and effect of IVIg on CD40 and MHC-II expression on 
B-cells was considered as negligible. These data are in line with studies showing that CD80 
remains poorly expressed on B cells after stimulation (Lenschow et al., 1994), while up-
regulation of CD86, CD83 and CD69 appear to be a clear signature of B-cell stimulation (Kohm 
et al., 2002; Prazma et al., 2007; Purtha et al., 2008). Moreover, we demonstrated that IVIg 
treatment triggered activation of B cells in a dose-dependent manner. In line with B cell 
activation, IVIg also promoted activation of T cells, as shown by the increased expression of 
CD69 on CD4+ T cells. Notably, B and T lymphocyte proliferation, as well as B-cell activation 
were visible as early as 2 days after a single shot of IVIg, reaching a maximum on day 3. 
Strikingly, administration of IVIg in mice provoked the formation of large and numerous GC in 
the draining lymph nodes and in the spleen, as compared to OVA-immunized mice. In line with a 
strong recruitment of immune cells ongoing after IVIg treatment, less re-circulating mature B 
cells were detected in the bone marrow of IVIg-treated mice compared to the OVA immunized 
group, suggesting that more B cells were trapped in the draining lymph nodes.  Further analyses 
indicated that IVIg greatly increased the number of IgG-secreting cells in the draining lymph 
nodes while reducing the proportion of OVA-specific IgG secreting cells. This is speaking 
against a direct inhibition of plasma cell differentiation or antibody synthesis, while pointing 
towards a broad immune activation rather than an inhibition. To consolidate the findings on the 
involvement of IVIg in triggering the stimulation of immune cells, the antibody response in mice 
was further characterized. IVIg did elicit a specific IgG antibody response in mice. Additional 
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assays revealed that mouse antibodies raised against IVIg in vivo were mostly directed towards 
IVIg-Fab regions. All together these data suggest that IVIg raises a powerful activation of the 
immune system, although the final outcome is the reduction of OVA-specific antibodies. IVIg 
didn’t impact the production of anti-NP antibodies when mice were immunized with NP-Ficoll, a 
TI antigen, whereas IVIg injections downregulated anti-NP antibodies in NP-OVA immunized 
mice, a TD antigen. These data clearly imply that IVIg inhibitory effects occur mainly in a T-cell 
dependent immune response. 
IVIg decreased the level of total mouse IgG measured in serum in a dose-dependent manner. 
Injection of Avastin, an IgG1 marketed human monoclonal antibody (mAb), had the same effect 
on the total mouse IgG titer. This suggests that high doses of IVIg or Avastin increased antibody 
clearance via FcRn blocking, as it has already been postulated (Bleeker et al., 2001). However, 
both Avastin and Vectibix (mAb IgG2) didn’t decrease the production of OVA-specific 
antibodies in mouse serum when administered at 50 mg/mouse in addition to OVA and adjuvant, 
whereas IVIg significantly did. These results demonstrate that FcRn saturation doesn’t seem to be 
the main driver of IVIg inhibitory effects in the OVA-specific response. In contrast to IVIg, both 
Avastin and Vectibix didn’t affect the weight of lymphoid organs, the number of B and T cells 
and their activation state, as compared to treatment with OVA and adjuvant. Unlike IVIg, Avastin 
treatment neither induced the extensive formation of GC, nor further reduced the number of 
mature re-circulating B cells in the bone-marrow, compared to treatment with OVA and adjuvant. 
These data demonstrate that the extensive activation of the immune system as observed upon 
IVIg treatment could not be achieved with monoclonal IgG molecules, although given at the 
same very high dose. These results collectively suggest that in the presence of adjuvant, IVIg is 
responsible for the powerful activation of the mouse immune system by the presence of many 
different variable regions from several thousand donors in IVIg preparation, comprising a huge 
number of very diverse foreign epitopes.  
Although the number of Tregs was increased upon IVIg injection, expression of Foxp3, 
CTLA-4 and CD25 on their surface remained unaffected, showing there was no activation of 
Tregs. De Groot and colleagues (De Groot et al., 2008) described a mechanism by which 
Tregitopes contained in IgG tip the balance towards tolerance by activating natural Tregs, which 
in turn convert the surrounding effector T cells present on the same APC into adaptive Tregs. In 
the model they propose, teaching the immune system to tolerate a given antigen by co-delivering 
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it with IVIg or Tregitope peptides implies that further re-introduction of this antigen in the body 
would not induce any immune response, despite the absence of IVIg or Tregitopes at this time. 
However, in vivo data revealed that when IVIg injection was discontinued whereas mice were 
continued to be challenged with OVA, the level of OVA-specific antibodies increased over time 
and therefore the inhibitory effects of IVIg were lost. This correlates well with the clinical 
situation, where it has been shown that 87.5% of CIPD patients improved after IVIg therapy, 
whereas 85.7% of the responsive patients worsened only a few months after IVIg discontinuation 
(Nobile-Orazio et al., 2014). In addition, it is well established that IVIg does not cure but rather 
ameliorate most autoimmune and inflammatory diseases, since monthly injections are required 
over years. IVIg seems to have only a short-term effect to enable the rapid resolution of an active 
episode in the context of an inflammatory disease. This disagrees with the notion that IVIg is 
capable of promoting immune tolerance, as suggested by De Groot and colleagues. MAPPs data 
described here revealed that Tregitopes peptides were not well presented in both human DCs and 
mouse splenocytes. Moreover, addition of Tregitopes didn’t induce any inhibitory effect neither 
on human T cell proliferation in vitro nor on the anti-OVA response in vivo in mice. These results 
are in line with a study performed by an independent group which investigated the potential of 
Tregitopes to prevent the onset of type 1 diabetes in NOD mice (Grant et al., 2013). Interestingly, 
there were no significant remissions observed in diabetic NOD mice treated with Tregitopes. The 
difficulty to reproduce De Groot and colleague’s work could be explained by differences in the 
experimental approaches. Indeed, none of their experiment shows the use of an irrelevant peptide 
as a control. Knowing that peptides are dissolved in DMSO and that DMSO is a toxic agent for 
cells, such a negative control appears to be essential to rule out any possible non-peptide specific 
decrease of the immune response. In any of their experiments they used IVIg as a positive control 
in suppressing the immune response. Moreover, most data presented from the various 
suppression assays are from one single donor, which does not consider the high inter-donor 
variability in T cell responses.  They didn’t use Foxp3 as a marker to gate Tregs, which could 
lead to miss-interpretation of the data. Moreover, the decrease in the antigen-specific-antibody 
level observed in vivo upon Tregitopes injection was not significant. Their in vivo model used 
transgenic mice, which may behave in a different manner than wildtype mice. Finally, to our 
knowledge no additional paper bringing some new experimental evidence on the Tregitopes 
suppressive activity has been published so far, but only reviews on possible new approaches for 
treatment of autoimmune diseases. 
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Interestingly, co-injection of adjuvant was required to mediate the pro-inflammatory effects 
of IVIg. Indeed, IVIg injected alone or in combination with OVA didn’t increase the weight of 
lymphoid organs and showed no effect on the number and activation state of T and B cells, unlike 
IVIg with adjuvant. A massive formation of GC was observed in lymphoid organs of mice treated 
with IVIg and adjuvant, but not in mice treated with IVIg alone. Anti-IVIg antibody response 
was detectable in serum only when mice were administered with IVIg and adjuvant with or 
without OVA, but not in mice treated without adjuvant. These data are in line with the fact that 
an adjuvant is usually required to stimulate the immune system and to mount a proper antibody 
response. Presence of adjuvant lead to up-regulation of co-stimulatory molecules on APCs, that is 
necessary to get T cells primed. Similarly, up-regulation of CD40 on B cells surface is required to 
receive an input signal from T helper cells. Thus, co-injection of adjuvant was required to initiate 
the immune response against IVIg in this mouse model. Furthermore, IVIg showed nice efficacy 
in an AIA model by significantly reducing the knee swelling when given prophylactically. 
Although in that case IVIg was injected without adjuvant MF59, a strong pro-inflammatory 
environment was set-up by the use of CFA to sensitize mice to BSA. Still, IVIg is administered 
in patients without adjuvant. To parallel our mouse model to the clinical situation, we suggest 
that inflammation that occurs during an active episode of an autoimmune disease in patients 
would provide danger signals in an “adjuvant-like” manner. This would likely be sufficient to 
activate immune cells against IVIg and reduce the recruitment of other immune cells that are 
antigen-disease specific. 
IVIg has been shown to target the cellular immune compartment at multiple levels, 
including innate and adaptive immune cells. All together our data highlight a massive activation 
of the adaptive immune response upon IVIg administration in mice, resulting in the production of 
IVIg-specific IgG. Although IVIg is generally considered as a safe therapy, some adverse effects 
still frequently occur in patients. These side effects mostly cause discomfort but are often mild 
and not serious. They commonly include headache, nausea, diarrhea, back pain, blood pressure 
changes or urticaria. To be highlighted, some of the frequent side effects also include fever, 
chills, fatigue, flushing, arthralgia (joint pain) or even myalgia (muscle pain) (Hamrock, 2006; 
Katz et al., 2007).  Intriguingly, these latter are common symptoms of infection, and are the 
consequence of the recruitment of effector immune cells to sites of infection. A recent study 
collected adverse events in patients given IVIg infusions over 10 years, mostly indicated for 
Kawasaki disease (Palabrica et al., 2013). 32 % experienced adverse reactions, and symptoms 
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occurred within a few hours after infusion. Notably, fever was the most common side effect 
(30.6 %), followed by rash (22.2 %) and chills (19.4 %). Another clinical study following 
patients treated with high dose IVIg for pemphigus and pemphigoid over 10 years reported for 
the first time hoarseness of voice and swelling of cervical lymph nodes as side effects (Gurcan 
and Ahmed, 2007). These are typical symptoms of an inflammation as well and correlate with our 
finding that IVIg increased the weight of cervical lymph nodes when administered in mice. Acute 
renal failure, a rare but serious adverse event, has also been reported to occur upon IVIg 
infusions. Products containing sucrose as a stabilizer are thought to be responsible for such 
kidney nephrosis (Dantal, 2013). Another clinical study performed over 119 IVIg-treated patients 
for a variety of indications revealed that 6.7 % of patients developed impairment of renal function 
(Levy and Pusey, 2000). However, they showed that this was not associated with the amount of 
sucrose in the IVIg preparation. Interestingly, production of large amounts of IgG and IgM 
subsequently to an inflammatory response can lead to the deposition of immune complexes in the 
kidney. This is a major cause of glomerulonephritis, a commonly associated condition as a result 
of type III hypersensitivity response (Rajan, 2003). Renal failure, although it occurs less 
frequently, could possibly indicate the overproduction of IgG following IVIg infusion and the 
accumulation of immune complexes in the kidney. Strikingly, all the adverse effects listed above 
that commonly occur after IVIg administration are “flu-like” symptoms and might possibly 
reflect a strong immune activation in patients, as we demonstrated in mice.  
 Based on the in vivo studies performed here and on the literature about IVIg-treated 
patients, we propose a model that may likely explain IVIg immunomodulatory properties, in 
which T-cell competition is the key inhibitory event, as illustrated in Figure 48. This model is 
based on antigenic competition.   
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Figure 48: A proposed mechanism of action of IVIg based on T-cell competition effects occurring at several 
stages of the adaptive immune response. (A) Classical immune response and germinal center formation after OVA 
immunization. T cells primed by OVA-derived epitopes presented on APCs differentiate into effector T helper cells 
(TH) and migrate at the T cell–B cell border of the lymph node. OVA-activated B cells take up and present antigenic 
peptides to TH. After receiving co-stimulatory signals they initiate the formation of a germinal center (GC). After a 
cycle of proliferation and somatic hypermutations in the dark zone, B cells moves to the light zone to meet with their 
antigen exposed on follicular dendritic cells (FDCs). If the affinity of the mutated B cell receptor (BCR) is very low, 
the B cell will not receive survival signals and will undergo apoptosis. The surviving B cells need to compete for 
help from T follicular helper cells (TFH), thus favoring the high affinity B cells. B cells can then either re-enter the 
dark zone to further mature its BCR affinity, or exit the GC as plasma cells or memory B cells. (B) IVIg blockade 
mechanism 1): T-cell competition for DCs access.  In addition to OVA-peptides, DCs present a lot of IVIg-derived 
diverse epitopes. This favors the attraction of many different IVIg-specific T cell clones that will compete out OVA-
T cell clones to receive priming from DCs. (C) IVIg blockade mechanism 2): competition for accessing T cell-B cell 
zones border. When a few OVA-T cells clones managed to get primed by DCs, they will be outnumbered by the 
numerous IVIg- TH clones to access the T cell-B cell zones border (2a), so the chances they can engage with their 
cognate OVA-B cells are pretty low. Likewise OVA-activated B cells will be competed out to access their cognate 
OVA-TH by the number of IVIg-B cells at the border (2b). This results in apoptosis of OVA-activated B cells. 
(D) IVIg blockade mechanism 3): TFH competition for centrocytes priming in GC. When a few OVA-T cells clones 
managed to get primed by DCs and to deliver helper signals to their cognate OVA-activated B cells, these latter will 
start forming a GC. However, the help delivered by TFH to centrocytes in GC is very limited. It is therefore more 
likely that OVA-centrocytes will die from apoptosis, the numerous IVIg-TFH competing out the few OVA- TFH for 
centrocytes access. 
 
 
Figure 48A illustrates the classical course of an immune reaction that occurs after OVA 
immunization and results in the production of OVA-specific antibodies. In this OVA-specific 
immune reaction, IVIg might potentially interfere at three different stages, as indicated in the 
figure with blue markings. First, T-cell competition can arise for access to DCs (Figure 48B). 
When IVIg is administered together with OVA, DCs will process both OVA and the polyclonal 
human IgG to peptides. The variable regions from billions of different IgG sequences will 
produce a lot of different peptides. When adjuvant is co-injected, highly diverse IVIg-derived 
potential T cell epitopes are presented on the surface of DCs in the presence of co-stimulatory 
molecules. Due to allelic restriction, normally only a few specific peptides from an antigen can 
stably bind to MHC-II. However, due to the sequence diversity and also to the high dose of IVIg 
injected, it is likely that many more MHC-II: IVIg peptide complexes can be presented by DCs, 
as compared to a conventional antigen. Even if efficiently presented, OVA-derived epitopes 
might be outnumbered by the many different IVIg-derived epitopes on the surface of DCs. Their 
presentation in presence of adjuvant will induce a massive recruitment of T cells with different 
specificities. Consequently, the presence of multiple T cell clones specific for IVIg-peptides 
scanning for their cognate peptides on DCs may compete with OVA-specific T cells regarding 
spatial access to the DCs. Indeed, several studies have already shown that a competition between 
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T cells occurs for antigenic complexes on the surface of APC, inhibiting activation of other 
potentially reactive T cells. This competition has been demonstrated for both CD4+ T cells 
(Hayball et al., 2004; Weaver et al., 2009) and CD8+ T cells (Willis et al., 2006). Heyball and 
colleagues have shown both in vitro and in vivo that T cells with the highest affinity compete 
more efficiently with T cells that are specific for a different antigen but of lower affinity, whereas 
the reverse is not true. Thus, T-cell competition for DCs access was shown to be independent of 
antigen specificity, meaning it can occur for the same antigen as well as for different antigens. 
Such competition resulted in fewer T cells recruited for the immune response, but the activation 
state of the cells that responded was not affected (Willis et al., 2006).  Several studies 
demonstrated in vivo and in vitro that interference between T cell responses doesn’t result from 
diminished presentation of peptides on MHC-II (Weaver et al., 2009; Wolpert et al., 1998).  
Moreover our data from MAPPs peptide competition experiments indicate that OVA-derived 
peptides were still presented at the same levels even when competed with high doses of IVIg of 
17 mg/ml. Interestingly, it has been collectively reported that competition is detectable only if 
target peptides were presented on the same DC (Weaver et al., 2009; Willis et al., 2006; Wolpert 
et al., 1998). In line with these findings, Weaver and colleagues determined in vivo that T-cell 
competition doesn’t occur systematically but is rather a local event that requires the competitor 
peptides to be in the same draining lymph node (Weaver et al., 2009). Two-photon microscopy 
imaging enabled to show that DCs can interact with up to 5000 T cells per hour in a process of 
stochastic T cell repertoire scanning (Miller et al., 2004a). Very importantly, the same group 
revealed that after T cells recognized their cognate antigen, they form dynamic but dense clusters 
on DCs, thereby supporting a possible competition for DCs access (Miller et al., 2004b). 
Strikingly, this clustering behavior on DCs was observed only under experimental conditions of 
abundant antigen and large numbers of cognate T cells, thus reinforcing the T-cell competition 
aspect upon high doses of IVIg. Through a series of experiments, Heyball and colleagues 
demonstrated that the most likely mechanism by which T-cell competition occurs is via steric 
hindrance on the cell surface of the APC. This finding is completely in line with the model we 
propose here for IVIg blockade mechanism (1) detailed in Figure 48B, where IVIg-T cells 
physically occupy the surface of DC, and as consequence limit the access of other potential 
OVA-reactive T cells. 
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Another possible mechanism for IVIg inhibition, referred to as (2), is depicted in Figure 
48C and implies a competition for accessing the T cell-B cell zone border. Despite the 
competition that occurs between T cells to access DCs, a few OVA-specific T cell clones may 
still get primed by DCs, as demonstrated by the residual OVA response in our studies. They will 
then proliferate and differentiate into TH cells. However, their access to the T cell-B cell zone 
border might be restricted once again by steric hindrance caused by the many IVIg specific TH 
clones interacting with their cognate B cells (2a). Therefore, a competition between the multiple 
TH cells might occur to prime their cognate B cells T cell-B cell zone border, since space is 
lacking for scanning peptide complexes on the surface of B cell. The reverse might also be true, 
meaning a competition might occur between the multiple activated B cells to get primed by their 
cognate TH. Indeed, the OVA-activated B cells might also be physically hindered by the many B 
cells activated by IVIg that have migrated to the T cell-B cell border (2b). Indeed, our data 
demonstrate a marked activation of B cells upon IVIg. Importantly, about 20% of B lymphocytes 
present in the peripheral blood of normal individuals produce polyreactive antibodies (Notkins, 
2004). They generally bind to a wide variety of self and non-self-antigens (Avrameas et al., 
2007). Therefore, owing to its polyreactive nature, IVIg may bind to a large number of BCRs and 
consequently lead to the extensive activation of B cells we observed. Our data correlate with a 
number of studies where they specifically demonstrated that IVIg stimulated B cells. Intravenous 
administration of high dose IVIg in Balb/c mice has been shown to increase B cell and CD4+ T 
cell numbers in the spleen, as well as to elevate the number of splenic IgG-secreting cells 
(Sundblad et al., 1991). IVIg treatment of CD40-activated B cells isolated from SLE patients 
accelerated their differentiation, characterized by increased secretion of IgG and IgM (Neron et 
al., 2009). In line with this study, de Grandmont and colleagues showed that addition of IVIg in 
vitro to CD40-activated B cells promoted their differentiation into IgG-secreting cells (de 
Grandmont et al., 2003). They revealed that these de novo synthesized IgG were reactive with 
self-antigens such as nucleoprotamine, dsDNA, or myoglobin. As expected, these IgG strongly 
reacted with tetanus toxin, because of the vaccination status of the respective donors. Notably, 
whereas no reactivity was observed for human IgG Fc fragments, IVIg-induced IgG were highly 
reactive against human IgG F(ab')2 fragments, which supports our data. Another study brought 
the evidence that IVIg induced BCR signaling, as demonstrated by an increased phosphorylation 
of intracellular transduction pathways such as ERK1/2, Gab1 and Akt in human B cells, when 
treated with IVIg in vitro (Dussault et al., 2008). Leucht and colleagues analyzed Fab fragments 
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derived from one Kawasaki patient that specifically bound to IVIg by phage display, before and 
after IVIg treatment (Leucht et al., 2001). Sequencing revealed that the favored VH germline gene 
segments of the isolated IVIg-bound Fabs were 3-23 or 3-30/3-30.5, the most frequently 
rearranged VH genes among human B cells. Of particular interest, they showed that the majority 
of Fab-phages selected from the patient after IVIg treatment displayed a significantly stronger 
reactivity with IVIg than those from the library before therapy. In addition, the expression of the 
above VH gene segments increased after the IVIg treatment. They concluded that IVIg can act as 
a superantigen in vivo and reshaped the B cell repertoire of this patient by activating and 
expanding B cells that presented BCRs derived from these two germline genes, with the highest 
affinity for IVIg. Overall the different studies published support the notion of a direct anti-
idiotypic interaction of IVIg with the BCR, followed by B cell activation, which is line with the 
data presented here. To summarize, we suggest the existence of a competition between TH for 
scanning peptides complexes on B cells surface, as well as an additional competition between the 
numerous activated B cells and T cells to access the T cell-B cell zone border. Both phenomena 
will inevitably result in less OVA-specific B cell priming. An antigen-activated B cell that fails to 
interact with its cognate TH cell will die by apoptosis within 24h. Therefore, we suggest that 
inhibition of priming of OVA-activated B cells by TH cells might account for the effect of IVIg in 
lowering anti-OVA antibodies in mouse serum.  
The third and last mechanism for IVIg blockade we propose in this model, depicted as (3) 
in Figure 48A, occurs via TFH competition for priming of centrocytes in the GC (Figure 48D). 
Similarly to T cells that have been demonstrated to compete for access to DCs, the numerous TFH 
activated by IVIg might compete out the few OVA-specific TFH for peptide scanning on 
centrocytes. Supporting this idea, it has been demonstrated that TFH cells are present in a limiting 
amount in the GC (Pratama and Vinuesa, 2014). This is essential to ensure competition amongst 
the different B cells clones generated by somatic hypermutation and to ensure optimal affinity 
maturation within the GC. Thus, in the eventuality that a few OVA-specific B cell clones can 
initiate the formation of a GC, they will rapidly die by apoptosis without receiving any input 
signal from their cognate OVA-TFH.  
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In presence of IVIg, cross-talk phenomena might also occur between T cells to provide help 
to B cells. The pool of IgG contained in IVIg shares some common epitopes since they are all 
from human origin. T cells that are triggered by the same T cell epitope on DCs (e.g. Fc peptide) 
can interact with several B cell showing this T cell epitope, although the BCR specificity of these 
B cells may be different. Therefore, an individual IgG can trigger the antibody response against a 
different IgG molecule via shared T cell epitopes. This is facilitated by the fact that the many T-
cell epitopes presented from IVIg trigger a high number of T cells and the many B cell epitopes 
in IVIg can be recognized by many different B cells. Thus, the diversity of the IgG molecules 
contained in IVIg might lead to an amplification of the immune response against IVIg, favoring 
the competition described in the model here.  
The model described above is based on adaptive immune cells fighting to physically access 
their cognate partner, and relies on antigenic competition. Antigenic competition is the 
diminution of the antibody response to an antigen by the simultaneous or sequential injection of 
an unrelated antigen. It has already been described several decades ago, by Brody and colleagues 
who performed a series of immunization experiments in the rabbit (Brody and Siskind, 1969).  
Very interestingly, they found that competition was enhanced when larger doses of antigen were 
used. This may explain the IVIg dose-dependency observed in our in vivo model, as well as the 
requirement of high doses of IVIg in the clinic to treat autoimmune diseases. Importantly, they 
demonstrated that antigenic competition occurred only if the two antigens were injected so that 
they drained into the same lymph nodes, which is well in line with the findings reported here. In 
another study, intraperitoneal injections of ferritin and human serum albumin in mice in various 
doses and ratios showed that the degree of suppression of both primary and secondary antibody 
responses to HSA was dependent on the dose of ferritin injected simultaneously, and vice versa 
(Rhodes and Larsen, 1972).  Another example where such competition occurs is a vaccine against 
ovine footrot that incorporates nine serogroups of pili from Dichelobacter nodosus. Such a 
multivalent vaccine elicited lower levels of pili serogroup-specific antibodies than the 
corresponding monovalent vaccine (Schwartzkoff et al., 1993). A murine model that parallels this 
phenomenon has been established, showing that competition was more pronounced in the 
presence of high doses of the heterologous antigens (Hunt et al., 1995). Hunt and colleagues 
demonstrated that there was an upper limit of the number of T cells that can be induced following 
vaccination with pili. They showed this limit in T cell responsiveness was not due to impaired 
antigen presentation on APC. This is in line with our MAPPs data showing that IVIg didn’t 
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compete with OVA for peptide presentation on MHC-II in human DCs in vitro. They concluded 
that under limited T cell stimulation within a lymph node, T cell help has to be shared between B 
cells specific for each serogroup of pili, which may explain the decrease of serogroup specific 
antibodies. All together these studies support the notion that antigenic competition may occur 
upon IVIg treatment. 
In this model based on antigenic competition, requirement for high doses of IVIg might 
likely be explained by the need to overcome immunodominance. Immunodominance is the 
phenomenon that the T cell response is mainly focused on few epitopes derived from the antigen, 
although the antigen may possess a multitude of potential epitopes that T cells are capable to 
recognize. Immunodominance likely ensures that the resources of the immune system are 
mobilized economically against foreign invaders (Yewdell and Bennink, 1999). Thus, we suggest 
that at low doses of IVIg, only the dominant epitopes will trigger a few T cells and raise a 
classical immune response, likely not enough to induce competition with OVA-specific T cells. 
Whereas upon high doses of IVIg, more epitopes are presented on DCs at a meaningful 
concentration, thereby increasing the chances of weak epitopes to activate their cognate T cell 
clones. The unusually large number of T cells recruited following IVIg high dose injection might 
consequently re-direct the immune system, increasing competition against OVA-specific T cells. 
This idea is supported by our data showing that the antibody response against IVIg is mostly 
directed towards its variable regions. With regards to the huge diversity of the variable regions 
contained in IVIg, high doses are likely required to concentrate weak epitopes on the surface of 
APCs, so that they are able to further induce T cell activation and ultimately competition.           
 
 To consolidate our findings involving antigenic competition as one possible IVIg inhibitory 
mechanism, several areas might be worth to look into in this context. For instance, some studies 
demonstrated that it was possible to tolerize mice against specific antigens when injecting them 
right after birth (Madoiwa et al., 2004). Such induction of immune tolerance against IVIg may 
provide a good basis for studying if IVIg inhibitory effects still occur in those adult mice. 
Antigen labeling might represent a nice tool to follow antigen-specific GC formation with and 
without IVIg. Since growing attention has been focused on sialylation of the IVIg-Fc part, testing 
de-sialylated IVIg in our mouse model would be of interest too. Finally, analyzing the anti-IVIg 
antibody response and the IVIg-specific B cell precursor frequency directly in samples from 
IVIg-treated patients would bring some more insights about a possible antigenic competition. 
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IVIg has been proven over the past decades as a safe and effective therapy in the context of 
autoimmune and severe inflammatory diseases. Still, the physiological means by which IVIg 
modulates the immune system had remained a mystery. Owing to the composition of IVIg 
comprising a broad spectrum of antibodies, it is likely that multifactorial and non-mutually 
exclusive mechanisms are involved in its immunomodulatory effect. Through the work presented 
here, it has been demonstrated for the first time in vivo that IVIg triggers a massive activation and 
recruitment of immune cells that lead to the formation of anti-IVIg antibodies. We suggest that 
this overwhelming of the immune system might consequently diminish its ability to respond to a 
specific antigen, most likely via a phenomenon of antigenic competition. We have provided 
evidence that IgG variable regions may mostly account for these effects. Therefore we propose 
that there might be no anti-inflammatory magic content in IVIg, but it rather comprises a 
multitude of potentially immunogenic epitopes through the unique high diversity it contains. 
Although research over the past decade has emphasized the role of IVIg in promoting anti-
inflammatory effects, the data presented here point to a paradigm shift and reveal that IVIg 
establish a pro-inflammatory environment that interferes with efficient immune response against 
a specific antigen. 
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